14. Literaturverzeichnis – Pankreaskarzinom
1. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften - Ständige Kommission, Leitlinien, AWMF-Regelwerk "Leitlinien", 2. Auflage, 2020., https://www.awmf.org/regelwerk/
2. Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V., Zentrum für Krebsregisterdaten am Robert-Koch-Institut, Krebs in Deutschland 2019/2020Robert-Koch-Institut, Gesundheitsberichterstattung des Bundes, 2023. 8:, https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/krebs_in_deutschland_2023.pdf?__blob=publicationFile
3. Glade, M. J., Food, nutrition, and the prevention of cancer: a global perspective. American Institute for Cancer Research/World Cancer Research Fund, American Institute for Cancer Research, 1997, Nutrition, 1999. 15(6): p. 523-6., https://pubmed.ncbi.nlm.nih.gov/10378216/
4. (WCRF), World Cancer Research Fund, Research, American Institute for Cancer, Diet, nutrition, physical activity and pancreatic cancer., Revised 2018.., https://www.wcrf.org/wp-content/uploads/2021/02/pancreatic-cancer-report.pdf.
5. Morze, J., Danielewicz, A., Przybylowicz, K., Zeng, H., Hoffmann, G., Schwingshackl, L., An updated systematic review and meta-analysis on adherence to mediterranean diet and risk of cancer, European Journal of Nutrition, 2021. 60(3): p. 1561-1586., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7987633/pdf/394_2020_Article_2346.pdf
6. Grosso, G., Bella, F., Godos, J., Sciacca, S., Del Rio, D., Ray, S., et.al. Possible role of diet in cancer: Systematic review and multiple meta-analyses of dietary patterns, lifestyle factors, and cancer risk, Nutrition Reviews, 2017. 75(6): p. 405-419., https://pubmed.ncbi.nlm.nih.gov/28969358/
7. Lu, PY, Shu, L, Shen, SS, Chen, XJ, Zhang, XY, Dietary Patterns and Pancreatic Cancer Risk: A Meta-Analysis., Nutrients, 2017. 9 (1)(1):, https://pubmed.ncbi.nlm.nih.gov/28067765/
8. Zheng, J, Guinter, MA, Merchant, AT, Wirth, MD, Zhang, J, Stolzenberg-Solomon, RZ, et.al. Dietary patterns and risk of pancreatic cancer: a systematic review., Nutr Rev, 2017. 75 (11)(11): p. 883-908., https://pubmed.ncbi.nlm.nih.gov/29025004/
9. Gao, Y., Ma, Y., Yu, M., Li, G., Chen, Y., Li, X., et.al. Poultry and Fish Intake and Pancreatic Cancer Risk: A Systematic Review and Meta-Analysis, Nutrition & Cancer, 2021. p. 1-13.
10. Zhao, Z., Yin, Z., Pu, Z., Zhao, Q., Association Between Consumption of Red and Processed Meat and Pancreatic Cancer Risk: A Systematic Review and Meta-analysis, Clinical Gastroenterology and Hepatology, 2017. 15(4): p. 486-493.e10., https://www.cghjournal.org/article/S1542-3565(16)30854-0/pdf
11. Mossine, V. V., Mawhinney, T. P., Giovannucci, E. L., Dried Fruit Intake and Cancer: A Systematic Review of Observational Studies, Advances in nutrition (Bethesda, Md.), 2020. 11(2): p. 237-250., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7442373/pdf/nmz085.pdf
12. Wu, Q. J., Wu, L., Zheng, L. Q., Xu, X., Ji, C., Gong, T. T., Consumption of fruit and vegetables reduces risk of pancreatic cancer: Evidence from epidemiological studies, European Journal of Cancer Prevention, 2016. 25(3): p. 196-205., https://pubmed.ncbi.nlm.nih.gov/26075658/
13. Zhao, Z., Yu, P., Feng, X., Yin, Z., Wang, S., Qiu, Z., et.al. No associations between fruit and vegetable consumption and pancreatic cancer risk: A meta-analysis of prospective studies, Oncotarget, 2018. 9(63): p. 32250-32261., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114958/
14. Darooghegi Mofrad, M., Mozaffari, H., Askari, M. R., Amini, M. R., Jafari, A., Surkan, P. J., et.al. Potato Consumption and Risk of Site-Specific Cancers in Adults: A Systematic Review and Dose-Response Meta-Analysis of Observational Studies, Advances in Nutrition, 2021. 16: p. 16., https://academic.oup.com/advances/article-abstract/12/5/1705/6228237?redirectedFrom=fulltext
15. Zhang, D., Dai, C., Zhou, L., Li, Y., Liu, K., Deng, Y. J., et.al. Meta-analysis of the association between nut consumption and the risks of cancer incidence and cancer-specific mortality, Aging, 2020. 12(11): p. 10772-10794., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346045/pdf/aging-12-103292.pdf
16. Gaesser, G. A., Whole grains, refined grains, and cancer risk: A systematic review of meta-analyses of observational studies, Nutrients, 2020. 12(12): p. 1-23., https://www.mdpi.com/2072-6643/12/12/3756/pdfhttps://mdpi-res.com/d_attachment/nutrients/nutrients-12-03756/article_deploy/nutrients-12-03756.pdf
17. McRae, M. P., The Benefits of Dietary Fiber Intake on Reducing the Risk of Cancer: An Umbrella Review of Meta-analyses, Journal of Chiropractic Medicine, 2018. 17(2): p. 90-96., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6112064/pdf/main.pdf
18. Llaha, F., Gil-Lespinard, M., Unal, P., de Villasante, I., Castaneda, J., Zamora-Ros, R., Consumption of sweet beverages and cancer risk. A systematic review and meta-analysis of observational studies, Nutrients, 2021. 13(2): p. 1-35., https://www.mdpi.com/2072-6643/13/2/516/pdfhttps://mdpi-res.com/d_attachment/nutrients/nutrients-13-00516/article_deploy/nutrients-13-00516-v3.pdf
19. Milajerdi, A., Larijani, B., Esmaillzadeh, A., Sweetened Beverages Consumption and Pancreatic Cancer: A Meta-Analysis, Nutrition & Cancer, 2019. 71(3): p. 375-384., https://www.tandfonline.com/doi/full/10.1080/01635581.2019.1578390
20. Ghadirian, P., Baillargeon, J., Simard, A., Perret, C., Food habits and pancreatic cancer: a case-control study of the Francophone community in Montreal, Canada, Cancer Epidemiol Biomarkers Prev, 1995. 4(8): p. 895-9., https://pubmed.ncbi.nlm.nih.gov/8634663/
21. Michaud, D. S., Liu, S., Giovannucci, E., Willett, W. C., Colditz, G. A., Fuchs, C. S., Dietary sugar, glycemic load, and pancreatic cancer risk in a prospective study, J Natl Cancer Inst, 2002. 94(17): p. 1293-300., https://pubmed.ncbi.nlm.nih.gov/12208894/
22. Silvera, S. A., Rohan, T. E., Jain, M., Terry, P. D., Howe, G. R., Miller, A. B., Glycemic index, glycemic load, and pancreatic cancer risk (Canada), Cancer Causes Control, 2005. 16(4): p. 431-6., https://pubmed.ncbi.nlm.nih.gov/15953985/
23. Stolzenberg-Solomon, R. Z., Pietinen, P., Taylor, P. R., Virtamo, J., Albanes, D., Prospective study of diet and pancreatic cancer in male smokers, Am J Epidemiol, 2002. 155(9): p. 783-92., https://pubmed.ncbi.nlm.nih.gov/11978580/
24. Nothlings, U., Wilkens, L. R., Murphy, S. P., Hankin, J. H., Henderson, B. E., Kolonel, L. N., Meat and fat intake as risk factors for pancreatic cancer: the multiethnic cohort study, J Natl Cancer Inst, 2005. 97(19): p. 1458-65., https://pubmed.ncbi.nlm.nih.gov/16204695/
25. Lin, Y., Tamakoshi, A., Hayakawa, T., Naruse, S., Kitagawa, M., Ohno, Y., Nutritional factors and risk of pancreatic cancer: a population-based case-control study based on direct interview in Japan, J Gastroenterol, 2005. 40(3): p. 297-301., https://pubmed.ncbi.nlm.nih.gov/15830290/
26. Michaud, D. S., Giovannucci, E., Willett, W. C., Colditz, G. A., Fuchs, C. S., Dietary meat, dairy products, fat, and cholesterol and pancreatic cancer risk in a prospective study, Am J Epidemiol, 2003. 157(12): p. 1115-25., https://pubmed.ncbi.nlm.nih.gov/12796048/
27. Bueno de Mesquita, H. B., Maisonneuve, P., Runia, S., Moerman, C. J., Intake of foods and nutrients and cancer of the exocrine pancreas: a population-based case-control study in The Netherlands, Int J Cancer, 1991. 48(4): p. 540-9., https://pubmed.ncbi.nlm.nih.gov/1646177/
28. Chen, J., Jiang, W., Shao, L., Zhong, D., Wu, Y., Cai, J., Association between intake of antioxidants and pancreatic cancer risk: a meta-analysis, International journal of food sciences and nutrition, 2016. 67(7): p. 744-753., https://www.tandfonline.com/doi/full/10.1080/09637486.2016.1197892
29. Wang, L., Wang, J., Liu, X., Liu, Q., Zhang, G., Liang, L., Association between selenium intake and the risk of pancreatic cancer: a meta-analysis of observational studies, Bioscience Reports, 2016. 36(5): p. 10.
30. Hua, Y. F., Wang, G. Q., Jiang, W., Huang, J., Chen, G. C., Lu, C. D., Vitamin C Intake and Pancreatic Cancer Risk: A Meta-Analysis of Published Case-Control and Cohort Studies, PLoS ONE [Electronic Resource], 2016. 11(2): p. e0148816., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747545/pdf/pone.0148816.pdf
31. Liu, Y., Wang, X., Sun, X., Lu, S., Liu, S., Vitamin intake and pancreatic cancer risk reduction: A meta-analysis of observational studies, Medicine, 2018. 97(13): p. e0114., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5895396/pdf/medi-97-e0114.pdf
32. Huang, X., Gao, Y., Zhi, X., Ta, N., Jiang, H., Zheng, J., Association between vitamin A, retinol and carotenoid intake and pancreatic cancer risk: Evidence from epidemiologic studies, Scientific Reports, 2016. 6: p. 38936., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5150257/pdf/srep38936.pdf
33. Zhang, T., Chen, H., Qin, S., Wang, M., Wang, X., Zhang, X., et.al. The association between dietary vitamin A intake and pancreatic cancer risk: a meta-analysis of 11 studies, Bioscience Reports, 2016. 36(6): p. 12., https://pubmed.ncbi.nlm.nih.gov/27756825/
34. Fu, H., Zeng, J., Liu, C., Gu, Y., Zou, Y., Chang, H., Folate Intake and Risk of Pancreatic Cancer: A Systematic Review and Updated Meta-Analysis of Epidemiological Studies, Digestive Diseases and Sciences, 2021. 66(7): p. 2368-2379., http://www.wkap.nl/journalhome.htm/0163-2116https://link.springer.com/content/pdf/10.1007/s10620-020-06525-7.pdf
35. Liu, W., Zhou, H., Zhu, Y., Tie, C., Associations between dietary folate intake and risks of esophageal, gastric and pancreatic cancers: An overall and dose-response meta-analysis, Oncotarget, 2017. 8(49): p. 86828-86842., http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=18775&path%5B%5D=60299https://www.oncotarget.com/article/18775/pdf/
36. DGE, 13. DGE-ErnährungsberichtDeutsche Gesellschaft für Ernährung e.V., 2016.
37. Wei, D. H., Mao, Q. Q., Vitamin B6, vitamin B12 and methionine and risk of pancreatic cancer: a meta-analysis, Nutrition Journal, 2020. 19(1): p. 111., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7534168/pdf/12937_2020_Article_628.pdf
38. Peng, Y. F., Han, M. M., Huang, R., Dong, B. B., Li, L., Vitamin B6 Intake and Pancreatic Carcinoma Risk: A Meta-Analysis, Nutrition and Cancer, 2019. 71(7): p. 1061-1066., http://www.tandfonline.com/toc/hnuc20/currenthttps://www.tandfonline.com/doi/full/10.1080/01635581.2019.1598562
39. Mocellin, S., Briarava, M., Pilati, P., Vitamin B6 and cancer risk: A field synopsis and meta-analysis, Journal of the National Cancer Institute, 2017. 109(3):, https://pubmed.ncbi.nlm.nih.gov/28376200/
40. Zhang, X., Huang, X. Z., Chen, W. J., Wu, J., Chen, Y., Wu, C. C., et.al. Plasma 25-hydroxyvitamin D levels, vitamin D intake, and pancreatic cancer risk or mortality: a meta-analysis, Oncotarget, 2017. 8(38): p. 64395-64406., https://www.oncotarget.com/article/18888/pdf/
41. Li, L., Gai, X., The association between dietary zinc intake and risk of pancreatic cancer: a meta-analysis, Bioscience Reports, 2017. 37(3): p. 30., https://pubmed.ncbi.nlm.nih.gov/28428431/
42. Abbasalizad Farhangi, M., Vajdi, M., Dietary Total Antioxidant Capacity (TAC) Significantly Reduces the Risk of Site-Specific Cancers: An Updated Systematic Review and Meta-Analysis, Nutrition and Cancer, 2021. 73(5): p. 721-739., http://www.tandfonline.com/toc/hnuc20/currenthttps://www.tandfonline.com/doi/full/10.1080/01635581.2020.1771385
43. Guo, Z., Hong, Y., Cheng, Y., Dietary inflammatory index and pancreatic cancer risk: a systematic review and dose-response meta-analysis, Public Health Nutrition, 2021. p. 1-9., https://www.cambridge.org/core/journals/public-health-nutrition/article/abs/dietary-inflammatory-index-and-pancreatic-cancer-risk-a-systematic-review-and-doseresponse-metaanalysis/F09C050021A2B14072043B74E84D2FFD
44. Xie, L., Mo, M., Jia, H. X., Liang, F., Yuan, J., Zhu, J., Association between dietary nitrate and nitrite intake and sitespecific cancer risk: Evidence from observational studies, Oncotarget, 2016. 7(35): p. 56915-56932., http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=10917&path%5B%5D=34570https://www.oncotarget.com/article/10917/pdf/
45. Gao, Y, Ma, Y, Yu, M, Li, G, Chen, Y, Li, X, et.al. Poultry and Fish Intake and Pancreatic Cancer Risk: A Systematic Review and Meta-Analysis., Nutr Cancer, 2022. 74 (1)(1): p. 55-67., https://pubmed.ncbi.nlm.nih.gov/33432844/
46. Mills, P. K., Beeson, W. L., Abbey, D. E., Fraser, G. E., Phillips, R. L., Dietary habits and past medical history as related to fatal pancreas cancer risk among Adventists, Cancer, 1988. 61(12): p. 2578-85., https://pubmed.ncbi.nlm.nih.gov/3365678/
47. Wang, YT, Gou, YW, Jin, WW, Xiao, M, Fang, HY, Association between alcohol intake and the risk of pancreatic cancer: a dose-response meta-analysis of cohort studies., BMC Cancer, 2016. 16 (): p. 212., https://pubmed.ncbi.nlm.nih.gov/26968702/
48. Lugo, A, Peveri, G, Bosetti, C, Bagnardi, V, Crippa, A, Orsini, N, et.al. Strong excess risk of pancreatic cancer for low frequency and duration of cigarette smoking: A comprehensive review and meta-analysis., Eur J Cancer, 2018. 104 (): p. 117-126., https://pubmed.ncbi.nlm.nih.gov/30347287/
49. Gupta, S, Gupta, R, Sinha, DN, Mehrotra, R, Relationship between type of smokeless tobacco & risk of cancer: A systematic review., Indian J Med Res, 2018. 148 (1)(1): p. 56-76., https://pubmed.ncbi.nlm.nih.gov/30264755/
50. Ordóñez-Mena, JM, Schöttker, B, Mons, U, Jenab, M, Freisling, H, Bueno-de-Mesquita, B, et.al. Quantification of the smoking-associated cancer risk with rate advancement periods: meta-analysis of individual participant data from cohorts of the CHANCES consortium., BMC Med, 2016. 14 (): p. 62., https://pubmed.ncbi.nlm.nih.gov/27044418/
51. Lee, P. N., Thornton, A. J., Hamling, J. S., Epidemiological evidence on environmental tobacco smoke and cancers other than lung or breast, Regulatory Toxicology & Pharmacology, 2016. 80: p. 134-63.
52. Li, T. D., Yang, H. W., Wang, P., Song, C. H., Wang, K. J., Dai, L. P., et.al. Coffee consumption and risk of pancreatic cancer: a systematic review and dose-response meta-analysis, International journal of food sciences and nutrition, 2019. 70(5): p. 519-529., https://www.tandfonline.com/doi/full/10.1080/09637486.2018.1551337
53. Ran, H. Q., Wang, J. Z., Sun, C. Q., Coffee consumption and pancreatic cancer risk: An update meta-analysis of cohort studies, Pakistan Journal of Medical Sciences, 2016. 32(1): p. 253-259., http://www.pjms.com.pk/index.php/pjms/article/download/8761/4012https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4794517/pdf/PJMS-32-253.pdf
54. Alguacil, J., Pollan, M., Gustavsson, P., Occupations with increased risk of pancreatic cancer in the Swedish population, Occup Environ Med, 2003. 60(8): p. 570-6., https://pubmed.ncbi.nlm.nih.gov/12883017/
55. Alguacil, J., Porta, M., Benavides, F. G., Malats, N., Kogevinas, M., Fernandez, E., et.al. Occupation and pancreatic cancer in Spain: a case-control study based on job titles. PANKRAS II Study Group, Int J Epidemiol, 2000. 29(6): p. 1004-13., https://pubmed.ncbi.nlm.nih.gov/11101541/
56. Laakkonen, A., Kauppinen, T., Pukkala, E., Cancer risk among Finnish food industry workers, Int J Cancer, 2006. 118(10): p. 2567-71., https://pubmed.ncbi.nlm.nih.gov/16380992/
57. Fryzek, J. P., Garabrant, D. H., Harlow, S. D., Severson, R. K., Gillespie, B. W., Schenk, M., et.al. A case-control study of self-reported exposures to pesticides and pancreas cancer in southeastern Michigan, Int J Cancer, 1997. 72(1): p. 62-7., https://pubmed.ncbi.nlm.nih.gov/9212224/
58. Ji, B. T., Silverman, D. T., Stewart, P. A., Blair, A., Swanson, G. M., Baris, D., et.al. Occupational exposure to pesticides and pancreatic cancer, Am J Ind Med, 2001. 39(1): p. 92-9., https://pubmed.ncbi.nlm.nih.gov/11148019/
59. Ojajarvi, I. A., Partanen, T. J., Ahlbom, A., Boffetta, P., Hakulinen, T., Jourenkova, N., et.al. Occupational exposures and pancreatic cancer: a meta-analysis, Occup Environ Med, 2000. 57(5): p. 316-24., https://pubmed.ncbi.nlm.nih.gov/10769297/
60. Ojajarvi, A., Partanen, T., Ahlbom, A., Boffetta, P., Hakulinen, T., Jourenkova, N., et.al. Risk of pancreatic cancer in workers exposed to chlorinated hydrocarbon solvents and related compounds: a meta-analysis, Am J Epidemiol, 2001. 153(9): p. 841-50., https://pubmed.ncbi.nlm.nih.gov/11323314/
61. Weiderpass, E., Vainio, H., Kauppinen, T., Vasama-Neuvonen, K., Partanen, T., Pukkala, E., Occupational exposures and gastrointestinal cancers among Finnish women, J Occup Environ Med, 2003. 45(3): p. 305-15., https://pubmed.ncbi.nlm.nih.gov/12661188/
62. Yassi, A., Tate, R. B., Routledge, M., Cancer incidence and mortality in workers employed at a transformer manufacturing plant: update to a cohort study, Am J Ind Med, 2003. 44(1): p. 58-62., https://pubmed.ncbi.nlm.nih.gov/12822136/
63. Ji, J., Hemminki, K., Socioeconomic and occupational risk factors for pancreatic cancer: a cohort study in Sweden, J Occup Environ Med, 2006. 48(3): p. 283-8., https://pubmed.ncbi.nlm.nih.gov/16531832/
64. Dun, A., Zhao, X., Jin, X., Wei, T., Gao, X., Wang, Y., et.al. Association between night-shift work and cancer risk: Updated systematic review and meta-analysis, Frontiers in Oncology, 2020. 10: p. 1-15., http://www.frontiersin.org/Oncology/about
65. Xie, F, You, Y, Huang, J, Guan, C, Chen, Z, Fang, M, et.al. Association between physical activity and digestive-system cancer: An updated systematic review and meta-analysis., J Sport Health Sci, 2021. 10 (1)(1): p. 4-13., https://pubmed.ncbi.nlm.nih.gov/33010525/
66. fSolans, M., Chan, D. S. M., Mitrou, P., Norat, T., Romaguera, D., A systematic review and meta-analysis of the 2007 WCRF/AICR score in relation to cancer-related health outcomes, Annals of Oncology, 2020. 31(3): p. 352-368., https://www.journals.elsevier.com/annals-of-oncologyhttps://www.annalsofoncology.org/article/S0923-7534(20)31921-9/pdf
67. Luo, A. J., Feng, R. H., Wang, X. W., Wang, F. Z., Older age at first birth is a risk factor for pancreatic cancer: A meta-analysis, Hepatobiliary and Pancreatic Diseases International, 2016. 15(2): p. 125-130., http://www.hbpdint.com/
68. Prizment, AE, Anderson, KE, Hong, CP, Folsom, AR, Pancreatic cancer incidence in relation to female reproductive factors: Iowa Women's Health Study., JOP, 2007. 8 (1)(1): p. 16-27., https://pubmed.ncbi.nlm.nih.gov/17228129/
69. Silveira, E. A., Kliemann, N., Noll, M., Sarrafzadegan, N., de Oliveira, C., Visceral obesity and incident cancer and cardiovascular disease: An integrative review of the epidemiological evidence, Obesity Reviews, 2021. 22(1):, http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1467-789Xhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/obr.13088?download=true
70. Hidayat, K., Du, X., Shi, B. M., Body fatness at a young age and risks of eight types of cancer: systematic review and meta-analysis of observational studies, Obesity Reviews, 2018. 19(10): p. 1385-1394., http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1467-789Xhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/obr.12705?download=true
71. Seo, M. S., Yeo, J., Hwang, I. C., Shim, J. Y., Risk of pancreatic cancer in patients with systemic lupus erythematosus: a meta-analysis, Clinical Rheumatology, 2019. 38(11): p. 3109-3116., https://link.springer.com/journal/10067https://link.springer.com/content/pdf/10.1007/s10067-019-04660-9.pdf
72. Zhang, J. J., Jia, J. P., Shao, Q., Wang, Y. K., Diabetes mellitus and risk of pancreatic cancer in China: A meta-analysis based on 26 case-control studies, Primary Care Diabetes, 2019. 13(3): p. 276-282., https://www.primary-care-diabetes.com/article/S1751-9918(18)30091-3/fulltext
73. Aune, D., Sen, A., Norat, T., Riboli, E., Folseraas, T., Primary sclerosing cholangitis and the risk of cancer, cardiovascular disease, and all-cause mortality: a systematic review and meta-analysis of cohort studies, Scientific reports, 2021. 11(1): p. 10646., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137938/pdf/41598_2021_Article_90175.pdf
74. Fan, Y., Hu, J., Feng, B., Wang, W., Yao, G., Zhai, J., et.al. Increased risk of pancreatic cancer related to gallstones and cholecystectomy a systematic review and meta-analysis, Pancreas, 2016. 45(4): p. 503-509., http://journals.lww.com/pancreasjournal
75. Trafford, A. M., Parisi, R., Kontopantelis, E., Griffiths, C. E. M., Ashcroft, D. M., Association of Psoriasis with the Risk of Developing or Dying of Cancer: A Systematic Review and Meta-analysis, JAMA Dermatology, 2019. 155(12): p. 1390-1403., http://archderm.jamanetwork.com/issues.aspxhttps://jamanetwork.com/journals/jamadermatology/articlepdf/2753127/jamadermatology_trafford_2019_oi_190054.pdf
76. Arafa, A., Eshak, E. S., Abdel Rahman, T. A., Anwar, M. M., Hepatitis C virus infection and risk of pancreatic cancer: A meta-analysis, Cancer Epidemiology, 2020. 65: p. 101691.
77. Leung, C. Y., Huang, H. L., Rahman, M. M., Nomura, S., Krull Abe, S., Saito, E., et.al. Cancer incidence attributable to tuberculosis in 2015: global, regional, and national estimates, BMC Cancer, 2020. 20(1): p. 412., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218646/pdf/12885_2020_Article_6891.pdf
78. Liu, H., Chen, Y. T., Wang, R., Chen, X. Z., Helicobacter pylori infection, atrophic gastritis, and pancreatic cancer risk: A meta-analysis of prospective epidemiologic studies, Medicine, 2017. 96(33): p. e7811., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571714/pdf/medi-96-e7811.pdf
79. Liu, S. S., Ma, X. F., Zhao, J., Du, S. X., Zhang, J., Dong, M. Z., et.al. Association between nonalcoholic fatty liver disease and extrahepatic cancers: a systematic review and meta-analysis, Lipids in Health & Disease, 2020. 19(1): p. 118., https://lipidworld.biomedcentral.com/track/pdf/10.1186/s12944-020-01288-6.pdf
80. Liu, X., Zhang, Z. H., Jiang, F., Hepatitis B virus infection increases the risk of pancreatic cancer: a meta-analysis, Scandinavian Journal of Gastroenterology, 2021. 56(3): p. 252-258., http://www.tandfonline.com/loi/igas20https://www.tandfonline.com/doi/full/10.1080/00365521.2020.1868568
81. Maisonneuve, P., Amar, S., Lowenfels, A. B., Periodontal disease, edentulism, and pancreatic cancer: a meta-analysis, Annals of oncology : official journal of the European Society for Medical Oncology, 2017. 28(5): p. 985-995., https://www.annalsofoncology.org/article/S0923-7534(19)32001-0/pdf
82. Michaud, D. S., Fu, Z., Shi, J., Chung, M., Periodontal disease, tooth loss, and cancer risk, Epidemiologic Reviews, 2017. 39(1): p. 49-58., http://epirev.oxfordjournals.org/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5868279/pdf/mxx006.pdf
83. Shi, J., Leng, W., Zhao, L., Deng, C., Xu, C., Wang, J., et.al. Tooth loss and cancer risk: a dose-response meta analysis of prospective cohort studies, Oncotarget, 2018. 9(19): p. 15090-15100., https://www.oncotarget.com/article/23850/pdf/
84. Wang, L., Bierbrier, R., Drucker, A. M., Chan, A. W., Noncutaneous and Cutaneous Cancer Risk in Patients With Atopic Dermatitis: A Systematic Review and Meta-analysis, JAMA Dermatology, 2020. 156(2): p. 158-171., https://jamanetwork.com/journals/jamadermatology/articlepdf/2757273/jamadermatology_wang_2019_oi_190064.pdf
85. Pang, Y, Kartsonaki, C, Guo, Y, Bragg, F, Yang, L, Bian, Z, et.al. Diabetes, plasma glucose and incidence of pancreatic cancer: A prospective study of 0.5 million Chinese adults and a meta-analysis of 22 cohort studies., Int J Cancer, 2017. 140 (8)(8): p. 1781-1788., https://pubmed.ncbi.nlm.nih.gov/28063165/
86. Wang, J., Yang, D. L., Chen, Z. Z., Gou, B. F., Associations of body mass index with cancer incidence among populations, genders, and menopausal status: A systematic review and meta-analysis, Cancer Epidemiology, 2016. 42: p. 1-8., http://www.elsevier.com
87. Kaleru, T., Vankeshwaram, V. K., Maheshwary, A., Mohite, D., Khan, S., Diabetes Mellitus in the Middle-Aged and Elderly Population (>45 Years) and Its Association With Pancreatic Cancer: An Updated Review, Cureus, 2020. 12(6): p. e8884., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388804/pdf/cureus-0012-00000008884.pdf
88. Sona, M. F., Myung, S. K., Park, K., Jargalsaikhan, G., Type 1 diabetes mellitus and risk of cancer: A meta-analysis of observational studies, Japanese Journal of Clinical Oncology, 2018. 48(5): p. 426-433., https://pubmed.ncbi.nlm.nih.gov/29635473/
89. Sharma, A., Kandlakunta, H., Nagpal, S. J. S., Feng, Z., Hoos, W., Petersen, G. M., et.al. Model to Determine Risk of Pancreatic Cancer in Patients With New-Onset Diabetes, Gastroenterology, 2018. 155(3): p. 730-739.e3., https://pubmed.ncbi.nlm.nih.gov/29775599/
90. Chari, ST, Maitra, A, Matrisian, LM, Shrader, EE, Wu, BU, Kambadakone, A, et.al. Early Detection Initiative: A randomized controlled trial of algorithm-based screening in patients with new onset hyperglycemia and diabetes for early detection of pancreatic ductal adenocarcinoma., Contemp Clin Trials, 2022. 113 (): p. 106659., https://pubmed.ncbi.nlm.nih.gov/34954100/
91. Hatami Marbini, M., Amiri, F., Sajadi Hezaveh, Z., Dietary glycemic index, glycemic load, insulin index, insulin load and risk of diabetes-related cancers: A systematic review of cohort studies, Clinical Nutrition ESPEN, 2021. 42: p. 22-31., http://www.journals.elsevier.com/clinical-nutrition-espenhttps://clinicalnutritionespen.com/article/S2405-4577(21)00077-2/fulltext
92. Ling, S., Brown, K., Miksza, J. K., Howells, L. M., Morrison, A., Issa, E., et.al. Risk of cancer incidence and mortality associated with diabetes: A systematic review with trend analysis of 203 cohorts, Nutrition, Metabolism and Cardiovascular Diseases, 2021. 31(1): p. 14-22., http://www.elsevier.com/wps/find/journaldescription.cws_home/704955/description#descriptionhttps://www.nmcd-journal.com/article/S0939-4753(20)30410-5/fulltext
93. Fang, H. J., Shan, S. B., Zhou, Y. H., Zhong, L. Y., Diabetes mellitus and the risk of gastrointestinal cancer in women compared with men: a meta-analysis of cohort studies, BMC Cancer, 2018. 18(1): p. 422., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5902961/pdf/12885_2018_Article_4351.pdf
94. Soltani, S., Abdollahi, S., Aune, D., Jayedi, A., Body mass index and cancer risk in patients with type 2 diabetes: a dose-response meta-analysis of cohort studies, Scientific reports, 2021. 11(1): p. 2479., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844243/pdf/41598_2021_Article_81671.pdf
95. Pergolini, I., Schorn, S., Jager, C., Gos, R., Novotny, A., Friess, H., et.al. Diabetes mellitus in intraductal papillary mucinous neoplasms: A systematic review and meta-analysis, Surgery, 2021. 169(2): p. 411-418., https://www.surgjournal.com/article/S0039-6060(20)30448-7/fulltext
96. Wang, Y., Yan, P., Fu, T., Yuan, J., Yang, G., Liu, Y., et.al. The association between gestational diabetes mellitus and cancer in women: A systematic review and meta-analysis of observational studies, Diabetes and Metabolism, 2020. 46(6): p. 461-471., http://www.elsevier.com/wps/find/journaldescription.cws_home/709654/description#description
97. Guo, Y., Liu, W., Wu, J., Helicobacter pylori infection and pancreatic cancer risk: A meta-Analysis, Journal of Cancer Research and Therapeutics, 2016. 12(8): p. C229-C232., http://www.cancerjournal.nethttps://www.cancerjournal.net/article.asp?issn=0973-1482;year=2016;volume=12;issue=8;spage=229;epage=232;aulast=Guo
98. Zhang, Y., Sun, C., Song, E. J., Liang, M., Shi, T., Min, M., et.al. Is periodontitis a risk indicator for gastrointestinal cancers? A meta-analysis of cohort studies, Journal of Clinical Periodontology, 2020. 47(2): p. 134-147., http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1600-051Xhttps://onlinelibrary.wiley.com/doi/10.1111/jcpe.13217
99. Beyer, G, Hoffmeister, A, Michl, P, Gress, TM, Huber, W, Algül, H, et.al. None, Z Gastroenterol, 2022. 60 (3)(3): p. 419-521., https://pubmed.ncbi.nlm.nih.gov/35263785/
100. Yamada, A., Komaki, Y., Komaki, F., Micic, D., Zullow, S., Sakuraba, A., Risk of gastrointestinal cancers in patients with cystic fibrosis: a systematic review and meta-analysis, The Lancet Oncology, 2018. 19(6): p. 758-767., http://www.journals.elsevier.com/the-lancet-oncology/https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30188-8/fulltext
101. Heydari, K., Rismantab, S., Alizadeh-Navaei, R., Shamshirian, A., Shadmehri, N., Lotfi, P., et.al. Risk of secondary malignancies in patients with ovarian cancer: A systematic review and meta-analysis, European Journal of Gynaecological Oncology, 2021. 42(2): p. 234-243., https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2021.02.2238
102. Wang, Y., Lan, G. B., Peng, F. H., Xie, X. B., Cancer risks in recipients of renal transplants: a meta-analysis of cohort studies, Oncotarget, 2018. 9(20): p. 15375-15385., https://www.oncotarget.com/article/23841/pdf/
103. Wang, G., Xu, Z., Zhu, J., Ren, J., Chen, M., He, G., et.al. Decreased Risk in the Pancreatic Cancer With History of Hay Fever: A Meta-Analysis, Frontiers in Public Health, 2020. 8: p. 551490., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7574341/pdf/fpubh-08-551490.pdf
104. Karim, A. F., Westenberg, L. E. H., Eurelings, L. E. M., Otten, R., Gerth van Wijk, R., The association between allergic diseases and cancer: a systematic review of the literature, Netherlands Journal of Medicine, 2019. 77(2): p. 42-66.
105. Cui, Y., Hill, A. W., Atopy and Specific Cancer Sites: a Review of Epidemiological Studies, Clinical Reviews in Allergy and Immunology, 2016. 51(3): p. 338-352., http://www.springer.com/humana+press/journal/12016https://link.springer.com/content/pdf/10.1007/s12016-016-8559-2.pdf
106. Pang, Y., Holmes, M. V., Kartsonaki, C., Guo, Y., Yang, L., Bian, Z., et.al. Young adulthood and adulthood adiposity in relation to incidence of pancreatic cancer: a prospective study of 0.5 million Chinese adults and a meta-analysis, Journal of epidemiology and community health, 2017. 71(11): p. 1059-1067., https://jech.bmj.com/content/jech/71/11/1059.full.pdf
107. Tan, J., You, Y., Guo, F., Xu, J., Dai, H., Bie, P., Association of elevated risk of pancreatic cancer in diabetic patients: A systematic review and meta-analysis, Oncology Letters, 2017. 13(3): p. 1247-1255., http://www.spandidos-publications.com/ol/13/3/1247/downloadhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5403376/pdf/ol-13-03-1247.pdf
108. Lowenfels, A. B., Maisonneuve, P., DiMagno, E. P., Elitsur, Y., Gates, L. K., Jr., Perrault, J., et.al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group, J Natl Cancer Inst, 1997. 89(6): p. 442-6., https://pubmed.ncbi.nlm.nih.gov/9091646/
109. Howes, N., Lerch, M. M., Greenhalf, W., Stocken, D. D., Ellis, I., Simon, P., et.al. Clinical and genetic characteristics of hereditary pancreatitis in Europe, Clin Gastroenterol Hepatol, 2004. 2(3): p. 252-61., https://pubmed.ncbi.nlm.nih.gov/15017610/
110. Rosendahl, J., Witt, H., Szmola, R., Bhatia, E., Ozsvári, B., Landt, O., et.al. Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis, Nat Genet, 2008. 40(1): p. 78-82., https://pubmed.ncbi.nlm.nih.gov/18059268/
111. Witt, H., Beer, S., Rosendahl, J., Chen, J. M., Chandak, G. R., Masamune, A., et.al. Variants in CPA1 are strongly associated with early onset chronic pancreatitis, Nat Genet, 2013. 45(10): p. 1216-20., https://pubmed.ncbi.nlm.nih.gov/23955596/
112. Whitcomb, D. C., Genetic risk factors for pancreatic disorders, Gastroenterology, 2013. 144(6): p. 1292-302., https://pubmed.ncbi.nlm.nih.gov/23622139/
113. Tamura, K., Yu, J., Hata, T., Suenaga, M., Shindo, K., Abe, T., et.al. Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer, Proc Natl Acad Sci U S A, 2018. 115(18): p. 4767-4772., https://pubmed.ncbi.nlm.nih.gov/29669919/
114. National Institute for, Health, Care, Excellence, Pancreatic cancer in adults: diagnosis and management. NICE Guideline NG85NICE, 2018., https://www.nice.org.uk/guidance/ng85
115. Raimondi, S, Lowenfels, AB, Morselli-Labate, AM, Maisonneuve, P, Pezzilli, R, Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection., Best Pract Res Clin Gastroenterol, 2010. 24 (3)(3): p. 349-58., https://pubmed.ncbi.nlm.nih.gov/20510834/
116. Klein, A. P., Brune, K. A., Petersen, G. M., Goggins, M., Tersmette, A. C., Offerhaus, G. J., et.al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds, Cancer Res, 2004. 64(7): p. 2634-8., https://pubmed.ncbi.nlm.nih.gov/15059921/
117. Bartsch, D. K., Slater, E. P., Carrato, A., Ibrahim, I. S., Guillen-Ponce, C., Vasen, H. F., et.al. Refinement of screening for familial pancreatic cancer, Gut, 2016. 65(8): p. 1314-21., https://www.ncbi.nlm.nih.gov/pubmed/27222532
118. Goggins, M., Overbeek, K. A., Brand, R., Syngal, S., Del Chiaro, M., Bartsch, D. K., et.al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium, Gut, 2020. 69(1): p. 7-17., https://www.ncbi.nlm.nih.gov/pubmed/31672839
119. McFaul, C. D., Greenhalf, W., Earl, J., Howes, N., Neoptolemos, J. P., Kress, R., et.al. Anticipation in familial pancreatic cancer, Gut, 2006. 55(2): p. 252-8., https://pubmed.ncbi.nlm.nih.gov/15972300/
120. Grover, S, Syngal, S, Hereditary pancreatic cancer., Gastroenterology, 2010. 139 (4)(4): p. 1076-80, 1080.e1-2., https://pubmed.ncbi.nlm.nih.gov/20727885/
121. Brune, KA, Lau, B, Palmisano, E, Canto, M, Goggins, MG, Hruban, RH, et.al. Importance of age of onset in pancreatic cancer kindreds., J Natl Cancer Inst, 2010. 102 (2)(2): p. 119-26., https://pubmed.ncbi.nlm.nih.gov/20068195/
122. Stoffel, E. M., McKernin, S. E., Brand, R., Canto, M., Goggins, M., Moravek, C., et.al. Evaluating susceptibility to pancreatic cancer: ASCO provisional clinical opinion, Journal of Clinical Oncology, 2019. 37(2): p. 153-164., https://pubmed.ncbi.nlm.nih.gov/30589608/
123. Park, Wungki, Chen, Jiapeng, Chou, Joanne, Varghese, Anna, Yu, Kenneth, Wong, Winston, et.al. Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection, Clinical Cancer Research, 2020. 26:, https://pubmed.ncbi.nlm.nih.gov/32444418/
124. Jahn, A, Rump, A, Widmann, TJ, Heining, C, Horak, P, Hutter, B, et.al. Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers., Ann Oncol, 2022. 33 (11)(11): p. 1186-1199., https://pubmed.ncbi.nlm.nih.gov/35988656/
125. Daly, MB, Pal, T, Berry, MP, Buys, SS, Dickson, P, Domchek, SM, et.al. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology., J Natl Compr Canc Netw, 2021. 19 (1)(1): p. 77-102., https://pubmed.ncbi.nlm.nih.gov/33406487/
126. Roberts, N. J., Norris, A. L., Petersen, G. M., Bondy, M. L., Brand, R., Gallinger, S., et.al. Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer, Cancer Discov, 2016. 6(2): p. 166-75., https://pubmed.ncbi.nlm.nih.gov/26658419/
127. Chaffee, K. G., Oberg, A. L., McWilliams, R. R., Majithia, N., Allen, B. A., Kidd, J., et.al. Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history, Genetics in Medicine, 2018. 20(1): p. 119-127., https://pubmed.ncbi.nlm.nih.gov/28726808/
128. Shindo, K., Yu, J., Suenaga, M., Fesharakizadeh, S., Cho, C., Macgregor-Das, A., et.al. Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma, Journal of Clinical Oncology, 2017. 35(30): p. 3382-3390., https://pubmed.ncbi.nlm.nih.gov/28767289/
129. Lowery, M. A., Wong, W., Jordan, E. J., Lee, J. W., Kemel, Y., Vijai, J., et.al. Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms, Journal of the National Cancer Institute, 2018. 110(10): p. djy024., https://pubmed.ncbi.nlm.nih.gov/29506128/
130. Wood, L. D., Yurgelun, M. B., Goggins, M. G., Genetics of Familial and Sporadic Pancreatic Cancer, Gastroenterology, 2019. 156(7): p. 2041-2055., https://pubmed.ncbi.nlm.nih.gov/30660730/
131. Yurgelun, M. B., Chittenden, A. B., Morales-Oyarvide, V., Rubinson, D. A., Dunne, R. F., Kozak, M. M., et.al. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer, Genetics in Medicine, 2019. 21(1): p. 213-223., https://pubmed.ncbi.nlm.nih.gov/29961768/
132. Bannon, S. A., Montiel, M. F., Goldstein, J. B., Dong, W., Mork, M. E., Borras, E., et.al. High Prevalence of Hereditary Cancer Syndromes and Outcomes in Adults with Early-Onset Pancreatic Cancer, Cancer Prev Res (Phila), 2018. 11(11): p. 679-686., https://www.ncbi.nlm.nih.gov/pubmed/30274973
133. Lucas, A. L., Frado, L. E., Hwang, C., Kumar, S., Khanna, L. G., Levinson, E. J., et.al. BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts, Cancer, 2014. 120(13): p. 1960-1967., https://pubmed.ncbi.nlm.nih.gov/24737347/
134. Abe, T, Blackford, AL, Tamura, K, Ford, M, McCormick, P, Chuidian, M, et.al. Deleterious Germline Mutations Are a Risk Factor for Neoplastic Progression Among High-Risk Individuals Undergoing Pancreatic Surveillance., J Clin Oncol, 2019. 37 (13)(13): p. 1070-1080., https://pubmed.ncbi.nlm.nih.gov/30883245/
135. Konings, Ingrid C. A. W., Harinck, Femme, Poley, Jan Werner, Aalfs, Cora M., van Rens, Anja, Krak, Nanda C., et.al. Prevalence and Progression of Pancreatic Cystic Precursor Lesions Differ Between Groups at High Risk of Developing Pancreatic Cancer, Pancreas, 2017. 46(1): p. 28-34., https://pubmed.ncbi.nlm.nih.gov/27846136/
136. Bjelakovic, G., Nikolova, D., Simonetti, R. G., Gluud, C., Antioxidant supplements for prevention of gastrointestinal cancers: a systematic review and meta-analysis, Lancet, 2004. 364(9441): p. 1219-28., https://pubmed.ncbi.nlm.nih.gov/15464182/
137. Coogan, P. F., Rosenberg, L., Palmer, J. R., Strom, B. L., Zauber, A. G., Stolley, P. D., et.al. Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel, Cancer Epidemiol Biomarkers Prev, 2000. 9(1): p. 119-23., https://pubmed.ncbi.nlm.nih.gov/10667472/
138. Harris, R. E., Beebe-Donk, J., Doss, H., Burr Doss, D., Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review), Oncol Rep, 2005. 13(4): p. 559-83., https://pubmed.ncbi.nlm.nih.gov/15756426/
139. Jacobs, E. J., Connell, C. J., Rodriguez, C., Patel, A. V., Calle, E. E., Thun, M. J., Aspirin use and pancreatic cancer mortality in a large United States cohort, J Natl Cancer Inst, 2004. 96(7): p. 524-8., https://pubmed.ncbi.nlm.nih.gov/15069114/
140. Hart, P. A., Chari, S. T., Is Screening for Pancreatic Cancer in High-Risk Individuals One Step Closer or a Fool's Errand?, Clin Gastroenterol Hepatol, 2019. 17(1): p. 36-38., https://www.ncbi.nlm.nih.gov/pubmed/30268560
141. Homma, T., Tsuchiya, R., The study of the mass screening of persons without symptoms and of the screening of outpatients with gastrointestinal complaints or icterus for pancreatic cancer in Japan, using CA19-9 and elastase-1 or ultrasonography, Int J Pancreatol, 1991. 9: p. 119-24., https://pubmed.ncbi.nlm.nih.gov/1744437/
142. Kim, J. E., Lee, K. T., Lee, J. K., Paik, S. W., Rhee, J. C., Choi, K. W., Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population, J Gastroenterol Hepatol, 2004. 19(2): p. 182-6., https://pubmed.ncbi.nlm.nih.gov/14731128/
143. Owens, D. K., Davidson, K. W., Krist, A. H., Barry, M. J., Cabana, M., Caughey, A. B., et.al. Screening for Pancreatic Cancer: US Preventive Services Task Force Reaffirmation Recommendation Statement, Jama, 2019. 322(5): p. 438-444., https://pubmed.ncbi.nlm.nih.gov/31386141/
144. Siegel, R. L., Miller, K. D., Jemal, A., Cancer statistics, 2019, CA Cancer J Clin, 2019. 69(1): p. 7-34., https://pubmed.ncbi.nlm.nih.gov/30620402/
145. Overbeek, Kasper A.., Goggins, Michael G., Dbouk, Mohamad, Levink, Iris J. M., Koopmann, Brechtje D. M., Chuidian, Miguel, et.al. Timeline of Development of Pancreatic Cancer and Implications for Successful Early Detection in High-Risk Individuals, Gastroenterology, 2022. 162(3): p. 772-785.e4.
146. Bartsch, DK, Matthäi, E, Mintziras, I, Bauer, C, Figiel, J, Sina-Boemers, M, et.al. The German National Case Collection for Familial Pancreatic Carcinoma (FaPaCa)—Knowledge Gained in 20 Years., Dtsch Arztebl Int, 2021. 118 (Forthcoming)(Forthcoming):, https://pubmed.ncbi.nlm.nih.gov/33531114/
147. Vasen, H, Ibrahim, I, Ponce, CG, Slater, EP, Matthäi, E, Carrato, A, et.al. Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers., J Clin Oncol, 2016. 34 (17)(17): p. 2010-9., https://pubmed.ncbi.nlm.nih.gov/27114589/
148. Antwi, SO, Fagan, SE, Chaffee, KG, Bamlet, WR, Hu, C, Polley, EC, et.al. Risk of Different Cancers Among First-degree Relatives of Pancreatic Cancer Patients: Influence of Probands' Susceptibility Gene Mutation Status., J Natl Cancer Inst, 2019. 111 (3)(3): p. 264-271., https://pubmed.ncbi.nlm.nih.gov/29982661/
149. Overbeek, KA, Levink, IJM, Koopmann, BDM, Harinck, F, Konings, ICAW, Ausems, MGEM, et.al. Long-term yield of pancreatic cancer surveillance in high-risk individuals., Gut, 2022. 71 (6)(6): p. 1152-1160., https://pubmed.ncbi.nlm.nih.gov/33820756/
150. Canto, M. I., Almario, J. A., Schulick, R. D., Yeo, C. J., Klein, A., Blackford, A., et.al. Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance, Gastroenterology, 2018. 155(3): p. 740., https://pubmed.ncbi.nlm.nih.gov/29803839/
151. Rebours, V, Boutron-Ruault, MC, Schnee, M, Férec, C, Le Maréchal, C, Hentic, O, et.al. The natural history of hereditary pancreatitis: a national series., Gut, 2009. 58 (1)(1): p. 97-103., https://pubmed.ncbi.nlm.nih.gov/18755888/
152. Canto, M. I., Goggins, M., Yeo, C. J., Griffin, C., Axilbund, J. E., Brune, K., et.al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach, Clin Gastroenterol Hepatol, 2004. 2(7): p. 606-21., https://pubmed.ncbi.nlm.nih.gov/15224285/
153. Canto, M. I., Goggins, M., Hruban, R. H., Petersen, G. M., Giardiello, F. M., Yeo, C., et.al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study, Clin Gastroenterol Hepatol, 2006. 4(6): p. 766-81; quiz 665., https://pubmed.ncbi.nlm.nih.gov/16682259/
154. Brentnall, T. A., Management strategies for patients with hereditary pancreatic cancer, Curr Treat Options Oncol, 2005. 6(5): p. 437-45., https://www.ncbi.nlm.nih.gov/pubmed/16107246
155. Kimmey, M. B., Bronner, M. P., Byrd, D. R., Brentnall, T. A., Screening and surveillance for hereditary pancreatic cancer, Gastrointest Endosc, 2002. 56(4 Suppl): p. S82-6., https://pubmed.ncbi.nlm.nih.gov/12297755/
156. Canto, MI, Hruban, RH, Fishman, EK, Kamel, IR, Schulick, R, Zhang, Z, et.al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals., Gastroenterology, 2012. 142 (4)(4): p. 796-804; quiz e14-5., https://pubmed.ncbi.nlm.nih.gov/22245846/
157. Falconi, M, Eriksson, B, Kaltsas, G, Bartsch, DK, Capdevila, J, Caplin, M, et.al. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors., Neuroendocrinology, 2016. 103 (2)(2): p. 153-71., https://pubmed.ncbi.nlm.nih.gov/26742109/
158. Canto, M. I., Harinck, F., Hruban, R. H., Offerhaus, G. J., Poley, J. W., Kamel, I., et.al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer, Gut, 2013. 62(3): p. 339-47., https://www.ncbi.nlm.nih.gov/pubmed/23135763
159. Corral, Juan E., Mareth, Karl F., Riegert-Johnson, Douglas L., Das, Ananya, Wallace, Michael B., Diagnostic Yield From Screening Asymptomatic Individuals at High Risk for Pancreatic Cancer: A Meta-analysis of Cohort Studies, Clinical Gastroenterology and Hepatology, 2019. 17(1): p. 41-53., http://dx.doi.org/10.1016/j.cgh.2018.04.065
160. Lowenfels, AB, Maisonneuve, P, Whitcomb, DC, Lerch, MM, DiMagno, EP, Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis., JAMA, 2001. 286 (2)(2): p. 169-70., https://pubmed.ncbi.nlm.nih.gov/11448279/
161. rBjornsson, E., Ismael, S., Nejdet, S., Kilander, A., Severe jaundice in Sweden in the new millennium: causes, investigations, treatment and prognosis, Scand J Gastroenterol, 2003. 38(1): p. 86-94., https://pubmed.ncbi.nlm.nih.gov/12608470/
162. Reisman, Y., Gips, C. H., Lavelle, S. M., Wilson, J. H., Clinical presentation of (subclinical) jaundice--the Euricterus project in The Netherlands. United Dutch Hospitals and Euricterus Project Management Group, Hepatogastroenterology, 1996. 43(11): p. 1190-5., https://pubmed.ncbi.nlm.nih.gov/8908550/
163. Watanabe, I., Sasaki, S., Konishi, M., Nakagohri, T., Inoue, K., Oda, T., et.al. Onset symptoms and tumor locations as prognostic factors of pancreatic cancer, Pancreas, 2004. 28(2): p. 160-5., https://pubmed.ncbi.nlm.nih.gov/15028948/
164. Mujica, V. R., Barkin, J. S., Go, V. L., Acute pancreatitis secondary to pancreatic carcinoma. Study Group Participants, Pancreas, 2000. 21(4): p. 329-32., https://pubmed.ncbi.nlm.nih.gov/11075985/
165. Balthazar, E. J., Pancreatitis associated with pancreatic carcinoma. Preoperative diagnosis: role of CT imaging in detection and evaluation, Pancreatology, 2005. 5(4-5): p. 330-44., https://pubmed.ncbi.nlm.nih.gov/16015017/
166. Adamek, H. E., Albert, J., Breer, H., Weitz, M., Schilling, D., Riemann, J. F., Pancreatic cancer detection with magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography: a prospective controlled study, Lancet, 2000. 356(9225): p. 190-3., https://pubmed.ncbi.nlm.nih.gov/10963196/
167. Hanninen, E. L., Ricke, J., Amthauer, H., Rottgen, R., Bohmig, M., Langrehr, J., et.al. Magnetic resonance cholangiopancreatography: image quality, ductal morphology, and value of additional T2- and T1-weighted sequences for the assessment of suspected pancreatic cancer, Acta Radiol, 2005. 46(2): p. 117-25., https://pubmed.ncbi.nlm.nih.gov/15902884/
168. Nazli, O., Bozdag, A. D., Tansug, T., Kir, R., Kaymak, E., The diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinoma, Hepatogastroenterology, 2000. 47(36): p. 1750-2., https://pubmed.ncbi.nlm.nih.gov/11149048/
169. Ritts, R. E., Jr., Nagorney, D. M., Jacobsen, D. J., Talbot, R. W., Zurawski, V. R., Jr., Comparison of preoperative serum CA19-9 levels with results of diagnostic imaging modalities in patients undergoing laparotomy for suspected pancreatic or gallbladder disease, Pancreas, 1994. 9(6): p. 707-16., https://pubmed.ncbi.nlm.nih.gov/7846013/
170. Tessler, D. A., Catanzaro, A., Velanovich, V., Havstad, S., Goel, S., Predictors of cancer in patients with suspected pancreatic malignancy without a tissue diagnosis, Am J Surg, 2006. 191(2): p. 191-7., https://pubmed.ncbi.nlm.nih.gov/16442944/
171. Forsmark, C. E., Lambiase, L., Vogel, S. B., Diagnosis of pancreatic cancer and prediction of unresectability using the tumor-associated antigen CA19-9, Pancreas, 1994. 9(6): p. 731-4., https://pubmed.ncbi.nlm.nih.gov/7846016/
172. Varadarajulu, S., Wallace, M. B., Applications of endoscopic ultrasonography in pancreatic cancer, Cancer Control, 2004. 11(1): p. 15-22., https://pubmed.ncbi.nlm.nih.gov/14749619/
173. Agarwal, B., Abu-Hamda, E., Molke, K. L., Correa, A. M., Ho, L., Endoscopic ultrasound-guided fine needle aspiration and multidetector spiral CT in the diagnosis of pancreatic cancer, Am J Gastroenterol, 2004. 99(5): p. 844-50., https://pubmed.ncbi.nlm.nih.gov/15128348/
174. Klapman, J. B., Chang, K. J., Lee, J. G., Nguyen, P., Negative predictive value of endoscopic ultrasound in a large series of patients with a clinical suspicion of pancreatic cancer, Am J Gastroenterol, 2005. 100(12): p. 2658-61., https://pubmed.ncbi.nlm.nih.gov/16393216/
175. David, O., Green, L., Reddy, V., Kluskens, L., Bitterman, P., Attal, H., et.al. Pancreatic masses: a multi-institutional study of 364 fine-needle aspiration biopsies with histopathologic correlation, Diagn Cytopathol, 1998. 19(6): p. 423-7., https://www.ncbi.nlm.nih.gov/pubmed/9839131
176. Bipat, S., Phoa, S. S., van Delden, O. M., Bossuyt, P. M., Gouma, D. J., Lameris, J. S., et.al. Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining resectability of pancreatic adenocarcinoma: a meta-analysis, J Comput Assist Tomogr, 2005. 29(4): p. 438-45., https://www.ncbi.nlm.nih.gov/pubmed/16012297
177. James, P. D., Meng, Z. W., Zhang, M., Belletrutti, P. J., Mohamed, R., Ghali, W., et.al. The incremental benefit of EUS for identifying unresectable disease among adults with pancreatic adenocarcinoma: A meta-analysis, PLoS One, 2017. 12(3): p. e0173687., https://pubmed.ncbi.nlm.nih.gov/28319148/
178. Krishna, Somashekar, Rao, Bhavana, Ugbarugba, Emmanuel, Shah, Zarine, Blaszczak, Alecia, Hinton, Alice, et.al. Diagnostic performance of endoscopic ultrasound for detection of pancreatic malignancy following an indeterminate multidetector CT scan: a systemic review and meta-analysis, Surgical Endoscopy, 2017. 31(11): p. 4558-4567., https://pubmed.ncbi.nlm.nih.gov/28378082/
179. D'Onofrio, M., Barbi, E., Dietrich, C. F., Kitano, M., Numata, K., Sofuni, A., et.al. Pancreatic multicenter ultrasound study (PAMUS), Eur J Radiol, 2012. 81(4): p. 630-8., https://www.ncbi.nlm.nih.gov/pubmed/21466935
180. D'Onofrio, M., de Sio, I., Mirk, P., Vidili, G., Bertolotto, M., Cantisani, V., et.al. SIUMB recommendations for focal pancreatic lesions, J Ultrasound, 2020. 23(4): p. 599-606., https://www.ncbi.nlm.nih.gov/pubmed/32886345
181. Sohal, Davendra P. S., Kennedy, Erin B., Khorana, Alok, Copur, Mehmet S., Crane, Christopher H., Garrido-Laguna, Ignacio, et.al. Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update, Journal of Clinical Oncology, 2018. 36(24): p. 2545-2556., https://pubmed.ncbi.nlm.nih.gov/29791286/
182. Sohal, Davendra P.S., Kennedy, Erin B., Cinar, Pelin, Conroy, Thierry, Copur, Mehmet S., Crane, Christopher H., et.al. Metastatic Pancreatic Cancer: ASCO Guideline Update, Journal of Clinical Oncology, 2020. 38(27): p. 3217-3230., https://ascopubs.org/doi/abs/10.1200/JCO.20.01364
183. Chew, C., O'Dwyer, P. J., The value of liver magnetic resonance imaging in patients with findings of resectable pancreatic cancer on computed tomography, Singapore Med J, 2016. 57(6): p. 334-8., https://www.ncbi.nlm.nih.gov/pubmed/27353741
184. Ito, T., Sugiura, T., Okamura, Y., Yamamoto, Y., Ashida, R., Aramaki, T., et.al. The diagnostic advantage of EOB-MR imaging over CT in the detection of liver metastasis in patients with potentially resectable pancreatic cancer, Pancreatology, 2017. 17(3): p. 451-456., https://pubmed.ncbi.nlm.nih.gov/28298257/
185. Jeon, Sun Kyung, Lee, Jeong Min, Joo, Ijin, Lee, Dong Ho, Ahn, Su Joa, Woo, Hyunsik, et.al. Magnetic resonance with diffusion-weighted imaging improves assessment of focal liver lesions in patients with potentially resectable pancreatic cancer on CT, European Radiology, 2018. 28(8): p. 3484-3493., https://pubmed.ncbi.nlm.nih.gov/29352379/
186. Kim, H. J., Park, M. S., Lee, J. Y., Han, K., Chung, Y. E., Choi, J. Y., et.al. Incremental Role of Pancreatic Magnetic Resonance Imaging after Staging Computed Tomography to Evaluate Patients with Pancreatic Ductal Adenocarcinoma, Cancer Res Treat, 2019. 51(1): p. 24-33., https://pubmed.ncbi.nlm.nih.gov/29397657/
187. Kim, H. W., Lee, J. C., Paik, K. H., Kang, J., Kim, Y. H., Yoon, Y. S., et.al. Adjunctive role of preoperative liver magnetic resonance imaging for potentially resectable pancreatic cancer, Surgery (United States), 2017. 161(6): p. 1579-1587., https://pubmed.ncbi.nlm.nih.gov/28237643/
188. Wang, L., Dong, P., Wang, W. G., Tian, B. L., Positron emission tomography modalities prevent futile radical resection of pancreatic cancer: A meta-analysis, International Journal of Surgery, 2017. 46: p. 119-125., https://pubmed.ncbi.nlm.nih.gov/28890410/
189. Ghaneh, P., Hanson, R., Titman, A., Lancaster, G., Plumpton, C., Lloyd-Williams, H., et.al. PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer, Health Technol Assess, 2018. 22(7): p. 1-114., https://www.ncbi.nlm.nih.gov/pubmed/29402376
190. Yoneyama, Tomohiro, Tateishi, Ukihide, Endo, Itaru, Inoue, Tomio, Staging accuracy of pancreatic cancer: comparison between non-contrast-enhanced and contrast-enhanced PET/CT, European Journal of Radiology, 2014. 83(10): p. 1734-1739., https://pubmed.ncbi.nlm.nih.gov/25043494/
191. Santhosh, S., Mittal, B. R., Bhasin, D. K., Rana, S. S., Gupta, R., Das, A., et.al. Fluorodeoxyglucose-positron emission tomography/computed tomography performs better than contrast-enhanced computed tomography for metastasis evaluation in the initial staging of pancreatic adenocarcinoma, Annals of Nuclear Medicine, 2017. 31(8): p. 575-581., https://pubmed.ncbi.nlm.nih.gov/28689356/
192. Rijkers, A. P., Valkema, R., Duivenvoorden, H. J., Van Eijck, C. H. J., Usefulness of F-18-fluorodeoxyglucose positron emission tomography to confirm suspected pancreatic cancer: A meta-analysis, European Journal of Surgical Oncology, 2014. 40(7): p. 794-804., https://pubmed.ncbi.nlm.nih.gov/24755095/
193. Kim, M. J., Lee, K. H., Lee, K. T., Lee, J. K., Ku, B. H., Oh, C. R., et.al. The value of positron emission tomography/computed tomography for evaluating metastatic disease in patients with pancreatic cancer, Pancreas, 2012. 41(6): p. 897-903., https://pubmed.ncbi.nlm.nih.gov/22699202/
194. Kim, H. R., Seo, M., Nah, Y. W., Park, H. W., Park, S. H., Clinical impact of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in patients with resectable pancreatic cancer: Diagnosing lymph node metastasis and predicting survival, Nuclear Medicine Communications, 2018. 39(7): p. 691-698., https://pubmed.ncbi.nlm.nih.gov/29893751/
195. Hillner, B. E., Siegel, B. A., Shields, A. F., Liu, D., Gareen, I. F., Hunt, E., et.al. Relationship between cancer type and impact of PET and PET/CT on intended management: Findings of the national oncologic PET registry, Journal of Nuclear Medicine, 2008. 49(12): p. 1928-1935., https://pubmed.ncbi.nlm.nih.gov/18997054/
196. Einersen, Peter, Epelboym, Irene, Winner, Megan D., Leung, David, Chabot, John A., Allendorf, John D., Positron emission tomography (PET) has limited utility in the staging of pancreatic adenocarcinoma, Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2014. 18(8): p. 1441-1444., https://pubmed.ncbi.nlm.nih.gov/24928186/
197. Buchs, N. C., Buhler, L., Bucher, P., Willi, J. P., Frossard, J. L., Roth, A. D., et.al. Value of contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography in detection and presurgical assessment of pancreatic cancer: a prospective study, J Gastroenterol Hepatol, 2011. 26(4): p. 657-62., https://www.ncbi.nlm.nih.gov/pubmed/21155879
198. Toft, J., Hadden, W. J., Laurence, J. M., Lam, V., Yuen, L., Janssen, A., et.al. Imaging modalities in the diagnosis of pancreatic adenocarcinoma: A systematic review and meta-analysis of sensitivity, specificity and diagnostic accuracy, Eur J Radiol, 2017. 92: p. 17-23., https://pubmed.ncbi.nlm.nih.gov/28624015/
199. Schachter, P. P., Avni, Y., Shimonov, M., Gvirtz, G., Rosen, A., Czerniak, A., The impact of laparoscopy and laparoscopic ultrasonography on the management of pancreatic cancer, Arch Surg, 2000. 135(11): p. 1303-7., https://pubmed.ncbi.nlm.nih.gov/11074885/
200. Vollmer, C. M., Drebin, J. A., Middleton, W. D., Teefey, S. A., Linehan, D. C., Soper, N. J., et.al. Utility of staging laparoscopy in subsets of peripancreatic and biliary malignancies, Ann Surg, 2002. 235(1): p. 1-7., https://pubmed.ncbi.nlm.nih.gov/11753036/
201. European Study Group on Cystic Tumours of the, Pancreas, European evidence-based guidelines on pancreatic cystic neoplasms, Gut, 2018. 67: p. 789-804., https://gut.bmj.com/content/67/5/789.long
202. van der Waaij, L. A., van Dullemen, H. M., Porte, R. J., Cyst fluid analysis in the differential diagnosis of pancreatic cystic lesions: a pooled analysis, Gastrointest Endosc, 2005. 62(3): p. 383-9., https://pubmed.ncbi.nlm.nih.gov/16111956/
203. Gillis, A., Cipollone, I., Cousins, G., Conlon, K., Does EUS-FNA molecular analysis carry additional value when compared to cytology in the diagnosis of pancreatic cystic neoplasm? A systematic review, HPB (Oxford), 2015. 17(5): p. 377-86., https://www.ncbi.nlm.nih.gov/pubmed/25428782
204. Ngamruengphong, S., Lennon, A. M., Analysis of Pancreatic Cyst Fluid, Surg Pathol Clin, 2016. 9(4): p. 677-684., https://pubmed.ncbi.nlm.nih.gov/27926366/
205. Tanaka, M., Fernández-Del Castillo, C., Kamisawa, T., Jang, J. Y., Levy, P., Ohtsuka, T., et.al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas, Pancreatology, 2017. 17(5): p. 738-753., https://pubmed.ncbi.nlm.nih.gov/28735806/
206. Marchegiani, G., Andrianello, S., Borin, A., Dal Borgo, C., Perri, G., Pollini, T., et.al. Systematic review, meta-analysis, and a high-volume center experience supporting the new role of mural nodules proposed by the updated 2017 international guidelines on IPMN of the pancreas, Surgery, 2018. 163(6): p. 1272-1279., https://pubmed.ncbi.nlm.nih.gov/29454468/
207. Han, Y., Lee, H., Kang, J. S., Kim, J. R., Kim, H. S., Lee, J. M., et.al. Progression of Pancreatic Branch Duct Intraductal Papillary Mucinous Neoplasm Associates With Cyst Size, Gastroenterology, 2018. 154(3): p. 576-584., https://www.ncbi.nlm.nih.gov/pubmed/29074452
208. Doi, R., Imamura, M., Hosotani, R., Imaizumi, T., Hatori, T., Takasaki, K., et.al. Surgery versus radiochemotherapy for resectable locally invasive pancreatic cancer: final results of a randomized multi-institutional trial, Surg Today, 2008. 38(11): p. 1021-8., https://pubmed.ncbi.nlm.nih.gov/18958561/
209. Ahola, R., Siiki, A., Vasama, K., Vornanen, M., Sand, J., Laukkarinen, J., Effect of centralization on long-term survival after resection of pancreatic ductal adenocarcinoma, Br J Surg, 2017. 104(11): p. 1532-1538., https://www.ncbi.nlm.nih.gov/pubmed/28517236
210. Alsfasser, G., Leicht, H., Gunster, C., Rau, B. M., Schillinger, G., Klar, E., Volume-outcome relationship in pancreatic surgery, Br J Surg, 2016. 103(1): p. 136-43., https://www.ncbi.nlm.nih.gov/pubmed/26505976
211. Amini, N., Spolverato, G., Kim, Y., Pawlik, T. M., Trends in Hospital Volume and Failure to Rescue for Pancreatic Surgery, J Gastrointest Surg, 2015. 19(9): p. 1581-92., https://www.ncbi.nlm.nih.gov/pubmed/25794484
212. Lidsky, M. E., Sun, Z., Nussbaum, D. P., Adam, M. A., Speicher, P. J., Blazer, D. G., 3rd, Going the Extra Mile: Improved Survival for Pancreatic Cancer Patients Traveling to High-volume Centers, Ann Surg, 2017. 266(2): p. 333-338., https://www.ncbi.nlm.nih.gov/pubmed/27429020
213. Stella, M., Bissolati, M., Gentile, D., Arriciati, A., Impact of surgical experience on management and outcome of pancreatic surgery performed in high- and low-volume centers, Updates Surg, 2017. 69(3): p. 351-358., https://www.ncbi.nlm.nih.gov/pubmed/28215039
214. van der Geest, L. G., van Rijssen, L. B., Molenaar, I. Q., de Hingh, I. H., Groot Koerkamp, B., Busch, O. R., et.al. Volume-outcome relationships in pancreatoduodenectomy for cancer, HPB (Oxford), 2016. 18(4): p. 317-24., https://www.ncbi.nlm.nih.gov/pubmed/27037200
215. Kutlu, O. C., Lee, J. E., Katz, M. H., Tzeng, C. D., Wolff, R. A., Varadhachary, G. R., et.al. Open Pancreaticoduodenectomy Case Volume Predicts Outcome of Laparoscopic Approach: A Population-based Analysis, Ann Surg, 2018. 267(3): p. 552-560., https://pubmed.ncbi.nlm.nih.gov/28045744/
216. Guller, U., Warschkow, R., Ackermann, C. J., Schmied, B., Cerny, T., Ess, S., Lower hospital volume is associated with higher mortality after oesophageal, gastric, pancreatic and rectal cancer resection, Swiss Med Wkly, 2017. 147: p. w14473., https://www.ncbi.nlm.nih.gov/pubmed/28750418
217. Gooiker, G. A., Lemmens, V. E., Besselink, M. G., Busch, O. R., Bonsing, B. A., Molenaar, I. Q., et.al. Impact of centralization of pancreatic cancer surgery on resection rates and survival, Br J Surg, 2014. 101(8): p. 1000-5., https://www.ncbi.nlm.nih.gov/pubmed/24844590
218. Derogar, M., Blomberg, J., Sadr-Azodi, O., Hospital teaching status and volume related to mortality after pancreatic cancer surgery in a national cohort, Br J Surg, 2015. 102(5): p. 548-57; discussion 557., https://www.ncbi.nlm.nih.gov/pubmed/25711855
219. Coupland, V. H., Konfortion, J., Jack, R. H., Allum, W., Kocher, H. M., Riaz, S. P., et.al. Resection rate, hospital procedure volume and survival in pancreatic cancer patients in England: Population-based study, 2005-2009, Eur J Surg Oncol, 2016. 42(2): p. 190-6., https://www.ncbi.nlm.nih.gov/pubmed/26705143
220. Brahmbhatt, B., Bhurwal, A., Lukens, F. J., Buchanan, M. A., Stauffer, J. A., Asbun, H. J., Pancreatic Surgery in the Older Population: A Single Institution's Experience over Two Decades, Curr Gerontol Geriatr Res, 2016. 2016: p. 8052175., https://www.ncbi.nlm.nih.gov/pubmed/28018428
221. Bliss, L. A., Yang, C. J., Chau, Z., Ng, S. C., McFadden, D. W., Kent, T. S., et.al. Patient selection and the volume effect in pancreatic surgery: unequal benefits?, HPB (Oxford), 2014. 16(10): p. 899-906., https://www.ncbi.nlm.nih.gov/pubmed/24905343
222. Bateni, S. B., Olson, J. L., Hoch, J. S., Canter, R. J., Bold, R. J., Drivers of Cost for Pancreatic Surgery: It's Not About Hospital Volume, Ann Surg Oncol, 2018. 25(13): p. 3804-3811., https://www.ncbi.nlm.nih.gov/pubmed/30218244
223. Balzano, G., Capretti, G., Callea, G., Cantu, E., Carle, F., Pezzilli, R., Overuse of surgery in patients with pancreatic cancer. A nationwide analysis in Italy, HPB (Oxford), 2016. 18(5): p. 470-8., https://www.ncbi.nlm.nih.gov/pubmed/27154812
224. Birkmeyer, J. D., Siewers, A. E., Finlayson, E. V., Stukel, T. A., Lucas, F. L., Batista, I., et.al. Hospital volume and surgical mortality in the United States, N Engl J Med, 2002. 346(15): p. 1128-37., https://www.ncbi.nlm.nih.gov/pubmed/11948273
225. Ansari, D., Williamsson, C., Tingstedt, B., Andersson, B., Lindell, G., Andersson, R., Pancreaticoduodenectomy-the transition from a low- to a high-volume center, Scandinavian Journal of Gastroenterology, 2014. 49(4): p. 481-484., https://pubmed.ncbi.nlm.nih.gov/24255988/
226. Healy, M. A., Krell, R. W., Abdelsattar, Z. M., McCahill, L. E., Kwon, D., Frankel, T. L., et.al. Pancreatic Resection Results in a Statewide Surgical Collaborative, Annals of Surgical Oncology, 2015. 22(8): p. 2468-2474., https://pubmed.ncbi.nlm.nih.gov/25820999/
227. Mehta, H. B., Parmar, A. D., Adhikari, D., Tamirisa, N. P., Dimou, F., Jupiter, D., et.al. Relative impact of surgeon and hospital volume on operative mortality and complications following pancreatic resection in Medicare patients, Journal of Surgical Research, 2016. 204(2): p. 326-334., https://pubmed.ncbi.nlm.nih.gov/27565068/
228. Capretti, G., Balzano, G., Gianotti, L., Stella, M., Ferrari, G., Baccari, P., et.al. Management and Outcomes of Pancreatic Resections Performed in High-Volume Referral and Low-Volume Community Hospitals Lead by Surgeons Who Shared the Same Mentor: The Importance of Training, Dig Surg, 2018. 35(1): p. 42-48., https://www.ncbi.nlm.nih.gov/pubmed/28278493
229. Nimptsch, U., Mansky, T., Hospital volume and mortality for 25 types of inpatient treatment in German hospitals: Observational study using complete national data from 2009 to 2014, BMJ Open, 2017. 7(9): p. e016184., https://pubmed.ncbi.nlm.nih.gov/28882913/
230. Krautz, C., Nimptsch, U., Weber, G. F., Mansky, T., Grutzmann, R., Effect of Hospital Volume on In-hospital Morbidity and Mortality Following Pancreatic Surgery in Germany, Annals of surgery, 2018. 267(3): p. 411-417., https://pubmed.ncbi.nlm.nih.gov/28379871/
231. Mamidanna, R., Ni, Z., Anderson, O., Spiegelhalter, S. D., Bottle, A., Aylin, P., et.al. Surgeon volume and cancer esophagectomy, gastrectomy, and pancreatectomy: A populatio n-based study in England, Annals of surgery, 2016. 263(4): p. 727-732., https://pubmed.ncbi.nlm.nih.gov/26501701/
232. Miura, F., Yamamoto, M., Gotoh, M., Konno, H., Fujimoto, J., Yanaga, K., et.al. Validation of the board certification system for expert surgeons (hepato-biliary-pancreatic field) using the data of the National Clinical Database of Japan: part 2 - Pancreatoduodenectomy, Journal of Hepato-Biliary-Pancreatic Sciences, 2016. 23(6): p. 353-363., http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed17&NEWS=N&AN=610915010
233. van der Geest, L. G., Besselink, M. G., Busch, O. R., de Hingh, I. H., van Eijck, C. H., Dejong, C. H., et.al. Elderly Patients Strongly Benefit from Centralization of Pancreatic Cancer Surgery: A Population-Based Study, Ann Surg Oncol, 2016. 23(6): p. 2002-9., https://www.ncbi.nlm.nih.gov/pubmed/26795767
234. Schwarz, R. E., Technical considerations to maintain a low frequency of postoperative biliary stent-associated infections, J Hepatobiliary Pancreat Surg, 2002. 9(1): p. 93-7., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12021902
235. Gerke, H., White, R., Byrne, M. F., Stiffier, H., Mitchell, R. M., Hurwitz, H. I., et.al. Complications of pancreaticoduodenectomy after neoadjuvant chemoradiation in patients with and without preoperative biliary drainage, Dig Liver Dis, 2004. 36(6): p. 412-8., https://www.ncbi.nlm.nih.gov/pubmed/15248382
236. Jagannath, P., Dhir, V., Shrikhande, S., Shah, R. C., Mullerpatan, P., Mohandas, K. M., Effect of preoperative biliary stenting on immediate outcome after pancreaticoduodenectomy, Br J Surg, 2005. 92(3): p. 356-61., https://pubmed.ncbi.nlm.nih.gov/15672425/
237. Martignoni, M. E., Wagner, M., Krahenbuhl, L., Redaelli, C. A., Friess, H., Buchler, M. W., Effect of preoperative biliary drainage on surgical outcome after pancreatoduodenectomy, Am J Surg, 2001. 181(1): p. 52-9; discussion 87., https://pubmed.ncbi.nlm.nih.gov/11248177/
238. Sohn, T. A., Yeo, C. J., Cameron, J. L., Pitt, H. A., Lillemoe, K. D., Do preoperative biliary stents increase postpancreaticoduodenectomy complications?, J Gastrointest Surg, 2000. 4(3): p. 258-67; discussion 267-8., https://pubmed.ncbi.nlm.nih.gov/10769088/
239. van der Gaag, N. A., Rauws, E. A., van Eijck, C. H., Bruno, M. J., van der Harst, E., Kubben, F. J., et.al. Preoperative biliary drainage for cancer of the head of the pancreas, N Engl J Med, 2010. 362(2): p. 129-37., http://www.ncbi.nlm.nih.gov/pubmed/20071702
240. Allen, VB, Gurusamy, KS, Takwoingi, Y, Kalia, A, Davidson, BR, Diagnostic accuracy of laparoscopy following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer., Cochrane Database Syst Rev, 2016. 7 (): p. CD009323., https://pubmed.ncbi.nlm.nih.gov/27383694/
241. De Rosa, A, Cameron, IC, Gomez, D, Indications for staging laparoscopy in pancreatic cancer., HPB (Oxford), 2016. 18 (1)(1): p. 13-20., https://pubmed.ncbi.nlm.nih.gov/26776846/
242. Levy, J, Tahiri, M, Vanounou, T, Maimon, G, Bergman, S, Diagnostic Laparoscopy with Ultrasound Still Has a Role in the Staging of Pancreatic Cancer: A Systematic Review of the Literature., HPB Surg, 2016. 2016 (): p. 8092109., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4829723/
243. Ta, R, O'Connor, DB, Sulistijo, A, Chung, B, Conlon, KC, The Role of Staging Laparoscopy in Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis., Dig Surg, 2019. 36 (3)(3): p. 251-260., https://pubmed.ncbi.nlm.nih.gov/29649825/
244. Isaji, S., Mizuno, S., Windsor, J. A., Bassi, C., Fernandez-Del Castillo, C., Hackert, T., et.al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017, Pancreatology, 2018. 18(1): p. 2-11., https://www.ncbi.nlm.nih.gov/pubmed/29191513
245. Wagner, M., Redaelli, C., Lietz, M., Seiler, C. A., Friess, H., Buchler, M. W., Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma, Br J Surg, 2004. 91(5): p. 586-94., https://pubmed.ncbi.nlm.nih.gov/15122610/
246. Fusai, G., Warnaar, N., Sabin, C. A., Archibong, S., Davidson, B. R., Outcome of R1 resection in patients undergoing pancreatico-duodenectomy for pancreatic cancer, Eur J Surg Oncol, 2008. 34(12): p. 1309-15., https://www.ncbi.nlm.nih.gov/pubmed/18325723
247. Gaedcke, J., Gunawan, B., Grade, M., Szoke, R., Liersch, T., Becker, H., et.al. The mesopancreas is the primary site for R1 resection in pancreatic head cancer: relevance for clinical trials, Langenbecks Arch Surg, 2010. 395(4): p. 451-8., https://www.ncbi.nlm.nih.gov/pubmed/19418067
248. Hartwig, W., Hackert, T., Hinz, U., Gluth, A., Bergmann, F., Strobel, O., et.al. Pancreatic cancer surgery in the new millennium: better prediction of outcome, Ann Surg, 2011. 254(2): p. 311-9., https://www.ncbi.nlm.nih.gov/pubmed/21606835
249. Esposito, I., Kleeff, J., Bergmann, F., Reiser, C., Herpel, E., Friess, H., et.al. Most pancreatic cancer resections are R1 resections, Ann Surg Oncol, 2008. 15(6): p. 1651-60., https://www.ncbi.nlm.nih.gov/pubmed/18351300
250. Raut, C. P., Tseng, J. F., Sun, C. C., Wang, H., Wolff, R. A., Crane, C. H., et.al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma, Ann Surg, 2007. 246(1): p. 52-60., http://www.ncbi.nlm.nih.gov/pubmed/17592291
251. Chang, D. K., Johns, A. L., Merrett, N. D., Gill, A. J., Colvin, E. K., Scarlett, C. J., et.al. Margin clearance and outcome in resected pancreatic cancer, J Clin Oncol, 2009. 27(17): p. 2855-62., https://www.ncbi.nlm.nih.gov/pubmed/19398572
252. Campbell, F., Smith, R. A., Whelan, P., Sutton, R., Raraty, M., Neoptolemos, J. P., et.al. Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin, Histopathology, 2009. 55(3): p. 277-83., https://www.ncbi.nlm.nih.gov/pubmed/19723142
253. Jamieson, N. B., Foulis, A. K., Oien, K. A., Going, J. J., Glen, P., Dickson, E. J., et.al. Positive mobilization margins alone do not influence survival following pancreatico-duodenectomy for pancreatic ductal adenocarcinoma, Ann Surg, 2010. 251(6): p. 1003-10., http://www.ncbi.nlm.nih.gov/pubmed/20485150
254. Diener Markus, K., Fitzmaurice, Christina, Schwarzer, Guido, Seiler Christoph, M., Antes, Gerd, Knaebel, Hanns-Peter, et.al. Pylorus-preserving pancreaticoduodenectomy (pp Whipple) versus pancreaticoduodenectomy (classic Whipple) for surgical treatment of periampullary and pancreatic carcinomaJohn Wiley & Sons, Ltd, Cochrane Database of Systematic Reviews, 2011., https://pubmed.ncbi.nlm.nih.gov/21563148/
255. Kawai, M., Tani, M., Hirono, S., Miyazawa, M., Shimizu, A., Uchiyama, K., et.al. Pylorus ring resection reduces delayed gastric emptying in patients undergoing pancreatoduodenectomy: a prospective, randomized, controlled trial of pylorus-resecting versus pylorus-preserving pancreatoduodenectomy, Annals of surgery, 2011. p. 495-501., https://pubmed.ncbi.nlm.nih.gov/21248633/
256. Verbeke, C. S., Resection margins and R1 rates in pancreatic cancer--are we there yet?, Histopathology, 2008. 52(7): p. 787-96., https://pubmed.ncbi.nlm.nih.gov/18081813/
257. Wittekind, C., Compton, C., Quirke, P., Nagtegaal, I., Merkel, S., Hermanek, P., et.al. A uniform residual tumor (R) classification: integration of the R classification and the circumferential margin status, Cancer, 2009. 115(15): p. 3483-8., https://pubmed.ncbi.nlm.nih.gov/19536900/
258. Gajda, M., Kenig, J., Treatment outcomes of pancreatic cancer in the elderly - literature review, Folia Med Cracov, 2018. 58(3): p. 49-66., https://www.ncbi.nlm.nih.gov/pubmed/30521511
259. Kim, S. Y., Weinberg, L., Christophi, C., Nikfarjam, M., The outcomes of pancreaticoduodenectomy in patients aged 80 or older: a systematic review and meta-analysis, HPB (Oxford), 2017. 19(6): p. 475-482., https://www.ncbi.nlm.nih.gov/pubmed/28292633
260. Sukharamwala, P., Thoens, J., Szuchmacher, M., Smith, J., DeVito, P., Advanced age is a risk factor for post-operative complications and mortality after a pancreaticoduodenectomy: a meta-analysis and systematic review, HPB (Oxford), 2012. 14(10): p. 649-57., https://www.ncbi.nlm.nih.gov/pubmed/22954000
261. van der Geest, L. G., Besselink, M. G., van Gestel, Y. R., Busch, O. R., de Hingh, I. H., de Jong, K. P., et.al. Pancreatic cancer surgery in elderly patients: Balancing between short-term harm and long-term benefit. A population-based study in the Netherlands, Acta Oncol, 2016. 55(3): p. 278-85., https://pubmed.ncbi.nlm.nih.gov/26552841/
262. Sho, M., Murakami, Y., Kawai, M., Motoi, F., Satoi, S., Matsumoto, I., et.al. Prognosis after surgical treatment for pancreatic cancer in patients aged 80 years or older: a multicenter study, J Hepatobiliary Pancreat Sci, 2016. 23(3): p. 188-97., https://www.ncbi.nlm.nih.gov/pubmed/26763744
263. Shirai, Y., Shiba, H., Horiuchi, T., Saito, N., Furukawa, K., Sakamoto, T., et.al. Assessment of Surgical Outcome After Pancreatic Resection in Extremely Elderly Patients, Anticancer Res, 2016. 36(4): p. 2011-7., https://www.ncbi.nlm.nih.gov/pubmed/27069195
264. Sahakyan, M. A., Edwin, B., Kazaryan, A. M., Barkhatov, L., Buanes, T., Ignjatovic, D., et.al. Perioperative outcomes and survival in elderly patients undergoing laparoscopic distal pancreatectomy, J Hepatobiliary Pancreat Sci, 2017. 24(1): p. 42-48., https://www.ncbi.nlm.nih.gov/pubmed/27794204
265. Renz, B. W., Khalil, P. N., Mikhailov, M., Graf, S., Schiergens, T. S., Niess, H., et.al. Pancreaticoduodenectomy for adenocarcinoma of the pancreatic head is justified in elderly patients: A Retrospective Cohort Study, Int J Surg, 2016. 28: p. 118-25., https://pubmed.ncbi.nlm.nih.gov/26906329/
266. Miyazaki, Y., Kokudo, T., Amikura, K., Kageyama, Y., Takahashi, A., Ohkohchi, N., et.al. Age does not affect complications and overall survival rate after pancreaticoduodenectomy: Single-center experience and systematic review of literature, Biosci Trends, 2016. 10(4): p. 300-6., https://pubmed.ncbi.nlm.nih.gov/27396698/
267. Hsu, C. C., Wolfgang, C. L., Laheru, D. A., Pawlik, T. M., Swartz, M. J., Winter, J. M., et.al. Early mortality risk score: identification of poor outcomes following upfront surgery for resectable pancreatic cancer, J Gastrointest Surg, 2012. 16(4): p. 753-61., https://www.ncbi.nlm.nih.gov/pubmed/22311282
268. He, W., Zhao, H., Chan, W., Lopez, D., Shroff, R. T., Giordano, S. H., Underuse of surgical resection among elderly patients with early-stage pancreatic cancer, Surgery, 2015. 158(5): p. 1226-34., https://pubmed.ncbi.nlm.nih.gov/26138347/
269. Ansari, D., Aronsson, L., Fredriksson, J., Andersson, B., Andersson, R., Safety of pancreatic resection in the elderly: a retrospective analysis of 556 patients, Ann Gastroenterol, 2016. 29(2): p. 221-5., https://www.ncbi.nlm.nih.gov/pubmed/27065736
270. Addeo, P., Delpero, J. R., Paye, F., Oussoultzoglou, E., Fuchshuber, P. R., Sauvanet, A., et.al. Pancreatic fistula after a pancreaticoduodenectomy for ductal adenocarcinoma and its association with morbidity: a multicentre study of the French Surgical Association, HPB (Oxford), 2014. 16(1): p. 46-55., https://pubmed.ncbi.nlm.nih.gov/23461663/
271. Lyu, H. G., Sharma, G., Brovman, E., Ejiofor, J., Repaka, A., Urman, R. D., et.al. Risk Factors of Reoperation After Pancreatic Resection, Dig Dis Sci, 2017. 62(6): p. 1666-1675., https://pubmed.ncbi.nlm.nih.gov/28341868/
272. Turrini, O., Paye, F., Bachellier, P., Sauvanet, A., Sa, Cunha A., Le Treut, Y. P., et.al. Pancreatectomy for adenocarcinoma in elderly patients: Postoperative outcomes and long term results: A study of the French Surgical Association, European Journal of Surgical Oncology, 2013. 39(2): p. 171-178., https://pubmed.ncbi.nlm.nih.gov/22999411/
273. Tas, F., Sen, F., Odabas, H., Kilic, L., Keskin, S., Yildiz, I., Performance status of patients is the major prognostic factor at all stages of pancreatic cancer, Int J Clin Oncol, 2013. 18(5): p. 839-46., https://www.ncbi.nlm.nih.gov/pubmed/22996141
274. Kleeff, J., Costello, E., Jackson, R., Halloran, C., Greenhalf, W., Ghaneh, P., et.al. The impact of diabetes mellitus on survival following resection and adjuvant chemotherapy for pancreatic cancer, Br J Cancer, 2016. 115(7): p. 887-94., https://pubmed.ncbi.nlm.nih.gov/27584663/
275. Feyko, J., Hazard, H., Cardinal, J., Thomay, A., Cho, S., Pancreatectomy in Patients with Impaired Renal Function: How Risky Is It?, Am Surg, 2016. 82(1): p. 16-21., https://www.ncbi.nlm.nih.gov/pubmed/26802844
276. Khorana, A. A., Mangu, P. B., Berlin, J., Engebretson, A., Hong, T. S., Maitra, A., et.al. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline, J Clin Oncol, 2016. 34(21): p. 2541-56., https://pubmed.ncbi.nlm.nih.gov/27247221/
277. Katz, Matthew H. G., Crane, Christopher H., Varadhachary, Gauri, Management of Borderline Resectable Pancreatic Cancer, Seminars in Radiation Oncology, 2014. 24(2): p. 105-112., https://pubmed.ncbi.nlm.nih.gov/24635867/
278. Allen, P. J., Kuk, D., Castillo, C. F., Basturk, O., Wolfgang, C. L., Cameron, J. L., et.al. Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients With Pancreatic Adenocarcinoma, Ann Surg, 2017. 265(1): p. 185-191., https://www.ncbi.nlm.nih.gov/pubmed/27163957
279. National Comprehensive Cancer, Network, Pancreatic Adenocarcinoma, Version 1.2020. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)NCCN, 2020., https://pubmed.ncbi.nlm.nih.gov/33845462/
280. Ferrone, C. R., Finkelstein, D. M., Thayer, S. P., Muzikansky, A., Fernandez-delCastillo, C., Warshaw, A. L., Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma, J Clin Oncol, 2006. 24(18): p. 2897-902., https://www.ncbi.nlm.nih.gov/pubmed/16782929
281. Barton, J. G., Bois, J. P., Sarr, M. G., Wood, C. M., Qin, R., Thomsen, K. M., et.al. Predictive and prognostic value of CA 19-9 in resected pancreatic adenocarcinoma, J Gastrointest Surg, 2009. 13(11): p. 2050-8., https://www.ncbi.nlm.nih.gov/pubmed/19756875
282. Hartwig, W., Strobel, O., Hinz, U., Fritz, S., Hackert, T., Roth, C., et.al. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy, Ann Surg Oncol, 2013. 20(7): p. 2188-96., https://www.ncbi.nlm.nih.gov/pubmed/23247983
283. Bergquist, John R., Puig, Carlos A., Shubert, Christopher R., Groeschl, Ryan T., Habermann, Elizabeth B., Kendrick, Michael L., et.al. Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study, Journal of the American College of Surgeons, 2016. 223(1): p. 52-65., https://pubmed.ncbi.nlm.nih.gov/27049786/
284. Michelakos, T., Pergolini, I., Castillo, C. F. D., Honselmann, K. C., Cai, L., Deshpande, V., et.al. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX, Annals of surgery, 2019. 269(4): p. 733-740., https://pubmed.ncbi.nlm.nih.gov/29227344/
285. Reni, M., Zanon, S., Balzano, G., Nobile, S., Pircher, C. C., Chiaravalli, M., et.al. Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma, Annals of Oncology, 2017. 28(11): p. 2786-2792., http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed18&NEWS=N&AN=619305107
286. Nikfarjam, M., Sehmbey, M., Kimchi, E. T., Gusani, N. J., Shereef, S., Avella, D. M., et.al. Additional organ resection combined with pancreaticoduodenectomy does not increase postoperative morbidity and mortality, J Gastrointest Surg, 2009. 13(5): p. 915-21., https://pubmed.ncbi.nlm.nih.gov/19198960/
287. Fuhrman, G. M., Leach, S. D., Staley, C. A., Cusack, J. C., Charnsangavej, C., Cleary, K. R., et.al. Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. Pancreatic Tumor Study Group, Ann Surg, 1996. 223(2): p. 154-62., https://pubmed.ncbi.nlm.nih.gov/8597509/
288. Leach, S. D., Lee, J. E., Charnsangavej, C., Cleary, K. R., Lowy, A. M., Fenoglio, C. J., et.al. Survival following pancreaticoduodenectomy with resection of the superior mesenteric-portal vein confluence for adenocarcinoma of the pancreatic head, Br J Surg, 1998. 85(5): p. 611-7., https://pubmed.ncbi.nlm.nih.gov/9635805/
289. Sasson, A. R., Hoffman, J. P., Ross, E. A., Kagan, S. A., Pingpank, J. F., Eisenberg, B. L., En bloc resection for locally advanced cancer of the pancreas: is it worthwhile?, J Gastrointest Surg, 2002. 6(2): p. 147-57; discussion 157-8., https://pubmed.ncbi.nlm.nih.gov/11992799/
290. Nakao, A., Takeda, S., Inoue, S., Nomoto, S., Kanazumi, N., Sugimoto, H., et.al. Indications and techniques of extended resection for pancreatic cancer, World J Surg, 2006. 30(6): p. 976-82; discussion 983-4., https://pubmed.ncbi.nlm.nih.gov/16736324/
291. Shrikhande, S. V., Kleeff, J., Reiser, C., Weitz, J., Hinz, U., Esposito, I., et.al. Pancreatic resection for M1 pancreatic ductal adenocarcinoma, Ann Surg Oncol, 2007. 14(1): p. 118-27., http://www.ncbi.nlm.nih.gov/pubmed/17066229
292. Burdelski, C. M., Reeh, M., Bogoevski, D., Gebauer, F., Tachezy, M., Vashist, Y. K., et.al. Multivisceral resections in pancreatic cancer: identification of risk factors, World J Surg, 2011. 35(12): p. 2756-63., https://pubmed.ncbi.nlm.nih.gov/21938586/
293. Hartwig, W., Hackert, T., Hinz, U., Hassenpflug, M., Strobel, O., Buchler, M. W., et.al. Multivisceral resection for pancreatic malignancies: risk-analysis and long-term outcome, Ann Surg, 2009. 250(1): p. 81-7., https://pubmed.ncbi.nlm.nih.gov/19561478/
294. Takaori, K., Bassi, C., Biankin, A., Brunner, T. B., Cataldo, I., Campbell, F., et.al. International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer, Pancreatology, 2016. 16(1): p. 14-27., https://pubmed.ncbi.nlm.nih.gov/26699808/
295. Al-Hawary, M. M., Francis, I. R., Chari, S. T., Fishman, E. K., Hough, D. M., Lu, D. S., et.al. Pancreatic ductal adenocarcinoma radiology reporting template: Consensus statement of the society of abdominal radiology and the american pancreatic association, Radiology, 2014. 270(1): p. 248-260., https://pubmed.ncbi.nlm.nih.gov/24355035/
296. Persigehl, T., Baumhauer, M., Baessler, B., Beyer, L. P., Bludau, M., Bruns, C., et.al. Structured Reporting of Solid and Cystic Pancreatic Lesions in CT and MRI: Consensus-Based Structured Report Templates of the German Society of Radiology (DRG), Rofo, 2020. 192(7): p. 641-656., https://www.ncbi.nlm.nih.gov/pubmed/32615626
297. Wittel, U. A., Lubgan, D., Ghadimi, M., Belyaev, O., Uhl, W., Bechstein, W. O., et.al. Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma – results of the Conko-007 multicenter trial, BMC Cancer, 2019. 19(1): p. 979., https://pubmed.ncbi.nlm.nih.gov/31640628/
298. ZfKD, GEKID, Krebs in Deutschland, Bauchspeicheldrüse, 2016., https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2019/kid_2019_c25_bauchspeicheldruese.pdf?__blob=publicationFile
299. Agalianos, C., Gouvas, N., Papaparaskeva, K., Dervenis, C., Positive para-aortic lymph nodes following pancreatectomy for pancreatic cancer. Systematic review and meta-analysis of impact on short term survival and association with clinicopathologic features, HPB (Oxford), 2016. 18(8): p. 633-41., https://pubmed.ncbi.nlm.nih.gov/27485057/
300. Cao, F., Li, J., Li, A., Li, F., Prognostic significance of positive peritoneal cytology in resectable pancreatic cancer: A systemic review and metaanalysis, Oncotarget, 2017. 8(9): p. 15004-15013., https://pubmed.ncbi.nlm.nih.gov/28122342/
301. Gebauer, F., Damanakis, A. I., Bruns, C., [Oligometastasis in pancreatic cancer : Current state of knowledge and spectrum of local therapy], Chirurg, 2018. 89(7): p. 510-515., https://www.ncbi.nlm.nih.gov/pubmed/29557488
302. Michalski, C. W., Erkan, M., Huser, N., Muller, M. W., Hartel, M., Friess, H., et.al. Resection of primary pancreatic cancer and liver metastasis: a systematic review, Dig Surg, 2008. 25(6): p. 473-80., http://www.ncbi.nlm.nih.gov/pubmed/19212120
303. Crippa, S., Bittoni, A., Sebastiani, E., Partelli, S., Zanon, S., Lanese, A., et.al. Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy?, European Journal of Surgical Oncology, 2016. 42(10): p. 1533-1539., https://pubmed.ncbi.nlm.nih.gov/27423449/
304. Hempel, S., Plodeck, V., Mierke, F., Distler, M., Aust, D. E., Saeger, H. D., et.al. Para-aortic lymph node metastases in pancreatic cancer should not be considered a watershed for curative resection, Scientific reports, 2017. 7(1): p. 7688., http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emexb&NEWS=N&AN=626324641
305. Kim, Y., Kim, S. C., Song, K. B., Kim, J., Kang, D. R., Lee, J. H., et.al. Improved survival after palliative resection of unsuspected stage IV pancreatic ductal adenocarcinoma, HPB, 2016. 18(4): p. 325-331., https://pubmed.ncbi.nlm.nih.gov/27037201/
306. Klaiber, U., Schnaidt, E. S., Hinz, U., Gaida, M. M., Heger, U., Hank, T., et.al. Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer, Annals of surgery, 2019., https://pubmed.ncbi.nlm.nih.gov/30921051/
307. Lowder, C. Y., Metkus, J., Epstein, J., Kozak, G. M., Lavu, H., Yeo, C. J., et.al. Clinical Implications of Extensive Lymph Node Metastases for Resected Pancreatic Cancer, Annals of Surgical Oncology, 2018. 25(13): p. 4004-4011., https://pubmed.ncbi.nlm.nih.gov/30225835/
308. Philips, Prejesh, Dunki-Jacobs, Erik, Agle, Steven C., Scoggins, Charles, McMasters, Kelly M., Martin, Robert C. G., The role of hepatic artery lymph node in pancreatic adenocarcinoma: prognostic factor or a selection criterion for surgery, HPB : the official journal of the International Hepato Pancreato Biliary Association, 2014. 16(12): p. 1051-1055., https://pubmed.ncbi.nlm.nih.gov/25123504/
309. Shi, H. J., Jin, C., Fu, D. L., Preoperative evaluation of pancreatic ductal adenocarcinoma with synchronous liver metastasis: Diagnosis and assessment of unresectability, World Journal of Gastroenterology, 2016. 22(45): p. 10024-10037., https://pubmed.ncbi.nlm.nih.gov/28018110/
310. Tachezy, Michael, Gebauer, Florian, Janot, Monika, Uhl, Waldemar, Zerbi, Alessandro, Montorsi, Marco, et.al. Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis, Surgery (United States), 2016. 160(1): p. 136-144., https://pubmed.ncbi.nlm.nih.gov/27048934/
311. Gleisner, A. L., Assumpcao, L., Cameron, J. L., Wolfgang, C. L., Choti, M. A., Herman, J. M., et.al. Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified?, Cancer, 2007. 110(11): p. 2484-2492., https://pubmed.ncbi.nlm.nih.gov/17941009/
312. Takada, T., Yasuda, H., Amano, H., Yoshida, M., Uchida, T., Simultaneous hepatic resection with pancreato-duodenectomy for metastatic pancreatic head carcinoma: does it improve survival?, Hepatogastroenterology, 1997. 44(14): p. 567-73., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9164539
313. Massucco, P., Ribero, D., Sgotto, E., Mellano, A., Muratore, A., Capussotti, L., Prognostic significance of lymph node metastases in pancreatic head cancer treated with extended lymphadenectomy: not just a matter of numbers, Ann Surg Oncol, 2009. 16(12): p. 3323-32., http://www.ncbi.nlm.nih.gov/pubmed/19777195
314. Doi, R., Kami, K., Ito, D., Fujimoto, K., Kawaguchi, Y., Wada, M., et.al. Prognostic implication of para-aortic lymph node metastasis in resectable pancreatic cancer, World J Surg, 2007. 31(1): p. 147-54., https://www.ncbi.nlm.nih.gov/pubmed/17171496
315. Kanda, M., Fujii, T., Nagai, S., Kodera, Y., Kanzaki, A., Sahin, T. T., et.al. Pattern of lymph node metastasis spread in pancreatic cancer, Pancreas, 2011. 40(6): p. 951-955., http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L51335124, http://dx.doi.org/10.1097/MPA.0b013e3182148342
316. Cordera, F., Arciero, C. A., Li, T., Watson, J. C., Hoffman, J. P., Significance of common hepatic artery lymph node metastases during pancreaticoduodenectomy for pancreatic head adenocarcinoma, Ann Surg Oncol, 2007. 14(8): p. 2330-6., https://www.ncbi.nlm.nih.gov/pubmed/17492334
317. Yamada, S., Nakao, A., Fujii, T., Sugimoto, H., Kanazumi, N., Nomoto, S., et.al. Pancreatic cancer with paraaortic lymph node metastasis: a contraindication for radical surgery?, Pancreas, 2009. 38(1): p. e13-7., https://pubmed.ncbi.nlm.nih.gov/18797422/
318. Tao, L., Yuan, C., Ma, Z., Jiang, B., Xiu, D., Surgical resection of a primary tumor improves survival of metastatic pancreatic cancer: A population-based study, Cancer Management and Research, 2017. 9: p. 471-479., https://pubmed.ncbi.nlm.nih.gov/29056856/
319. Liu, X., Fu, Y., Chen, Q., Wu, J., Gao, W., Jiang, K., et.al. Predictors of distant metastasis on exploration in patients with potentially resectable pancreatic cancer, BMC Gastroenterology, 2018. 18(1): p. 168., https://pubmed.ncbi.nlm.nih.gov/30400836/
320. Murakami, Y., Uemura, K., Sudo, T., Hashimoto, Y., Yuasa, Y., Sueda, T., Prognostic impact of para-aortic lymph node metastasis in pancreatic ductal adenocarcinoma, World J Surg, 2010. 34(8): p. 1900-7., http://www.ncbi.nlm.nih.gov/pubmed/20376442
321. Hackert, T., Niesen, W., Hinz, U., Tjaden, C., Strobel, O., Ulrich, A., et.al. Radical surgery of oligometastatic pancreatic cancer, Eur J Surg Oncol, 2017. 43(2): p. 358-363., https://www.ncbi.nlm.nih.gov/pubmed/27856064
322. Yang, J., Zhang, J., Lui, W., Huo, Y., Fu, X., Yang, M., et.al. Patients with hepatic oligometastatic pancreatic body/tail ductal adenocarcinoma may benefit from synchronous resection, HPB (Oxford), 2020. 22(1): p. 91-101., https://pubmed.ncbi.nlm.nih.gov/31262486/
323. Damanakis, A. I., Ostertag, L., Waldschmidt, D., Kutting, F., Quaas, A., Plum, P., et.al. Proposal for a definition of "Oligometastatic disease in pancreatic cancer", BMC Cancer, 2019. 19(1): p. 1261., https://www.ncbi.nlm.nih.gov/pubmed/31888547
324. Kandel, P., Wallace, M. B., Stauffer, J., Bolan, C., Raimondo, M., Woodward, T. A., et.al. Survival of Patients with Oligometastatic Pancreatic Ductal Adenocarcinoma Treated with Combined Modality Treatment Including Surgical Resection: A Pilot Study, Journal of Pancreatic Cancer, 2018. 4(1): p. 88-94., https://pubmed.ncbi.nlm.nih.gov/30631861/
325. Antoniou, E., Margonis, G. A., Sasaki, K., Andreatos, N., Polychronidis, G., Pawlik, T. M., et.al. Is resection of pancreatic adenocarcinoma with synchronous hepatic metastasis justified? A review of current literature, ANZ journal of surgery, 2016. 86(12): p. 973-977., http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed17&NEWS=N&AN=614761362
326. Oweira, H., Petrausch, U., Helbling, D., Schmidt, J., Mannhart, M., Mehrabi, A., et.al. Prognostic value of site-specific metastases in pancreatic adenocarcinoma: A Surveillance Epidemiology and End Results database analysis, World J Gastroenterol, 2017. 23(10): p. 1872-1880., https://pubmed.ncbi.nlm.nih.gov/28348494/
327. Lovecek, M., Skalicky, P., Chudacek, J., Szkorupa, M., Svebisova, H., Lemstrova, R., et.al. Different clinical presentations of metachronous pulmonary metastases after resection of pancreatic ductal adenocarcinoma: Retrospective study and review of the literature, World Journal of Gastroenterology, 2017. 23(35): p. 6420-6428., http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed18&NEWS=N&AN=618507189
328. Liu, Keng-Hao, Hung, Chia-Yen, Hsueh, Shu-Wen, Chang, Pei-Hung, Chen, Yen-Yang, Lu, Chang-Hsien, et.al. Lung Metastases in Patients with Stage IV Pancreatic Cancer: Prevalence, Risk Factors, and Survival Impact, Journal of clinical medicine, 2019. 8(9): p. 1402., https://pubmed.ncbi.nlm.nih.gov/31500146/
329. Ilmer, Matthias, Schiergens, Tobias S., Renz, Bernhard W., Schneider, Christian, Sargut, Mine, Waligora, Rita, et.al. Oligometastatic pulmonary metastasis in pancreatic cancer patients: Safety and outcome of resection, Surgical Oncology, 2019. 31: p. 16-21., http://www.sciencedirect.com/science/article/pii/S096074041930074X
330. Liu, Q., Zhang, R., Michalski, C. W., Liu, B., Liao, Q., Kleeff, J., Surgery for synchronous and metachronous single-organ metastasis of pancreatic cancer: a SEER database analysis and systematic literature review, Sci Rep, 2020. 10(1): p. 4444., https://www.ncbi.nlm.nih.gov/pubmed/32157155
331. Sakaguchi, T., Valente, R., Tanaka, K., Satoi, S., Del Chiaro, M., Surgical treatment of metastatic pancreatic ductal adenocarcinoma: A review of current literature, Pancreatology, 2019. 19(5): p. 672-680., https://www.ncbi.nlm.nih.gov/pubmed/31285145
332. Schwarz, M., Isenmann, R., Thomsen, J., Gaus, W., Beger, H. G., Efficacy of oral ofloxacin for single-dose perioperative prophylaxis in general surgery--a controlled randomized clinical study, Langenbecks Arch Surg, 2001. 386(6): p. 397-401., http://www.ncbi.nlm.nih.gov/pubmed/11735011
333. Targarona, E. M., Garau, J., Munoz-Ramos, C., Roset, F., Lite, J., Matas, E., et.al. Single-dose antibiotic prophylaxis in patients at high risk for infection in biliary surgery: a prospective and randomized study comparing cefonicid with mezlocillin, Surgery, 1990. 107(3): p. 327-34., https://pubmed.ncbi.nlm.nih.gov/2106732/
334. Kujath, P., Bouchard, R., Scheele, J., Esnaashari, H., [Current perioperative antibiotic prophylaxis], Chirurg, 2006. 77(6): p. 490, 492-8., https://pubmed.ncbi.nlm.nih.gov/16773347/
335. Barnett, S. P., Hodul, P. J., Creech, S., Pickleman, J., Arahna, G. V., Octreotide does not prevent postoperative pancreatic fistula or mortality following Pancreaticoduodenectomy, Am Surg, 2004. 70(3): p. 222-6; discussion 227., https://www.ncbi.nlm.nih.gov/pubmed/15055845
336. Friess, H., Buchler, M. W., Efficacy of somatostatin and its analogues in pancreatic surgery and pancreatic disorders, Digestion, 1996. 57 Suppl 1: p. 97-102., https://www.ncbi.nlm.nih.gov/pubmed/8813484
337. Gouillat, C., Chipponi, J., Baulieux, J., Partensky, C., Saric, J., Gayet, B., Randomized controlled multicentre trial of somatostatin infusion after pancreaticoduodenectomy, Br J Surg, 2001. 88(11): p. 1456-62., https://www.ncbi.nlm.nih.gov/pubmed/11683740
338. Hesse, U. J., DeDecker, C., Houtmeyers, P., Demetter, P., Ceelen, W., Pattyn, P., et.al. Prospectively randomized trial using perioperative low-dose octreotide to prevent organ-related and general complications after pancreatic surgery and pancreatico-jejunostomy, World J Surg, 2005. 29(10): p. 1325-8., http://www.ncbi.nlm.nih.gov/pubmed/16132406
339. Montorsi, M., Zago, M., Mosca, F., Capussotti, L., Zotti, E., Ribotta, G., et.al. Efficacy of octreotide in the prevention of pancreatic fistula after elective pancreatic resections: a prospective, controlled, randomized clinical trial, Surgery, 1995. 117(1): p. 26-31., http://www.ncbi.nlm.nih.gov/pubmed/7809832
340. Pederzoli, P., Bassi, C., Falconi, M., Camboni, M. G., Efficacy of octreotide in the prevention of complications of elective pancreatic surgery. Italian Study Group, Br J Surg, 1994. 81(2): p. 265-9., http://www.ncbi.nlm.nih.gov/pubmed/8156354
341. Yeo, C. J., Cameron, J. L., Lillemoe, K. D., Sauter, P. K., Coleman, J., Sohn, T. A., et.al. Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial, Ann Surg, 2000. 232(3): p. 419-29., https://pubmed.ncbi.nlm.nih.gov/10973392/
342. Connor, S., Alexakis, N., Garden, O. J., Leandros, E., Bramis, J., Wigmore, S. J., Meta-analysis of the value of somatostatin and its analogues in reducing complications associated with pancreatic surgery, Br J Surg, 2005. 92(9): p. 1059-67., https://www.ncbi.nlm.nih.gov/pubmed/16044410
343. Konishi, M., Kinoshita, T., Nakagohri, T., Inoue, K., Oda, T., Takahashi, S., Prognostic value of cytologic examination of peritoneal washings in pancreatic cancer, Arch Surg, 2002. 137(4): p. 475-80., https://pubmed.ncbi.nlm.nih.gov/11926958/
344. Yachida, S., Fukushima, N., Sakamoto, M., Matsuno, Y., Kosuge, T., Hirohashi, S., Implications of peritoneal washing cytology in patients with potentially resectable pancreatic cancer, Br J Surg, 2002. 89(5): p. 573-8., https://pubmed.ncbi.nlm.nih.gov/11972546/
345. Heeckt, P., Safi, F., Binder, T., Buchler, M., [Free intraperitoneal tumors cells in pancreatic cancer--significance for clinical course and therapy], Chirurg, 1992. 63(7): p. 563-7., https://pubmed.ncbi.nlm.nih.gov/1380421/
346. Kinoshita, T., Ozaki, H., Kosuge, T., Shimada, K., [Effectiveness of intraoperative cytological examination of peritoneal washings for patients with pancreatic cancer], Nihon Geka Gakkai Zasshi, 1992. 93(11): p. 1410-5., https://pubmed.ncbi.nlm.nih.gov/1448048/
347. Makary, M. A., Warshaw, A. L., Centeno, B. A., Willet, C. G., Rattner, D. W., Fernandez-del Castillo, C., Implications of peritoneal cytology for pancreatic cancer management, Arch Surg, 1998. 133(4): p. 361-5., https://pubmed.ncbi.nlm.nih.gov/9565114/
348. Nakao, A., Oshima, K., Takeda, S., Kaneko, T., Kanazumi, N., Inoue, S., et.al. Peritoneal washings cytology combined with immunocytochemical staining in pancreatic cancer, Hepatogastroenterology, 1999. 46(29): p. 2974-7., https://pubmed.ncbi.nlm.nih.gov/10576385/
349. Warshaw, A. L., Implications of peritoneal cytology for staging of early pancreatic cancer, Am J Surg, 1991. 161(1): p. 26-9; discussion 29-30., https://pubmed.ncbi.nlm.nih.gov/1824810/
350. Bachellier, P., Nakano, H., Oussoultzoglou, P. D., Weber, J. C., Boudjema, K., Wolf, P. D., et.al. Is pancreaticoduodenectomy with mesentericoportal venous resection safe and worthwhile?, Am J Surg, 2001. 182(2): p. 120-9., https://www.ncbi.nlm.nih.gov/pubmed/11574081
351. Bassi, C., Stocken, D. D., Olah, A., Friess, H., Buckels, J., Hickey, H., et.al. Influence of surgical resection and post-operative complications on survival following adjuvant treatment for pancreatic cancer in the ESPAC-1 randomized controlled trial, Dig Surg, 2005. 22(5): p. 353-63., https://www.ncbi.nlm.nih.gov/pubmed/16293966
352. Capussotti, L., Massucco, P., Ribero, D., Vigano, L., Muratore, A., Calgaro, M., Extended lymphadenectomy and vein resection for pancreatic head cancer: outcomes and implications for therapy, Arch Surg, 2003. 138(12): p. 1316-22., https://www.ncbi.nlm.nih.gov/pubmed/14662531
353. Farnell, M. B., Pearson, R. K., Sarr, M. G., DiMagno, E. P., Burgart, L. J., Dahl, T. R., et.al. A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma, Surgery, 2005. 138(4): p. 618-28; discussion 628-30., https://www.ncbi.nlm.nih.gov/pubmed/16269290
354. Fernandez-del Castillo, C., Rattner, D. W., Warshaw, A. L., Standards for pancreatic resection in the 1990s, Arch Surg, 1995. 130(3): p. 295-9; discussion 299-300., https://www.ncbi.nlm.nih.gov/pubmed/7887797
355. Hartel, M., Niedergethmann, M., Farag-Soliman, M., Sturm, J. W., Richter, A., Trede, M., et.al. Benefit of venous resection for ductal adenocarcinoma of the pancreatic head, Eur J Surg, 2002. 168(12): p. 707-12., https://www.ncbi.nlm.nih.gov/pubmed/15362580
356. Ishikawa, O., Ohigashi, H., Sasaki, Y., Kabuto, T., Furukawa, H., Nakamori, S., et.al. Practical grouping of positive lymph nodes in pancreatic head cancer treated by an extended pancreatectomy, Surgery, 1997. 121(3): p. 244-9., http://www.ncbi.nlm.nih.gov/pubmed/9068665
357. Jurowich, C., Meyer, W., Adamus, R., Kaiser, A., [Portal vein resection in the framework of surgical therapy of pancreatic head carcinoma: clarification of indication by improved preoperative diagnostic procedures?], Chirurg, 2000. 71(7): p. 803-7., http://www.ncbi.nlm.nih.gov/pubmed/10986602
358. Kawarada, Y., Yokoi, H., Isaji, S., Naganuma, T., Tabata, M., Machishi, H., et.al. Modified standard pancreaticoduodenectomy for the treatment of pancreatic head cancer, Digestion, 1999. 60 Suppl 1: p. 120-5., http://www.ncbi.nlm.nih.gov/pubmed/10026445
359. Klempnauer, J., Ridder, G. J., Bektas, H., Pichlmayr, R., Extended resections of ductal pancreatic cancer--impact on operative risk and prognosis, Oncology, 1996. 53(1): p. 47-53., http://www.ncbi.nlm.nih.gov/pubmed/8570131
360. Klinkenbijl, J. H., van der Schelling, G. P., Hop, W. C., van Pel, R., Bruining, H. A., Jeekel, J., The advantages of pylorus-preserving pancreatoduodenectomy in malignant disease of the pancreas and periampullary region, Ann Surg, 1992. 216(2): p. 142-5., http://www.ncbi.nlm.nih.gov/pubmed/1354435
361. Kremer, B., Vogel, I., Luttges, J., Kloppel, G., Henne-Bruns, D., Surgical possibilities for pancreatic cancer: extended resection, Ann Oncol, 1999. 10 Suppl 4: p. 252-6., http://www.ncbi.nlm.nih.gov/pubmed/10436834
362. Lin, P. W., Shan, Y. S., Lin, Y. J., Hung, C. J., Pancreaticoduodenectomy for pancreatic head cancer: PPPD versus Whipple procedure, Hepatogastroenterology, 2005. 52(65): p. 1601-4., http://www.ncbi.nlm.nih.gov/pubmed/16201125
363. Lygidakis, N. J., Singh, G., Bardaxoglou, E., Dedemadi, G., Sgourakis, G., Nestoridis, J., et.al. Mono-bloc total spleno-pancreaticoduodenectomy for pancreatic head carcinoma with portal-mesenteric venous invasion. A prospective randomized study, Hepatogastroenterology, 2004. 51(56): p. 427-33., http://www.ncbi.nlm.nih.gov/pubmed/15086174
364. Mu, D. Q., Peng, S. Y., Wang, G. F., Extended radical operation of pancreatic head cancer: appraisal of its clinical significance, World J Gastroenterol, 2005. 11(16): p. 2467-71., http://www.ncbi.nlm.nih.gov/pubmed/15832419
365. Nakao, A., Takeda, S., Sakai, M., Kaneko, T., Inoue, S., Sugimoto, H., et.al. Extended radical resection versus standard resection for pancreatic cancer: the rationale for extended radical resection, Pancreas, 2004. 28(3): p. 289-92., http://www.ncbi.nlm.nih.gov/pubmed/15084973
366. Pedrazzoli, S., DiCarlo, V., Dionigi, R., Mosca, F., Pederzoli, P., Pasquali, C., et.al. Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group, Ann Surg, 1998. 228(4): p. 508-17., https://pubmed.ncbi.nlm.nih.gov/9790340/
367. Roher, H. D., Heise, J. W., Goretzki, P. E., [Stomach saving duodenopancreatectomy. Indications and contraindications. The most important surgical steps], Zentralbl Chir, 2000. 125(12): p. 961-5., http://www.ncbi.nlm.nih.gov/pubmed/11190613
368. Schafer, M., Mullhaupt, B., Clavien, P. A., Evidence-based pancreatic head resection for pancreatic cancer and chronic pancreatitis, Ann Surg, 2002. 236(2): p. 137-48., http://www.ncbi.nlm.nih.gov/pubmed/12170018
369. Takada, T., Yasuda, H., Amano, H., Yoshida, M., Ando, H., Results of a pylorus-preserving pancreatoduodenectomy for pancreatic cancer: a comparison with results of the Whipple procedure, Hepatogastroenterology, 1997. 44(18): p. 1536-40., http://www.ncbi.nlm.nih.gov/pubmed/9427018
370. Tran, K. T., Smeenk, H. G., van Eijck, C. H., Kazemier, G., Hop, W. C., Greve, J. W., et.al. Pylorus preserving pancreaticoduodenectomy versus standard Whipple procedure: a prospective, randomized, multicenter analysis of 170 patients with pancreatic and periampullary tumors, Ann Surg, 2004. 240(5): p. 738-45., http://www.ncbi.nlm.nih.gov/pubmed/15492552
371. Tseng, J. F., Raut, C. P., Lee, J. E., Pisters, P. W., Vauthey, J. N., Abdalla, E. K., et.al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration, J Gastrointest Surg, 2004. 8(8): p. 935-49; discussion 949-50., http://www.ncbi.nlm.nih.gov/pubmed/15585381
372. Zerbi, A., Balzano, G., Patuzzo, R., Calori, G., Braga, M., Di Carlo, V., Comparison between pylorus-preserving and Whipple pancreatoduodenectomy, Br J Surg, 1995. 82(7): p. 975-9., https://pubmed.ncbi.nlm.nih.gov/7648124/
373. Diener, M. K., Knaebel, H. P., Heukaufer, C., Antes, G., Buchler, M. W., Seiler, C. M., A systematic review and meta-analysis of pylorus-preserving versus classical pancreaticoduodenectomy for surgical treatment of periampullary and pancreatic carcinoma, Ann Surg, 2007. 245(2): p. 187-200., https://pubmed.ncbi.nlm.nih.gov/17245171/
374. Christein, J. D., Kendrick, M. L., Iqbal, C. W., Nagorney, D. M., Farnell, M. B., Distal pancreatectomy for resectable adenocarcinoma of the body and tail of the pancreas, J Gastrointest Surg, 2005. 9(7): p. 922-7., https://www.ncbi.nlm.nih.gov/pubmed/16137585
375. Gebhardt, C., Meyer, W., Jurowich, C., [Is resection of left-sided ductal pancreatic carcinoma of value?]], Zentralbl Chir, 2000. 125(12): p. 966-9., https://www.ncbi.nlm.nih.gov/pubmed/11190614
376. Kayahara, M., Nagakawa, T., Ueno, K., Ohta, T., Kitagawa, H., Arakawa, H., et.al. Distal pancreatectomy--does it have a role for pancreatic body and tail cancer, Hepatogastroenterology, 1998. 45(21): p. 827-32., http://www.ncbi.nlm.nih.gov/pubmed/9684142
377. Mayumi, T., Nimura, Y., Kamiya, J., Kondo, S., Nagino, M., Kanai, M., et.al. Distal pancreatectomy with en bloc resection of the celiac artery for carcinoma of the body and tail of the pancreas, Int J Pancreatol, 1997. 22(1): p. 15-21., http://www.ncbi.nlm.nih.gov/pubmed/9387020
378. Shimada, K., Sakamoto, Y., Sano, T., Kosuge, T., Prognostic factors after distal pancreatectomy with extended lymphadenectomy for invasive pancreatic adenocarcinoma of the body and tail, Surgery, 2006. 139(3): p. 288-95., https://pubmed.ncbi.nlm.nih.gov/16546491/
379. Shoup, M., Conlon, K. C., Klimstra, D., Brennan, M. F., Is extended resection for adenocarcinoma of the body or tail of the pancreas justified?, J Gastrointest Surg, 2003. 7(8): p. 946-52; discussion 952., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14675703
380. Kondo, S., Katoh, H., Hirano, S., Ambo, Y., Tanaka, E., Okushiba, S., et.al. Results of radical distal pancreatectomy with en bloc resection of the celiac artery for locally advanced cancer of the pancreatic body, Langenbecks Arch Surg, 2003. 388(2): p. 101-6., http://www.ncbi.nlm.nih.gov/pubmed/12684805
381. Choi, SB, Han, HJ, Park, P, Kim, WB, Song, TJ, Choi, SY, Systematic review of the clinical significance of lymph node micrometastases of pancreatic adenocarcinoma following surgical resection., Pancreatology, 2017. 17 (3)(3): p. 342-349., https://pubmed.ncbi.nlm.nih.gov/28336226/
382. Dasari, BV, Pasquali, S, Vohra, RS, Smith, AM, Taylor, MA, Sutcliffe, RP, et.al. Extended Versus Standard Lymphadenectomy for Pancreatic Head Cancer: Meta-Analysis of Randomized Controlled Trials., J Gastrointest Surg, 2015. 19 (9)(9): p. 1725-32., https://pubmed.ncbi.nlm.nih.gov/26055135/
383. Elshaer, M, Gravante, G, Kosmin, M, Riaz, A, Al-Bahrani, A, A systematic review of the prognostic value of lymph node ratio, number of positive nodes and total nodes examined in pancreatic ductal adenocarcinoma., Ann R Coll Surg Engl, 2017. 99 (2)(2): p. 101-106., https://pubmed.ncbi.nlm.nih.gov/27869496/
384. Karjol, U, Chandranath, A, Jonnada, P, Cherukuru, S, Annavarjula, V, Morla, SA, Lymph Node Ratio as a Prognostic Marker in Pancreatic Cancer Survival: A Systematic Review and Meta-Analysis., Cureus, 2020. 12 (8)(8): p. e9597., https://pubmed.ncbi.nlm.nih.gov/32789099/
385. Ke, K, Chen, W, Chen, Y, Standard and extended lymphadenectomy for adenocarcinoma of the pancreatic head: a meta-analysis and systematic review., J Gastroenterol Hepatol, 2014. 29 (3)(3): p. 453-62., https://pubmed.ncbi.nlm.nih.gov/24164704/
386. Kotb, A, Hajibandeh, S, Hajibandeh, S, Satyadas, T, Meta-analysis and trial sequential analysis of randomised controlled trials comparing standard versus extended lymphadenectomy in pancreatoduodenectomy for adenocarcinoma of the head of pancreas., Langenbecks Arch Surg, 2021. 406 (3)(3): p. 547-561., https://pubmed.ncbi.nlm.nih.gov/32978673/
387. Orci, LA, Meyer, J, Combescure, C, Bühler, L, Berney, T, Morel, P, et.al. A meta-analysis of extended versus standard lymphadenectomy in patients undergoing pancreatoduodenectomy for pancreatic adenocarcinoma., HPB (Oxford), 2015. 17 (7)(7): p. 565-72., https://pubmed.ncbi.nlm.nih.gov/25913578/
388. Pedrazzoli, S, Extent of lymphadenectomy to associate with pancreaticoduodenectomy in patients with pancreatic head cancer for better tumor staging., Cancer Treat Rev, 2015. 41 (7)(7): p. 577-87., https://pubmed.ncbi.nlm.nih.gov/26045226/
389. Staerkle, RF, Vuille-Dit-Bille, RN, Soll, C, Troller, R, Samra, J, Puhan, MA, et.al. Extended lymph node resection versus standard resection for pancreatic and periampullary adenocarcinoma., Cochrane Database Syst Rev, 2021. 1 (): p. CD011490., https://pubmed.ncbi.nlm.nih.gov/33471373/
390. Svoronos, C, Tsoulfas, G, Katsourakis, A, Noussios, G, Chatzitheoklitos, E, Marakis, NG, Role of extended lymphadenectomy in the treatment of pancreatic head adenocarcinoma: review and meta-analysis., ANZ J Surg, 2014. 84 (10)(10): p. 706-11., https://pubmed.ncbi.nlm.nih.gov/24165093/
391. Wang, W, He, Y, Wu, L, Ye, L, Yao, L, Tang, Z, Efficacy of extended versus standard lymphadenectomy in pancreatoduodenectomy for pancreatic head adenocarcinoma. An update meta-analysis., Pancreatology, 2019. 19 (8)(8): p. 1074-1080., https://pubmed.ncbi.nlm.nih.gov/31668841/
392. Franceschilli, M, Vinci, D, Di Carlo, S, Sensi, B, Siragusa, L, Guida, A, et.al. Central vascular ligation and mesentery based abdominal surgery., Discov Oncol, 2021. 12 (1)(1): p. 24., https://pubmed.ncbi.nlm.nih.gov/35201479/
393. Bhatti, I., Peacock, O., Awan, A. K., Semeraro, D., Larvin, M., Hall, R. I., Lymph node ratio versus number of affected lymph nodes as predictors of survival for resected pancreatic adenocarcinoma, World J Surg, 2010. 34(4): p. 768-75., https://pubmed.ncbi.nlm.nih.gov/20052471/
394. Garcea, G., Dennison, A. R., Ong, S. L., Pattenden, C. J., Neal, C. P., Sutton, C. D., et.al. Tumour characteristics predictive of survival following resection for ductal adenocarcinoma of the head of pancreas, Eur J Surg Oncol, 2007. 33(7): p. 892-7., https://pubmed.ncbi.nlm.nih.gov/17398060/
395. Hellan, M., Sun, C. L., Artinyan, A., Mojica-Manosa, P., Bhatia, S., Ellenhorn, J. D., et.al. The impact of lymph node number on survival in patients with lymph node-negative pancreatic cancer, Pancreas, 2008. 37(1): p. 19-24., https://pubmed.ncbi.nlm.nih.gov/18580439/
396. House, M. G., Gonen, M., Jarnagin, W. R., D'Angelica, M., DeMatteo, R. P., Fong, Y., et.al. Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer, J Gastrointest Surg, 2007. 11(11): p. 1549-55., https://pubmed.ncbi.nlm.nih.gov/17786531/
397. Konstantinidis, I. T., Deshpande, V., Zheng, H., Wargo, J. A., Fernandez-del Castillo, C., Thayer, S. P., et.al. Does the mechanism of lymph node invasion affect survival in patients with pancreatic ductal adenocarcinoma?, J Gastrointest Surg, 2010. 14(2): p. 261-7., https://pubmed.ncbi.nlm.nih.gov/19937477/
398. La Torre, M., Cavallini, M., Ramacciato, G., Cosenza, G., del Monte, S. R., Nigri, G., et.al. Role of the Lymph node ratio in pancreatic ductal adenocarcinoma. Impact on patient stratification and prognosis, Journal of Surgical Oncology, 2011., https://pubmed.ncbi.nlm.nih.gov/21713779/
399. Murakami, Y., Uemura, K., Sudo, T., Hayashidani, Y., Hashimoto, Y., Nakashima, A., et.al. Number of metastatic lymph nodes, but not lymph node ratio, is an independent prognostic factor after resection of pancreatic carcinoma, J Am Coll Surg, 2010. 211(2): p. 196-204., https://pubmed.ncbi.nlm.nih.gov/20670857/
400. Pai, R. K., Beck, A. H., Mitchem, J., Linehan, D. C., Chang, D. T., Norton, J. A., Pattern of lymph node involvement and prognosis in pancreatic adenocarcinoma: direct lymph node invasion has similar survival to node-negative disease, Am J Surg Pathol, 2011. 35(2): p. 228-34., https://pubmed.ncbi.nlm.nih.gov/21263243/
401. Pawlik, T. M., Gleisner, A. L., Cameron, J. L., Winter, J. M., Assumpcao, L., Lillemoe, K. D., et.al. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer, Surgery, 2007. 141(5): p. 610-8., https://pubmed.ncbi.nlm.nih.gov/17462460/
402. Prenzel, K. L., Holscher, A. H., Vallbohmer, D., Drebber, U., Gutschow, C. A., Monig, S. P., et.al. Lymph node size and metastatic infiltration in adenocarcinoma of the pancreatic head, Eur J Surg Oncol, 2010. 36(10): p. 993-6., https://pubmed.ncbi.nlm.nih.gov/20594789/
403. Riediger, H., Keck, T., Wellner, U., zur Hausen, A., Adam, U., Hopt, U. T., et.al. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer, J Gastrointest Surg, 2009. 13(7): p. 1337-44., https://pubmed.ncbi.nlm.nih.gov/19418101/
404. Sahin, T. T., Fujii, T., Kanda, M., Nagai, S., Kodera, Y., Kanzaki, A., et.al. Prognostic Implications of Lymph Node Metastases in Carcinoma of the Body and Tail of the Pancreas, Pancreas, 2011., https://pubmed.ncbi.nlm.nih.gov/21705947/
405. Showalter, T. N., Winter, K. A., Berger, A. C., Regine, W. F., Abrams, R. A., Safran, H., et.al. The Influence of Total Nodes Examined, Number of Positive Nodes, and Lymph Node Ratio on Survival after Surgical Resection and Adjuvant Chemoradiation for Pancreatic Cancer: A Secondary Analysis of RTOG 9704, Int J Radiat Oncol Biol Phys, 2010., https://pubmed.ncbi.nlm.nih.gov/20934270/
406. Slidell, M. B., Chang, D. C., Cameron, J. L., Wolfgang, C., Herman, J. M., Schulick, R. D., et.al. Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis, Ann Surg Oncol, 2008. 15(1): p. 165-74., https://pubmed.ncbi.nlm.nih.gov/17896141/
407. Chen, S., Zhan, Q., Jin, J. B., Wu, Z. C., Shi, Y., Cheng, D. F., et.al. Robot-assisted laparoscopic versus open middle pancreatectomy: short-term results of a randomized controlled trial, Surg Endosc, 2017. 31(2): p. 962-971., https://www.ncbi.nlm.nih.gov/pubmed/27402095
408. Xourafas, D., Ashley, S. W., Clancy, T. E., Comparison of Perioperative Outcomes between Open, Laparoscopic, and Robotic Distal Pancreatectomy: an Analysis of 1815 Patients from the ACS-NSQIP Procedure-Targeted Pancreatectomy Database, J Gastrointest Surg, 2017. 21(9): p. 1442-1452., https://pubmed.ncbi.nlm.nih.gov/28573358/
409. Mirkin, K. A., Greenleaf, E. K., Hollenbeak, C. S., Wong, J., Minimally invasive surgical approaches offer earlier time to adjuvant chemotherapy but not improved survival in resected pancreatic cancer, Surg Endosc, 2018. 32(5): p. 2387-2396., https://pubmed.ncbi.nlm.nih.gov/29101568/
410. Kauffmann, E. F., Napoli, N., Menonna, F., Iacopi, S., Lombardo, C., Bernardini, J., et.al. A propensity score-matched analysis of robotic versus open pancreatoduodenectomy for pancreatic cancer based on margin status, Surgical Endoscopy, 2019. 33(1): p. 234-242., https://pubmed.ncbi.nlm.nih.gov/29943061/
411. Boggi, U., Napoli, N., Costa, F., Kauffmann, E. F., Menonna, F., Iacopi, S., et.al. Robotic-Assisted Pancreatic Resections, World J Surg, 2016. 40(10): p. 2497-506., https://www.ncbi.nlm.nih.gov/pubmed/27206401
412. Adam, M. A., Thomas, S., Youngwirth, L., Pappas, T., Roman, S. A., Sosa, J. A., Defining a Hospital Volume Threshold for Minimally Invasive Pancreaticoduodenectomy in the United States, JAMA Surg, 2017. 152(4): p. 336-342., https://www.ncbi.nlm.nih.gov/pubmed/28030713
413. Abu Hilal, M., Hamdan, M., Di Fabio, F., Pearce, N. W., Johnson, C. D., Laparoscopic versus open distal pancreatectomy: a clinical and cost-effectiveness study, Surg Endosc, 2012. 26(6): p. 1670-4., https://pubmed.ncbi.nlm.nih.gov/22179475/
414. Raoof, M., Ituarte, P. H. G., Woo, Y., Warner, S. G., Singh, G., Fong, Y., et.al. Propensity score-matched comparison of oncological outcomes between laparoscopic and open distal pancreatic resection, The British journal of surgery, 2018. 105(5): p. 578-586., http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emexb&NEWS=N&AN=625133363
415. de Rooij, T., van Hilst, J., van Santvoort, H., Boerma, D., van den Boezem, P., Daams, F., et.al. Minimally Invasive Versus Open Distal Pancreatectomy (LEOPARD): A Multicenter Patient-blinded Randomized Controlled Trial, Ann Surg, 2019. 269(1): p. 2-9., https://www.ncbi.nlm.nih.gov/pubmed/30080726
416. de Rooij, T., van Hilst, J., Boerma, D., Bonsing, B. A., Daams, F., van Dam, R. M., et.al. Impact of a Nationwide Training Program in Minimally Invasive Distal Pancreatectomy (LAELAPS), Ann Surg, 2016. 264(5): p. 754-762., https://www.ncbi.nlm.nih.gov/pubmed/27741008
417. Klompmaker, S., de Rooij, T., Koerkamp, B. G., Shankar, A. H., Siebert, U., Besselink, M. G., et.al. International Validation of Reduced Major Morbidity After Minimally Invasive Distal Pancreatectomy Compared With Open Pancreatectomy, Ann Surg, 2019., https://pubmed.ncbi.nlm.nih.gov/31756173/
418. Plotkin, Anastasia, Ceppa, Eugene P., Zarzaur, Ben L., Kilbane, Elizabeth M., Riall, Taylor S., Pitt, Henry A., Reduced morbidity with minimally invasive distal pancreatectomy for pancreatic adenocarcinoma, HPB : the official journal of the International Hepato Pancreato Biliary Association, 2017. 19(3): p. 279-285., https://pubmed.ncbi.nlm.nih.gov/28161217/
419. Tran Cao, Hop S., Lopez, Nicole, Chang, David C., Lowy, Andrew M., Bouvet, Michael, Baumgartner, Joel M., et.al. Improved perioperative outcomes with minimally invasive distal pancreatectomy: results from a population-based analysis, JAMA Surgery, 2014. 149(3): p. 237-243., https://pubmed.ncbi.nlm.nih.gov/24402232/
420. Bauman, Marita D., Becerra, David G., Kilbane, E. Molly, Zyromski, Nicholas J., Schmidt, C. Max, Pitt, Henry A., et.al. Laparoscopic distal pancreatectomy for pancreatic cancer is safe and effective, Surgical Endoscopy, 2018. 32(1): p. 53-61., https://pubmed.ncbi.nlm.nih.gov/28643065/
421. Huang, Bin, Feng, Lu, Zhao, Jichun, Systematic review and meta-analysis of robotic versus laparoscopic distal pancreatectomy for benign and malignant pancreatic lesions, Surgical Endoscopy, 2016. 30(9): p. 4078-4085., https://pubmed.ncbi.nlm.nih.gov/26743110/
422. Zhao, W., Liu, C., Li, S., Geng, D., Feng, Y., Sun, M., Safety and efficacy for robot-assisted versus open pancreaticoduodenectomy and distal pancreatectomy: A systematic review and meta-analysis, Surg Oncol, 2018. 27(3): p. 468-478., https://pubmed.ncbi.nlm.nih.gov/30217304/
423. Lyman, W. B., Passeri, M., Sastry, A., Cochran, A., Iannitti, D. A., Vrochides, D., et.al. Robotic-assisted versus laparoscopic left pancreatectomy at a high-volume, minimally invasive center, Surgical Endoscopy, 2018., http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emexb&NEWS=N&AN=624876156
424. Kornaropoulos, Michail, Moris, Demetrios, Beal, Eliza, Makris, Marinos, Mitrousias, Apostolos, Petrou, Athanasios, et.al. Total robotic pancreaticoduodenectomy: a systematic review of the literature, Surgical Endoscopy, 2017. 31(11): p. 4382-4392., https://pubmed.ncbi.nlm.nih.gov/28389798/
425. McMillan, M. T., Zureikat, A. H., Hogg, M. E., Kowalsky, S. J., Zeh, H. J., Sprys, M. H., et.al. A propensity score-matched analysis of robotic vs open pancreatoduodenectomy on incidence of pancreatic fistula, JAMA Surgery, 2017. 152(4): p. 327-335., https://pubmed.ncbi.nlm.nih.gov/28030724/
426. Nickel, F., Haney, C. M., Kowalewski, K. F., Probst, P., Limen, E. F., Kalkum, E., et.al. Laparoscopic Versus Open Pancreaticoduodenectomy: A Systematic Review and Meta-analysis of Randomized Controlled Trials, Ann Surg, 2020. 271(1): p. 54-66., https://pubmed.ncbi.nlm.nih.gov/30973388/
427. Palanivelu, C., Senthilnathan, P., Sabnis, S. C., Babu, N. S., Srivatsan Gurumurthy, S., Anand Vijai, N., et.al. Randomized clinical trial of laparoscopic versus open pancreatoduodenectomy for periampullary tumours, Br J Surg, 2017. 104(11): p. 1443-1450., https://pubmed.ncbi.nlm.nih.gov/28895142/
428. Poves, I., Burdío, F., Morató, O., Iglesias, M., Radosevic, A., Ilzarbe, L., et.al. Comparison of Perioperative Outcomes Between Laparoscopic and Open Approach for Pancreatoduodenectomy: The PADULAP Randomized Controlled Trial, Ann Surg, 2018. 268(5): p. 731-739., https://pubmed.ncbi.nlm.nih.gov/30138162/
429. van Hilst, J., de Rooij, T., Bosscha, K., Brinkman, D. J., van Dieren, S., Dijkgraaf, M. G., et.al. Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial, Lancet Gastroenterol Hepatol, 2019. 4(3): p. 199-207., https://pubmed.ncbi.nlm.nih.gov/30685489/
430. Pędziwiatr, M., Małczak, P., Pisarska, M., Major, P., Wysocki, M., Stefura, T., et.al. Minimally invasive versus open pancreatoduodenectomy-systematic review and meta-analysis, Langenbecks Arch Surg, 2017. 402(5): p. 841-851., https://pubmed.ncbi.nlm.nih.gov/28488004/
431. Nassour, Ibrahim, Choti, Michael A., Porembka, Matthew R., Yopp, Adam C., Wang, Sam C., Polanco, Patricio M., Robotic-assisted versus laparoscopic pancreaticoduodenectomy: oncological outcomes, Surgical Endoscopy, 2018. 32(6): p. 2907-2913., https://pubmed.ncbi.nlm.nih.gov/29280014/
432. Schmidt, C. M., Glant, J., Winter, J. M., Kennard, J., Dixon, J., Zhao, Q., et.al. Total pancreatectomy (R0 resection) improves survival over subtotal pancreatectomy in isolated neck margin positive pancreatic adenocarcinoma, Surgery, 2007. 142(4): p. 572-8; discussion 578-80., https://pubmed.ncbi.nlm.nih.gov/17950350/
433. Hernandez, J., Mullinax, J., Clark, W., Toomey, P., Villadolid, D., Morton, C., et.al. Survival after pancreaticoduodenectomy is not improved by extending resections to achieve negative margins, Ann Surg, 2009. 250(1): p. 76-80., https://pubmed.ncbi.nlm.nih.gov/19561479/
434. Munding, J., Uhl, W., Tannapfel, A., [R classification and pancreatic ductal adenocarcinoma--R 0 is R 0], Z Gastroenterol, 2011. 49(10): p. 1423-7., https://pubmed.ncbi.nlm.nih.gov/21964897/
435. C, Wittekind, HJ, Meyer, TNM Klassifikation maligner TumoreWiley-Blackwell, 2010.
436. Shimada, K., Nara, S., Esaki, M., Sakamoto, Y., Kosuge, T., Hiraoka, N., Intrapancreatic nerve invasion as a predictor for recurrence after pancreaticoduodenectomy in patients with invasive ductal carcinoma of the pancreas, Pancreas, 2011. 40(3): p. 464-468., https://pubmed.ncbi.nlm.nih.gov/21289526/
437. Zacharias, T., Jaeck, D., Oussoultzoglou, E., Neuville, A., Bachellier, P., Impact of lymph node involvement on long-term survival after R0 pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas, J Gastrointest Surg, 2007. 11(3): p. 350-6., https://pubmed.ncbi.nlm.nih.gov/17458610/
438. Wasif, N., Ko, C. Y., Farrell, J., Wainberg, Z., Hines, O. J., Reber, H., et.al. Impact of tumor grade on prognosis in pancreatic cancer: Should we include grade in AJCC staging?, Annals of Surgical Oncology, 2010. 17(9): p. 2312-2320., https://pubmed.ncbi.nlm.nih.gov/20422460/
439. Fujita, T., Nakagohri, T., Gotohda, N., Takahashi, S., Konishi, M., Kojima, M., et.al. Evaluation of the prognostic factors and significance of lymph node status in invasive ductal carcinoma of the body or tail of the pancreas, Pancreas, 2010. 39(1): p. e48-54., https://pubmed.ncbi.nlm.nih.gov/19910836/
440. Bosman, F. T., Carneiro, F., Hruban, R. H., Theise, N. D., WHO Classification of Tumours, Volume 3, 2010. 3:
441. Lee, S. E., Jang, J. Y., Kim, M. A., Kim, S. W., Clinical implications of immunohistochemically demonstrated lymph node micrometastasis in resectable pancreatic cancer, J Korean Med Sci, 2011. 26(7): p. 881-5., http://www.ncbi.nlm.nih.gov/pubmed/21738340
442. Kanda, M., Fujii, T., Sahin, T. T., Kanzaki, A., Nagai, S., Yamada, S., et.al. Invasion of the splenic artery is a crucial prognostic factor in carcinoma of the body and tail of the pancreas, Ann Surg, 2010. 251(3): p. 483-7., http://www.ncbi.nlm.nih.gov/pubmed/20101172
443. Boggi, U., Del Chiaro, M., Croce, C., Vistoli, F., Signori, S., Moretto, C., et.al. Prognostic implications of tumor invasion or adhesion to peripancreatic vessels in resected pancreatic cancer, Surgery, 2009. 146(5): p. 869-881., https://pubmed.ncbi.nlm.nih.gov/19744432/
444. Fatima, J., Schnelldorfer, T., Barton, J., Wood, C. M., Wiste, H. J., Smyrk, T. C., et.al. Pancreatoduodenectomy for ductal adenocarcinoma: implications of positive margin on survival, Arch Surg, 2010. 145(2): p. 167-72., https://pubmed.ncbi.nlm.nih.gov/20157085/
445. Kurahara, H., Takao, S., Maemura, K., Shinchi, H., Natsugoe, S., Aikou, T., Impact of lymph node micrometastasis in patients with pancreatic head cancer, World J Surg, 2007. 31(3): p. 483-90; discussion 491-2., https://pubmed.ncbi.nlm.nih.gov/17219277/
446. Menon, K. V., Gomez, D., Smith, A. M., Anthoney, A., Verbeke, C. S., Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds Pathology Protocol (LEEPP), HPB (Oxford), 2009. 11(1): p. 18-24., https://pubmed.ncbi.nlm.nih.gov/19590619/
447. Mitsunaga, S., Hasebe, T., Kinoshita, T., Konishi, M., Takahashi, S., Gotohda, N., et.al. Detail histologic analysis of nerve plexus invasion in invasive ductal carcinoma of the pancreas and its prognostic impact, Am J Surg Pathol, 2007. 31(11): p. 1636-44., https://pubmed.ncbi.nlm.nih.gov/18059219/
448. Hishinuma, S., Ogata, Y., Tomikawa, M., Ozawa, I., Hirabayashi, K., Igarashi, S., Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings, J Gastrointest Surg, 2006. 10(4): p. 511-8., http://www.ncbi.nlm.nih.gov/pubmed/16627216
449. Oettle, H., Post, S., Neuhaus, P., Gellert, K., Langrehr, J., Ridwelski, K., et.al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial, JAMA, 2007. 297(3): p. 267-77., http://www.ncbi.nlm.nih.gov/pubmed/17227978
450. Ueno, H., Kosuge, T., Matsuyama, Y., Yamamoto, J., Nakao, A., Egawa, S., et.al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer, Br J Cancer, 2009. 101(6): p. 908-15., http://www.ncbi.nlm.nih.gov/pubmed/19690548
451. Neoptolemos, J. P., Stocken, D. D., Friess, H., Bassi, C., Dunn, J. A., Hickey, H., et.al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer, N Engl J Med, 2004. 350(12): p. 1200-10., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15028824
452. Stocken, D. D., Buchler, M. W., Dervenis, C., Bassi, C., Jeekel, H., Klinkenbijl, J. H., et.al. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer, Br J Cancer, 2005. 92(8): p. 1372-81., https://pubmed.ncbi.nlm.nih.gov/15812554/
453. Neoptolemos, J. P., Stocken, D. D., Bassi, C., Ghaneh, P., Cunningham, D., Goldstein, D., et.al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial, JAMA, 2010. 304(10): p. 1073-81., http://www.ncbi.nlm.nih.gov/pubmed/20823433
454. Yoshitomi, H., Togawa, A., Kimura, F., Ito, H., Shimizu, H., Yoshidome, H., et.al. A randomized phase II trial of adjuvant chemotherapy with uracil/tegafur and gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer, Cancer, 2008. 113(9): p. 2448-56., https://pubmed.ncbi.nlm.nih.gov/18823024/
455. Neoptolemos, J. P., Palmer, D. H., Ghaneh, P., Psarelli, E. E., Valle, J. W., Halloran, C. M., et.al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial, The Lancet, 2017. (no pagination):, https://pubmed.ncbi.nlm.nih.gov/28129987/
456. Conroy, T., Hammel, P., Hebbar, M., Abdelghani, M. Ben, Wei, A. C., Raoul, J. L., et.al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer, New England Journal of Medicine, 2018. 379(25): p. 2395-5406., https://pubmed.ncbi.nlm.nih.gov/30575490/
457. Oettle, Helmut, Neuhaus, Peter, Hochhaus, Andreas, Hartmann, JÇôrg Thomas, Gellert, Klaus, Ridwelski, Karsten, et.al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial, JAMA: Journal of the American Medical Association, 2013. 310(14): p. 1473-1481., https://pubmed.ncbi.nlm.nih.gov/24104372/
458. Van Cutsem, E., Vervenne, W. L., Bennouna, J., Humblet, Y., Gill, S., Van Laethem, J. L., et.al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer, Journal of Clinical Oncology, 2009. 27(13): p. 2231-2237., https://pubmed.ncbi.nlm.nih.gov/19307500/
459. Sinn, M., Liersch, T., Riess, H., Gellert, K., Stübs, P., Waldschmidt, D., et.al. CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer - Final results, Eur J Cancer, 2020. 138: p. 172-181., https://pubmed.ncbi.nlm.nih.gov/32890813/
460. Sinn, M., Liersch, T., Gellert, K., Riess, H., Stübs, P., Waldschmidt, D. T., et.al. LBA18 - Conko-006: a Randomized Double-Blinded Phase Iib-Study of Adjuvant Therapy with Gemcitabine + Sorafenib/Placebo for Patients with R1-Resection of Pancreatic Cancer, Annals of Oncology, 2014. 25: p. v1., https://pubmed.ncbi.nlm.nih.gov/32890813/
461. Tempero, Margaret A., Reni, Michele, Riess, Hanno, Pelzer, Uwe, O'Reilly, Eileen Mary, Winter, Jordan Michael, et.al. APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma, Journal of Clinical Oncology, 2019. 37(15_suppl): p. 4000-4000., https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.4000
462. Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., et.al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline, J Clin Oncol, 2018. 36(17): p. 1714-1768., https://www.ncbi.nlm.nih.gov/pubmed/29442540
463. Sinn, Marianne, Bahra, Marcus, Liersch, Torsten, Gellert, Klaus, Messmann, Helmut, Bechstein, Wolf, et.al. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial, Journal of Clinical Oncology, 2017. 35(29): p. 3330-3337., https://pubmed.ncbi.nlm.nih.gov/28817370/
464. Valle, J. W., Palmer, D., Jackson, R., Cox, T., Neoptolemos, J. P., Ghaneh, P., et.al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: Ongoing lessons from the ESPAC-3 study, Journal of Clinical Oncology, 2014. 32(6): p. 504-512., https://pubmed.ncbi.nlm.nih.gov/24419109/
465. Saeed, H., Hnoosh, D., Huang, B., Durbin, E. B., McGrath, P. C., Desimone, P., et.al. Defining the optimal timing of adjuvant therapy for resected pancreatic adenocarcinoma: A statewide cancer registry analysis, Journal of Surgical Oncology, 2016. 114(4): p. 451-455., https://pubmed.ncbi.nlm.nih.gov/27238300/
466. American Society of Clinical, Oncology, Khorana, A. A., Mangu, P. B., Berlin, J., Engebretson, A., Hong, T. S., et.al. Potentially curable pancreatic cancer: American society of clinical oncology clinical practice guideline update, Journal of Clinical Oncology, 2017. p. 2324-2328., https://pubmed.ncbi.nlm.nih.gov/28398845/
467. Sun, W., Leong, C. N., Zhang, Z., Lu, J. J., Proposing the lymphatic target volume for elective radiation therapy for pancreatic cancer: a pooled analysis of clinical evidence, Radiat Oncol, 2010. 5: p. 28., https://pubmed.ncbi.nlm.nih.gov/20398316/
468. Kalser, M. H., Ellenberg, S. S., Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection, Arch Surg, 1985. 120(8): p. 899-903., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=4015380
469. Smeenk, H. G., van Eijck, C. H., Hop, W. C., Erdmann, J., Tran, K. C., Debois, M., et.al. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891, Ann Surg, 2007. 246(5): p. 734-40., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17968163
470. Morak, M. J., van der Gaast, A., Incrocci, L., van Dekken, H., Hermans, J. J., Jeekel, J., et.al. Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled trial, Ann Surg, 2008. 248(6): p. 1031-41., https://pubmed.ncbi.nlm.nih.gov/19092348/
471. Neoptolemos, J. P., Dunn, J. A., Stocken, D. D., Almond, J., Link, K., Beger, H., et.al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial, Lancet, 2001. 358(9293): p. 1576-85., https://pubmed.ncbi.nlm.nih.gov/11716884/
472. Carter, R., Stocken, D. D., Ghaneh, P., Bramhall, S. R., Olah, A., Kelemen, D., et.al. Longitudinal quality of life data can provide insights on the impact of adjuvant treatment for pancreatic cancer-Subset analysis of the ESPAC-1 data, Int J Cancer, 2009. 124(12): p. 2960-5., https://www.ncbi.nlm.nih.gov/pubmed/19330830
473. Klinkenbijl, J. H., Jeekel, J., Sahmoud, T., van Pel, R., Couvreur, M. L., Veenhof, C. H., et.al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group, Ann Surg, 1999. 230(6): p. 776-82; discussion 782-4., https://pubmed.ncbi.nlm.nih.gov/10615932/
474. Van Laethem, J. L., Hammel, P., Mornex, F., Azria, D., Van Tienhoven, G., Vergauwe, P., et.al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study, J Clin Oncol, 2010. 28(29): p. 4450-6., https://pubmed.ncbi.nlm.nih.gov/20837948/
475. Regine, W. F., Winter, K. A., Abrams, R., Safran, H., Hoffman, J. P., Konski, A., et.al. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial, Ann Surg Oncol, 2011. 18(5): p. 1319-26., https://pubmed.ncbi.nlm.nih.gov/21499862/
476. Reni, M., Balzano, G., Aprile, G., Cereda, S., Passoni, P., Zerbi, A., et.al. Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: A randomized phase II trial, Annals of Surgical Oncology, 2012. 19(7): p. 2256-2263., https://pubmed.ncbi.nlm.nih.gov/22237835/
477. Bosset, J. F., Pavy, J. J., Gillet, M., Mantion, G., Pelissier, E., Schraub, S., Conventional external irradiation alone as adjuvant treatment in resectable pancreatic cancer: results of a prospective study, Radiother Oncol, 1992. 24(3): p. 191-4., https://www.ncbi.nlm.nih.gov/pubmed/1357725
478. Brunner, T. B., Merkel, S., Grabenbauer, G. G., Meyer, T., Baum, U., Papadopoulos, T., et.al. Definition of elective lymphatic target volume in ductal carcinoma of the pancreatic head based on histopathologic analysis, Int J Radiat Oncol Biol Phys, 2005. 62(4): p. 1021-9., https://www.ncbi.nlm.nih.gov/pubmed/15990004
479. Yeo, C. J., Abrams, R. A., Grochow, L. B., Sohn, T. A., Ord, S. E., Hruban, R. H., et.al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience, Ann Surg, 1997. 225(5): p. 621-33; discussion 633-6., https://pubmed.ncbi.nlm.nih.gov/9193189/
480. Abrams, R. A., Winter, K. A., Safran, H., Goodman, K. A., Regine, W. F., Berger, A. C., et.al. Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question-Erlotinib+Gemcitabine for Resected Cancer of the Pancreatic Head: A Phase II Randomized Clinical Trial, Am J Clin Oncol, 2020. 43(3): p. 173-179., https://pubmed.ncbi.nlm.nih.gov/31985516/
481. Goodman, K. A., Regine, W. F., Dawson, L. A., Ben-Josef, E., Haustermans, K., Bosch, W. R., et.al. Radiation Therapy Oncology Group consensus panel guidelines for the delineation of the clinical target volume in the postoperative treatment of pancreatic head cancer, Int J Radiat Oncol Biol Phys, 2012. 83(3): p. 901-8., https://www.ncbi.nlm.nih.gov/pubmed/22483737
482. Herman, J. M., Swartz, M. J., Hsu, C. C., Winter, J., Pawlik, T. M., Sugar, E., et.al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital, J Clin Oncol, 2008. 26(21): p. 3503-10., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18640931
483. Butturini, G., Stocken, D. D., Wente, M. N., Jeekel, H., Klinkenbijl, J. H., Bakkevold, K. E., et.al. Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials, Arch Surg, 2008. 143(1): p. 75-83; discussion 83., https://www.ncbi.nlm.nih.gov/pubmed/18209156
484. Andriulli, A., Festa, V., Botteri, E., Valvano, M. R., Koch, M., Bassi, C., et.al. Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies, Ann Surg Oncol, 2012. 19(5): p. 1644-62., https://www.ncbi.nlm.nih.gov/pubmed/22012027
485. Assifi, M. M., Lu, X., Eibl, G., Reber, H. A., Li, G., Hines, O. J., Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials, Surgery, 2011. 150(3): p. 466-73., https://www.ncbi.nlm.nih.gov/pubmed/21878232
486. Bradley, A., Van Der Meer, R., Upfront Surgery versus Neoadjuvant Therapy for Resectable Pancreatic Cancer: Systematic Review and Bayesian Network Meta-analysis, Sci Rep, 2019. 9(1): p. 4354., https://www.ncbi.nlm.nih.gov/pubmed/30867522
487. Gillen, S., Schuster, T., Meyer Zum Buschenfelde, C., Friess, H., Kleeff, J., Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages, PLoS Med, 2010. 7(4): p. e1000267., https://www.ncbi.nlm.nih.gov/pubmed/20422030
488. Palmer, D. H., Stocken, D. D., Hewitt, H., Markham, C. E., Hassan, A. B., Johnson, P. J., et.al. A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin, Ann Surg Oncol, 2007. 14(7): p. 2088-96., http://www.ncbi.nlm.nih.gov/pubmed/17453298
489. Versteijne, E., Suker, M., Groothuis, K., Akkermans-Vogelaar, J. M., Besselink, M. G., Bonsing, B. A., et.al. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial, J Clin Oncol, 2020. p. JCO1902274., https://www.ncbi.nlm.nih.gov/pubmed/32105518
490. Barbier, L., Turrini, O., Gregoire, E., Viret, F., Le Treut, Y. P., Delpero, J. R., Pancreatic head resectable adenocarcinoma: preoperative chemoradiation improves local control but does not affect survival, HPB (Oxford), 2011. 13(1): p. 64-9., https://www.ncbi.nlm.nih.gov/pubmed/21159106
491. Takahashi, S., Kinoshita, T., Konishi, M., Gotohda, N., Kato, Y., Kobayashi, T., et.al. Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment, J Hepatobiliary Pancreat Sci, 2011. 18(4): p. 567-74., http://www.ncbi.nlm.nih.gov/pubmed/21331805
492. Chun, Y. S., Cooper, H. S., Cohen, S. J., Konski, A., Burtness, B., Denlinger, C. S., et.al. Significance of pathologic response to preoperative therapy in pancreatic cancer, Ann Surg Oncol, 2011. 18(13): p. 3601-7., https://www.ncbi.nlm.nih.gov/pubmed/21947697
493. Heinrich, S., Schafer, M., Weber, A., Hany, T. F., Bhure, U., Pestalozzi, B. C., et.al. Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial, Ann Surg, 2008. 248(6): p. 1014-22., http://www.ncbi.nlm.nih.gov/pubmed/19092346
494. Lutfi, Waseem, Talamonti, Mark S., Kantor, Olga, Wang, Chi Hsiung, Liederbach, Erik, Stocker, Susan J., et.al. Perioperative chemotherapy is associated with a survival advantage in early stage adenocarcinoma of the pancreatic head, Surgery (United Kingdom), 2016. 160(3): p. 714-724., https://pubmed.ncbi.nlm.nih.gov/27422328/
495. Czosnyka, N. M., Borgert, A. J., Smith, T. J., Pancreatic adenocarcinoma: effects of neoadjuvant therapy on post-pancreatectomy outcomes - an American College of Surgeons National Surgical Quality Improvement Program targeted variable review, HPB (Oxford), 2017. 19(10): p. 927-932., https://www.ncbi.nlm.nih.gov/pubmed/28747265
496. de Geus, S. W., Eskander, M. F., Bliss, L. A., Kasumova, G. G., Ng, S. C., Callery, M. P., et.al. Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matched analysis, Surgery, 2017. 161(3): p. 592-601., https://www.ncbi.nlm.nih.gov/pubmed/28341441
497. Mirkin, Katelin A., Hollenbeak, Christopher S., Wong, Joyce, Survival impact of neoadjuvant therapy in resected pancreatic cancer: A Prospective Cohort Study involving 18,332 patients from the National Cancer Data Base, International Journal of Surgery, 2016. 34: p. 96-102., https://pubmed.ncbi.nlm.nih.gov/27573691/
498. Dhir, M., Zenati, M. S., Hamad, A., Singhi, A. D., Bahary, N., Hogg, M. E., et.al. FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma, Ann Surg Oncol, 2018. 25(7): p. 1896-1903., https://www.ncbi.nlm.nih.gov/pubmed/29761331
499. Haeno, H., Gonen, M., Davis, M. B., Herman, J. M., Iacobuzio-Donahue, C. A., Michor, F., Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies, Cell, 2012. 148(1-2): p. 362-75., https://www.ncbi.nlm.nih.gov/pubmed/22265421
500. Zhao, Q., Rashid, A., Gong, Y., Katz, M. H., Lee, J. E., Wolf, R., et.al. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis, Ann Diagn Pathol, 2012. 16(1): p. 29-37., https://pubmed.ncbi.nlm.nih.gov/22050964/
501. Estrella, J. S., Rashid, A., Fleming, J. B., Katz, M. H., Lee, J. E., Wolf, R. A., et.al. Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation, Cancer, 2012. 118(1): p. 268-77., https://www.ncbi.nlm.nih.gov/pubmed/21735446
502. Versteijne, E., Vogel, J. A., Besselink, M. G., Busch, O. R. C., Wilmink, J. W., Daams, J. G., et.al. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer, The British journal of surgery, 2018. 105(8): p. 946-958., http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emexb&NEWS=N&AN=625681595, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033157/pdf/BJS-105-946.pdf
503. Mokdad, Ali A., Minter, Rebecca M., Hong, Zhu, Augustine, Mathew M., Porembka, Matthew R., Wang, Sam C., et.al. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis, Journal of Clinical Oncology, 2017. 35(5): p. 515-522., https://pubmed.ncbi.nlm.nih.gov/27621388/
504. Versteijne, E, van Dam, JL, Suker, M, Janssen, QP, Groothuis, K, Akkermans-Vogelaar, JM, et.al. Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial., J Clin Oncol, 2022. 40 (11)(11): p. 1220-1230., https://pubmed.ncbi.nlm.nih.gov/35084987/
505. Motoi, F., Kosuge, T., Ueno, H., Yamaue, H., Satoi, S., Sho, M., et.al. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05), Japanese Journal of Clinical Oncology, 2019. 49(2): p. 190-194., https://pubmed.ncbi.nlm.nih.gov/30608598/
506. Golcher, H., Brunner, T. B., Witzigmann, H., Marti, L., Bechstein, W. O., Bruns, C., et.al. Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial, Strahlenther Onkol, 2015. 191(1): p. 7-16., https://www.ncbi.nlm.nih.gov/pubmed/25252602
507. Truty, M. J., Kendrick, M. L., Nagorney, D. M., Smoot, R. L., Cleary, S. P., Graham, R. P., et.al. Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer, Annals of surgery, 2019., https://pubmed.ncbi.nlm.nih.gov/30946090/
508. de Geus, S. W., Evans, D. B., Bliss, L. A., Eskander, M. F., Smith, J. K., Wolff, R. A., et.al. Neoadjuvant therapy versus upfront surgical strategies in resectable pancreatic cancer: A Markov decision analysis, Eur J Surg Oncol, 2016. 42(10): p. 1552-60., https://www.ncbi.nlm.nih.gov/pubmed/27570116
509. Franko, J., Hsu, H. W., Thirunavukarasu, P., Frankova, D., Goldman, C. D., Chemotherapy and radiation components of neoadjuvant treatment of pancreatic head adenocarcinoma: Impact on perioperative mortality and long-term survival, Eur J Surg Oncol, 2017. 43(2): p. 351-357., https://www.ncbi.nlm.nih.gov/pubmed/27863846
510. Fisher, A. V., Abbott, D. E., Venkatesh, M., Leverson, G. E., Campbell-Flohr, S. A., Ronnekleiv-Kelly, S. M., et.al. The Impact of Hospital Neoadjuvant Therapy Utilization on Survival Outcomes for Pancreatic Cancer, Ann Surg Oncol, 2018. 25(9): p. 2661-2668., https://www.ncbi.nlm.nih.gov/pubmed/30003452
511. Oba, Atsushi, Croce, Chiara, Hosokawa, Patrick, Meguid, Cheryl, Torphy, Robert J., Al-Musawi, Mohammed H., et.al. Prognosis Based Definition of Resectability in Pancreatic Cancer: A Road Map to New Guidelines, Annals of surgery, 2020., http://europepmc.org/abstract/MED/32149822, https://doi.org/10.1097/SLA.0000000000003859
512. Ghaneh, Paula, Palmer, Daniel H., Cicconi, Silvia, Halloran, Christopher, Psarelli, Eftychia Eirini, Rawcliffe, Charlotte Louise, et.al. ESPAC-5F: Four-arm, prospective, multicenter, international randomized phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer, Journal of Clinical Oncology, 2020. 38(15_suppl): p. 4505-4505., https://doi.org/10.1200/JCO.2020.38.15_suppl.4505
513. Hammel, Pascal, Huguet, Florence, Van Laethem, Jean Luc, Goldstein, David, Glimelius, Bengt, Artru, Pascal, et.al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial, JAMA: Journal of the American Medical Association, 2016. 315(17): p. 1844-1853., https://pubmed.ncbi.nlm.nih.gov/27139057/
514. Jang, J. Y., Han, Y., Lee, H., Kim, S. W., Kwon, W., Lee, K. H., et.al. Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial, Annals of surgery, 2018. 268(2): p. 215-222., https://pubmed.ncbi.nlm.nih.gov/29462005/
515. Chen, X., Liu, G., Wang, K., Chen, G., Sun, J., Neoadjuvant radiation followed by resection versus upfront resection for locally advanced pancreatic cancer patients: a propensity score matched analysis, Oncotarget, 2017. 8(29): p. 47831-47840., https://www.ncbi.nlm.nih.gov/pubmed/28599299
516. Gemenetzis, Georgios, Groot, Vincent P., Blair, Alex B., Laheru, Daniel A., Zheng, Lei, Narang, Amol K., et.al. Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection, Annals of surgery, 2018., https://pubmed.ncbi.nlm.nih.gov/29596120/
517. Hackert, T., Sachsenmaier, M., Hinz, U., Schneider, L., Michalski, C. W., Springfeld, C., et.al. Locally Advanced Pancreatic Cancer: Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients, Ann Surg, 2016. 264(3): p. 457-63., https://www.ncbi.nlm.nih.gov/pubmed/27355262
518. Nagakawa, Y., Sahara, Y., Hosokawa, Y., Murakami, Y., Yamaue, H., Satoi, S., et.al. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery, Annals of Surgical Oncology, 2019., https://pubmed.ncbi.nlm.nih.gov/30610555/
519. Pietrasz, D., Turrini, O., Vendrely, V., Simon, J. M., Hentic, O., Coriat, R., et.al. How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRENCH Multicentric Cohort, Annals of Surgical Oncology, 2019. 26(1): p. 109-117., https://pubmed.ncbi.nlm.nih.gov/30362063/
520. Conroy, T., Desseigne, F., Ychou, M., Bouche, O., Guimbaud, R., Becouarn, Y., et.al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer, N Engl J Med, 2011. 364(19): p. 1817-25., https://pubmed.ncbi.nlm.nih.gov/21561347/
521. Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., et.al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine, New England Journal of Medicine, 2013. 369(18): p. 1691-1703., https://pubmed.ncbi.nlm.nih.gov/24131140/
522. Macarulla, Teresa, Pazo-Cid, Roberto, GuillǸn-Ponce, Carmen, LÇüpez, Rafael, Vera, Ruth, Reboredo, Margarita, et.al. Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2, Journal of Clinical Oncology, 2019. 37(3): p. 230-238., https://pubmed.ncbi.nlm.nih.gov/30523758/
523. Kasperk, R., Klever, P., Andreopoulos, D., Schumpelick, V., Intraoperative radiotherapy for pancreatic carcinoma, Br J Surg, 1995. 82(9): p. 1259-61., http://www.ncbi.nlm.nih.gov/pubmed/7552013
524. Reni, M., Panucci, M. G., Ferreri, A. J., Balzano, G., Passoni, P., Cattaneo, G. M., et.al. Effect on local control and survival of electron beam intraoperative irradiation for resectable pancreatic adenocarcinoma, Int J Radiat Oncol Biol Phys, 2001. 50(3): p. 651-8., http://www.ncbi.nlm.nih.gov/pubmed/11395232
525. Yamaguchi, K., Nakamura, K., Kobayashi, K., Nakano, K., Konomi, H., Mizumoto, K., et.al. ERT following IORT improves survival of patients with resectable pancreatic cancer, Hepatogastroenterology, 2005. 52(64): p. 1244-9., https://pubmed.ncbi.nlm.nih.gov/16001672/
526. Messick, C., Hardacre, J. M., McGee, M. F., Siegel, C. T., Stellato, T. A., Sanabria, J. R., et.al. Early experience with intraoperative radiotherapy in patients with resected pancreatic adenocarcinoma, Am J Surg, 2008. 195(3): p. 308-11; discussion 312., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18207129
527. Showalter, T. N., Rao, A. S., Rani Anne, P., Rosato, F. E., Rosato, E. L., Andrel, J., et.al. Does intraoperative radiation therapy improve local tumor control in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma? A propensity score analysis, Ann Surg Oncol, 2009. 16(8): p. 2116-22., http://www.ncbi.nlm.nih.gov/pubmed/19437078
528. Ruano-Ravina, A., Almazan Ortega, R., Guedea, F., Intraoperative radiotherapy in pancreatic cancer: a systematic review, Radiother Oncol, 2008. 87(3): p. 318-25., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18199514
529. Zygogianni, G. A., Kyrgias, G., Kouvaris, J., Antypas, C., Skarlatos, J., Armpilia, C., et.al. Intraoperative radiation therapy on pancreatic cancer patients: a review of the literature, Minerva Chir, 2011. 66(4): p. 361-9., https://pubmed.ncbi.nlm.nih.gov/21873971/
530. Karasawa, K., Sunamura, M., Okamoto, A., Nemoto, K., Matsuno, S., Nishimura, Y., et.al. Efficacy of novel hypoxic cell sensitiser doranidazole in the treatment of locally advanced pancreatic cancer: long-term results of a placebo-controlled randomised study, Radiother Oncol, 2008. 87(3): p. 326-30., https://pubmed.ncbi.nlm.nih.gov/18342968/
531. Nagai, S., Fujii, T., Kodera, Y., Kanda, M., Sahin, T. T., Kanzaki, A., et.al. Prognostic implications of intraoperative radiotherapy for unresectable pancreatic cancer, Pancreatology, 2011. 11(1): p. 68-75., https://pubmed.ncbi.nlm.nih.gov/21525774/
532. Suker, Mustafa, Beumer, Berend R., Sadot, Eran, Marthey, Lysiane, Faris, Jason E., Mellon, Eric A., et.al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis, Lancet Oncology, 2016. 17(6): p. 801-810., https://pubmed.ncbi.nlm.nih.gov/27160474/
533. Kunzmann, V., Siveke, J. T., Algül, H., Goekkurt, E., Siegler, G., Martens, U., et.al. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial, Lancet Gastroenterol Hepatol, 2021. 6(2): p. 128-138., https://pubmed.ncbi.nlm.nih.gov/33338442/
534. Bernard, V., Kim, D. U., San Lucas, F. A., Castillo, J., Allenson, K., Mulu, F. C., et.al. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer, Gastroenterology, 2019. 156(1): p. 108-118 e4., https://www.ncbi.nlm.nih.gov/pubmed/30240661
535. Tsai, S., George, B., Wittmann, D., Ritch, P. S., Krepline, A. N., Aldakkak, M., et.al. Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer, Ann Surg, 2020. 271(4): p. 740-747., https://pubmed.ncbi.nlm.nih.gov/30312198/
536. Akita, H., Takahashi, H., Ohigashi, H., Tomokuni, A., Kobayashi, S., Sugimura, K., et.al. FDG-PET predicts treatment efficacy and surgical outcome of pre-operative chemoradiation therapy for resectable and borderline resectable pancreatic cancer, Eur J Surg Oncol, 2017. 43(6): p. 1061-1067., https://pubmed.ncbi.nlm.nih.gov/28389044/
537. Aldakkak, Mohammed, Christians, Kathleen K., Krepline, Ashley N., George, Ben, Ritch, Paul S., Erickson, Beth A., et.al. Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer, HPB : the official journal of the International Hepato Pancreato Biliary Association, 2015. 17(10): p. 942-952., https://pubmed.ncbi.nlm.nih.gov/26255895/
538. Aoki, S., Motoi, F., Murakami, Y., Sho, M., Satoi, S., Honda, G., et.al. Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients, BMC Cancer, 2019. 19(1): p. 252., https://www.ncbi.nlm.nih.gov/pubmed/30898101
539. Ferrone, C. R., Marchegiani, G., Hong, T. S., Ryan, D. P., Deshpande, V., McDonnell, E. I., et.al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer, Ann Surg, 2015. 261(1): p. 12-7., https://www.ncbi.nlm.nih.gov/pubmed/25599322
540. Reni, M., Zanon, S., Pircher, C., Chiaravalli, M., Macchini, M., Peretti, U., et.al. Randomized phase 2 trial of nab-paclitaxel plus gemcitabine, 6 capecitabine, cisplatin (PAXG regimen) in metastatic pancreatic adenocarcinoma, Annals of Oncology, 2017. 28: p. v252., https://pubmed.ncbi.nlm.nih.gov/30220407/
541. Mallinson, C. N., Rake, M. O., Cocking, J. B., Fox, C. A., Cwynarski, M. T., Diffey, B. L., et.al. Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial, Br Med J, 1980. 281(6255): p. 1589-91., https://pubmed.ncbi.nlm.nih.gov/7004559/
542. Palmer, K. R., Kerr, M., Knowles, G., Cull, A., Carter, D. C., Leonard, R. C., Chemotherapy prolongs survival in inoperable pancreatic carcinoma, Br J Surg, 1994. 81(6): p. 882-5., https://pubmed.ncbi.nlm.nih.gov/8044610/
543. Glimelius, B., Hoffman, K., Sjoden, P. O., Jacobsson, G., Sellstrom, H., Enander, L. K., et.al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer, Ann Oncol, 1996. 7(6): p. 593-600., https://pubmed.ncbi.nlm.nih.gov/8879373/
544. Yip, D., Karapetis, C., Strickland, A., Steer, C. B., Goldstein, D., Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer, Cochrane Database Syst Rev, 2006. 3: p. CD002093., https://pubmed.ncbi.nlm.nih.gov/16855985/
545. Wainberg, ZA, Melisi, D, Macarulla, T, Pazo Cid, R, Chandana, SR, De La Fouchardière, C, et.al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial., Lancet, 2023. 402 (10409)(10409): p. 1272-1281., https://pubmed.ncbi.nlm.nih.gov/37708904/
546. Burris, H. A., 3rd, Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., et.al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial, J Clin Oncol, 1997. 15(6): p. 2403-13., https://www.ncbi.nlm.nih.gov/pubmed/9196156
547. Sohal, Davendra P. S., Mangu, Pamela B., Khorana, Alok A., Shah, Manish A., Philip, Philip A., O'Reilly, Eileen M., et.al. Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline, Journal of Clinical Oncology, 2016. 34(23): p. 2784-2796., https://pubmed.ncbi.nlm.nih.gov/27247222/
548. Sultana, A., Smith, C. T., Cunningham, D., Starling, N., Neoptolemos, J. P., Ghaneh, P., Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer, Journal of Clinical Oncology, 2007. 25(18): p. 2607-2615., https://pubmed.ncbi.nlm.nih.gov/17577041/
549. Conroy, T., Desseigne, F., Ychou, M., Bouche, O., Guimbaud, R., Becouarn, Y., et.al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer, N Engl J Med, 2011. 364(19): p. 1817-25., https://www.ncbi.nlm.nih.gov/pubmed/21561347
550. Louvet, C., Labianca, R., Hammel, P., Lledo, G., Zampino, M. G., Andre, T., et.al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial, J Clin Oncol, 2005. 23(15): p. 3509-16., https://pubmed.ncbi.nlm.nih.gov/15908661/
551. Heinemann, V., Quietzsch, D., Gieseler, F., Gonnermann, M., Schonekas, H., Rost, A., et.al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer, J Clin Oncol, 2006. 24(24): p. 3946-52., https://pubmed.ncbi.nlm.nih.gov/16921047/
552. Berlin, J. D., Catalano, P., Thomas, J. P., Kugler, J. W., Haller, D. G., Benson, A. B., 3rd, Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297, J Clin Oncol, 2002. 20(15): p. 3270-5., https://pubmed.ncbi.nlm.nih.gov/12149301/
553. Van Cutsem, E., van de Velde, H., Karasek, P., Oettle, H., Vervenne, W. L., Szawlowski, A., et.al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer, J Clin Oncol, 2004. 22(8): p. 1430-8., https://pubmed.ncbi.nlm.nih.gov/15084616/
554. Storniolo, A. M., Enas, N. H., Brown, C. A., Voi, M., Rothenberg, M. L., Schilsky, R., An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma, Cancer, 1999. 85(6): p. 1261-8., https://pubmed.ncbi.nlm.nih.gov/10189130/
555. Herrmann, R., Bodoky, G., Rushstaller, T., al., et, Gemcitabine (G) plus capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer: a randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG), J Clin Oncol, 2005. 23(S16): p. A4010., https://pubmed.ncbi.nlm.nih.gov/17538165/
556. Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., et.al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group, Journal of Clinical Oncology, 2007. 25(15): p. 1960-1966., https://pubmed.ncbi.nlm.nih.gov/17452677/
557. Heinemann, V., Boeck, S., Hinke, A., Labianca, R., Louvet, C., Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer, BMC Cancer, 2008. 8: p. 82., http://www.ncbi.nlm.nih.gov/pubmed/18373843
558. Goldstein, D., El-Maraghi, R. H., Hammel, P., Heinemann, V., Kunzmann, V., Sastre, J., et.al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial, J Natl Cancer Inst, 2015. 107(2):, https://www.ncbi.nlm.nih.gov/pubmed/25638248
559. Gargiulo, P., Dietrich, D., Herrmann, R., Bodoky, G., Ruhstaller, T., Scheithauer, W., et.al. Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores, Ther Adv Med Oncol, 2019. 11: p. 1758835918818351., https://www.ncbi.nlm.nih.gov/pubmed/30636977
560. Cunningham, D., Chau, I., Stocken, D. D., Valle, J. W., Smith, D., Steward, W., et.al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009. p. 5513-8., https://pubmed.ncbi.nlm.nih.gov/19858379/
561. Romanus, D., Kindler, H. L., Archer, L., Basch, E., Niedzwiecki, D., Weeks, J., et.al. Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303), Journal of Pain and Symptom Management, 2012. 43(2): p. 205-217., https://pubmed.ncbi.nlm.nih.gov/22104618/
562. Poplin, E., Feng, Y., Berlin, J., Rothenberg, M. L., Hochster, H., Mitchell, E., et.al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009. p. 3778-85., https://pubmed.ncbi.nlm.nih.gov/19581537/
563. Colucci, G., Labianca, R., Di Costanzo, F., Gebbia, V., Carteni, G., Massidda, B., et.al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study, J Clin Oncol, 2010. 28(10): p. 1645-51., https://www.ncbi.nlm.nih.gov/pubmed/20194854
564. Herrmann, R., Bodoky, G., Ruhstaller, T., Glimelius, B., Bajetta, E., Schüller, J., et.al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007. p. 2212-7., https://pubmed.ncbi.nlm.nih.gov/17538165/
565. Philip, P. A., Benedetti, J., Corless, C. L., Wong, R., O'Reilly, E. M., Flynn, P. J., et.al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest oncology group-directed intergroup trial S0205, Journal of Clinical Oncology, 2010. 28(22): p. 3605-3610., http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L361304545, http://jco.ascopubs.org/content/28/22/3605.full.pdf+html, http://dx.doi.org/10.1200/JCO.2009.25.7550
566. Okusaka, Takuji, Miyakawa, H., Fujii, H., Nakamori, S., Satoh, T., Hamamoto, Y., et.al. Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer, Journal of Cancer Research and Clinical Oncology, 2017. 143(6): p. 1053-1059., https://pubmed.ncbi.nlm.nih.gov/28210843/
567. Yamaue, H., Shimizu, A., Hagiwara, Y., Sho, M., Yanagimoto, H., Nakamori, S., et.al. Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patients with unresectable advanced pancreatic cancer, Cancer Chemotherapy and Pharmacology, 2017. 79(4): p. 813-823., https://pubmed.ncbi.nlm.nih.gov/28251282/
568. Gourgou-Bourgade, S., Bascoul-Mollevi, C., Desseigne, F., Ychou, M., Bouche, O., Guimbaud, R., et.al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial, J Clin Oncol, 2013. 31(1): p. 23-9., https://www.ncbi.nlm.nih.gov/pubmed/23213101
569. Thibodeau, S., Voutsadakis, I. A., FOLFIRINOX chemotherapy in metastatic pancreatic cancer: A systematic review and meta-analysis of retrospective and phase II studies, Journal of Clinical Medicine, 2018. 7(1): p. 7., https://pubmed.ncbi.nlm.nih.gov/29300345/
570. Stein, S. M., James, E. S., Deng, Y., Cong, X., Kortmansky, J. S., Li, J., et.al. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer, British Journal of Cancer, 2016. 114(7): p. 737-743., https://pubmed.ncbi.nlm.nih.gov/27022826/
571. Maisey, N., Chau, I., Cunningham, D., Norman, A., Seymour, M., Hickish, T., et.al. Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer, J Clin Oncol, 2002. 20(14): p. 3130-3136., https://pubmed.ncbi.nlm.nih.gov/12118027/
572. Reni, M., Cordio, S., Milandri, C., Passoni, P., Bonetto, E., Oliani, C., et.al. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial, Lancet Oncol, 2005. 6(6): p. 369-76., https://pubmed.ncbi.nlm.nih.gov/15925814/
573. Ducreux, M., Rougier, P., Pignon, J. P., Douillard, J. Y., Seitz, J. F., Bugat, R., et.al. A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma, Ann Oncol, 2002. 13(8): p. 1185-91., https://www.ncbi.nlm.nih.gov/pubmed/12181240
574. Dahan, L., Bonnetain, F., Ychou, M., Mitry, E., Gasmi, M., Raoul, J. L., et.al. Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301), Gut, 2010. 59(11): p. 1527-34., https://www.ncbi.nlm.nih.gov/pubmed/20947887
575. Tu, C., Zheng, F., Wang, J. Y., Li, Y. Y., Qian, K. Q., An Updated Meta-analysis and System Review:is Gemcitabine+Fluoropyrimidine in Combination a Better Therapy Versus Gemcitabine Alone for Advanced and Unresectable Pancreatic Cancer?, Asian Pacific journal of cancer prevention : APJCP, 2015. 16(14): p. 5681-5686., https://pubmed.ncbi.nlm.nih.gov/26320435/
576. Trouilloud, I., Dupont-Gossard, A. C., et al., Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM), European journal of cancer (Oxford, England : 1990), 2014. 50(18): p. 3116-3124., https://pubmed.ncbi.nlm.nih.gov/25454414/
577. Bachet, J. B., Hammel, P., Desrame, J., Meurisse, A., Chibaudel, B., Andre, T., et.al. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial, Lancet Gastroenterol Hepatol, 2017. 2(5): p. 337-346., https://www.ncbi.nlm.nih.gov/pubmed/28397697
578. Zhang, S., Xie, W., Zou, Y., Xie, S., Zhang, J., Yuan, W., et.al. First-line chemotherapy regimens for locally advanced and metastatic pancreatic adenocarcinoma: A Bayesian analysis, Cancer Management and Research, 2018. 10: p. 5965-5978., https://pubmed.ncbi.nlm.nih.gov/30538546/
579. Chin, V., Nagrial, A., Sjoquist, K., O'Connor, C. A., Chantrill, L., Biankin, A. V., et.al. Chemotherapy and radiotherapy for advanced pancreatic cancer, Cochrane Database Syst Rev, 2018. 3(3): p. CD011044., https://www.ncbi.nlm.nih.gov/pubmed/29557103
580. Li, Q., Yan, H., Liu, W., Zhen, H., Yang, Y., Cao, B., Efficacy and safety of gemcitabine-fluorouracil combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomized controlled trials, PLoS ONE, 2014. 9(8): p. e104346., https://pubmed.ncbi.nlm.nih.gov/25093849/
581. Di Costanzo, F., Carlini, P., Doni, L., Massidda, B., Mattioli, R., Iop, A., et.al. Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC), Br J Cancer, 2005. 93(2): p. 185-9., https://www.ncbi.nlm.nih.gov/pubmed/15986036
582. Scheithauer, W., Schüll, B., Ulrich-Pur, H., Schmid, K., Raderer, M., Haider, K., et.al. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial, Ann Oncol, 2003. 14(1): p. 97-104., https://pubmed.ncbi.nlm.nih.gov/12488300/
583. Nakai, Y., Isayama, H., Sasaki, T., Sasahira, N., Tsujino, T., Toda, N., et.al. A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study, Br J Cancer, 2012. 106(12): p. 1934-9., https://pubmed.ncbi.nlm.nih.gov/22555398/
584. Ueno, H., Ioka, T., Ikeda, M., Ohkawa, S., Yanagimoto, H., Boku, N., et.al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study, Journal of Clinical Oncology, 2013. 31(13): p. 1640-1648., https://pubmed.ncbi.nlm.nih.gov/23547081/
585. Sudo, K., Ishihara, T., Hirata, N., Ozawa, F., Ohshima, T., Azemoto, R., et.al. Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer, Cancer Chemother Pharmacol, 2014. 73(2): p. 389-96., https://pubmed.ncbi.nlm.nih.gov/24322377/
586. Rocha Lima, C. M., Green, M. R., Rotche, R., Miller, W. H., Jr., Jeffrey, G. M., Cisar, L. A., et.al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate, J Clin Oncol, 2004. 22(18): p. 3776-3783., PM:15365074
587. Stathopoulos, G. P., Syrigos, K., Aravantinos, G., Polyzos, A., Papakotoulas, P., Fountzilas, G., et.al. A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer, Br J Cancer, 2006. 95(5): p. 587-592., PM:16909140, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360678/pdf/95-6603301a.pdf
588. Oettle, H., Richards, D., Ramanathan, R. K., van Laethem, J. L., Peeters, M., Fuchs, M., et.al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer, Ann Oncol, 2005. 16(10): p. 1639-45., https://pubmed.ncbi.nlm.nih.gov/16087696/
589. Abou-Alfa, G. K., Letourneau, R., Harker, G., Modiano, M., Hurwitz, H., Tchekmedyian, N. S., et.al. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer, J Clin Oncol, 2006. 24(27): p. 4441-7., https://pubmed.ncbi.nlm.nih.gov/16983112/
590. Kulke, M. H., Tempero, M. A., Niedzwiecki, D., Hollis, D. R., Kindler, H. L., Cusnir, M., et.al. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904, J Clin Oncol, 2009. 27(33): p. 5506-5512., https://pubmed.ncbi.nlm.nih.gov/19858396/
591. Hu, J., Zhao, G., Wang, H. X., Tang, L., Xu, Y. C., Ma, Y., et.al. A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma, Journal of Hematology and Oncology, 2011. 4:, http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L51343155, http://dx.doi.org/10.1186/1756-8722-4-11
592. Wang, Y., Hu, G. F., Zhang, Q. Q., Tang, N., Guo, J., Liu, L. Y., et.al. Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: A systematic review and meta-analysis, Drug Design, Development and Therapy, 2016. 10: p. 1961-1972., https://pubmed.ncbi.nlm.nih.gov/27358556/
593. Heinemann, V., Vehling-Kaiser, U., Waldschmidt, D., Kettner, E., Marten, A., Winkelmann, C., et.al. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104), Gut, 2013. 62(5): p. 751-759., https://pubmed.ncbi.nlm.nih.gov/22773551/
594. Haas, M., Siveke, J. T., Schenk, M., Lerch, M. M., Caca, K., Freiberg-Richter, J., et.al. Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the Arbeitsgemeinschaft Internistische Onkologie-T, European Journal of Cancer, 2018. 94: p. 95-103., https://pubmed.ncbi.nlm.nih.gov/29549862/
595. Eltawil, K. M., Renfrew, P. D., Molinari, M., Meta-analysis of phase III randomized trials of molecular targeted therapies for advanced pancreatic cancer, HPB (Oxford), 2012. 14(4): p. 260-8., https://www.ncbi.nlm.nih.gov/pubmed/22404265
596. Ciliberto, D., Botta, C., Correale, P., Rossi, M., Caraglia, M., Tassone, P., et.al. Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials, Eur J Cancer, 2013. 49(3): p. 593-603., https://www.ncbi.nlm.nih.gov/pubmed/22989511
597. Tong, M., Wang, J., Zhang, H., Xing, H., Wang, Y., Fang, Y., et.al. Efficacy and safety of gemcitabine plus anti-angiogenesis therapy for advanced pancreatic cancer: A systematic review and meta-analysis of clinical randomized phase III trials, Journal of Cancer, 2019. 10(4): p. 968-978., https://pubmed.ncbi.nlm.nih.gov/30854103/
598. Ciliberto, D., Staropoli, N., Chiellino, S., Botta, C., Tassone, P., Tagliaferri, P., Systematic review and meta-analysis on targeted therapy in advanced pancreatic cancer, Pancreatology, 2016. 16(2): p. 249-58., https://www.ncbi.nlm.nih.gov/pubmed/26852170
599. Bramhall, S. R., Schulz, J., Nemunaitis, J., Brown, P. D., Baillet, M., Buckels, J. A., A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer, Br J Cancer, 2002. 87(2): p. 161-167., https://pubmed.ncbi.nlm.nih.gov/12107836/
600. Kindler, H. L., Niedzwiecki, D., Hollis, D., Sutherland, S., Schrag, D., Hurwitz, H., et.al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303), J Clin Oncol, 2010. 28(22): p. 3617-22., http://www.ncbi.nlm.nih.gov/pubmed/20606091
601. Kindler, H. L., Ioka, T., Richel, D. J., Bennouna, J., Letourneau, R., Okusaka, T., et.al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: A double-blind randomised phase 3 study, The Lancet Oncology, 2011. 12(3): p. 256-262., http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L51266088, http://dx.doi.org/10.1016/S1470-2045(11)70004-3
602. Goncalves, A., Gilabert, M., Francois, E., Dahan, L., Perrier, H., Lamy, R., et.al. BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer, Ann Oncol, 2012. 23(11): p. 2799-2805., https://www.ncbi.nlm.nih.gov/pubmed/22771827
603. Rougier, P., Riess, H., Manges, R., Karasek, P., Humblet, Y., Barone, C., et.al. Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer, European Journal of Cancer, 2013. 49(12): p. 2633-2642., https://pubmed.ncbi.nlm.nih.gov/23642329/
604. Fuchs, C. S., Azevedo, S., Okusaka, T., Van Laethem, J. L., Lipton, L. R., Riess, H., et.al. A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial, Annals of oncology : official journal of the European Society for Medical Oncology, 2015. 26(5): p. 921-927., https://pubmed.ncbi.nlm.nih.gov/25609246/
605. Deplanque, G., Demarchi, M., Hebbar, M., Flynn, P., Melichar, B., Atkins, J., et.al. A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer, Ann Oncol, 2015. 26(6): p. 1194-1200., https://www.ncbi.nlm.nih.gov/pubmed/25858497
606. Hurwitz, Herbert I., Uppal, Nikhil, Wagner, Stephanie A., Bendell, Johanna C., Beck, J. Thaddeus, Wade Iii, Seaborn M., et.al. Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed, Journal of Clinical Oncology, 2015. 33(34): p. 4039-4047., https://pubmed.ncbi.nlm.nih.gov/26351344/
607. Yamaue, H., Tsunoda, T., Tani, M., Miyazawa, M., Yamao, K., Mizuno, N., et.al. Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study, Cancer Science, 2015. 106(7): p. 883-890., https://pubmed.ncbi.nlm.nih.gov/25867139/
608. Middleton, G., Palmer, D. H., Greenhalf, W., Ghaneh, P., Jackson, R., Cox, T., et.al. Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial, Lancet Oncology, 2017. (no pagination):, https://pubmed.ncbi.nlm.nih.gov/28259610/
609. Schultheis, B., Reuter, D., Ebert, M. P., Siveke, J., Kerkhoff, A., Berdel, W. E., et.al. Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study, Annals of oncology : official journal of the European Society for Medical Oncology, 2017. 28(10): p. 2429-2435., https://pubmed.ncbi.nlm.nih.gov/28961832/
610. Evans, T. R. J., Van Cutsem, E., Moore, M. J., Bazin, I. S., Rosemurgy, A., Bodoky, G., et.al. Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer, Ann Oncol, 2017. 28(2): p. 354-361., https://www.ncbi.nlm.nih.gov/pubmed/27998964
611. Melisi, D., Garcia-Carbonero, R., Macarulla, T., Pezet, D., Deplanque, G., Fuchs, M., et.al. Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer, British Journal of Cancer, 2018. 119(10): p. 1208-1214., https://pubmed.ncbi.nlm.nih.gov/30318515/
612. Schwartzberg, L. S., Arena, F. P., Bienvenu, B. J., Kaplan, E. H., Camacho, L. H., Campos, L. T., et.al. A randomized, open-label, safety and exploratory efficacy study of Kanglaite Injection (KLTi) plus gemcitabine versus gemcitabine in patients with advanced pancreatic cancer, Journal of Cancer, 2017. 8(10): p. 1872-1883., https://pubmed.ncbi.nlm.nih.gov/28819385/
613. Golan, T., Geva, R., Richards, D., Madhusudan, S., Lin, B. K., Wang, H. T., et.al. LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial, J Cachexia Sarcopenia Muscle, 2018. 9(5): p. 871-879., https://www.ncbi.nlm.nih.gov/pubmed/30051975
614. Reni, M., Cereda, S., Milella, M., Novarino, A., Passardi, A., Mambrini, A., et.al. Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: A phase II randomised trial, European Journal of Cancer, 2013. 49(17): p. 3609-3615., https://pubmed.ncbi.nlm.nih.gov/23899530/
615. O'Reilly, E. M., Lee, J. W., Zalupski, M., Capanu, M., Park, J., Golan, T., et.al. Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation, J Clin Oncol, 2020. 38(13): p. 1378-1388., https://www.ncbi.nlm.nih.gov/pubmed/31976786
616. Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., et.al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer, N Engl J Med, 2019. 381(4): p. 317-327., https://www.ncbi.nlm.nih.gov/pubmed/31157963
617. Holter, Spring, Borgida, Ayelet, Dodd, Anna, Grant, Robert, Semotiuk, Kara, Hedley, David, et.al. Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015. 33(28): p. 3124-3129., https://pubmed.ncbi.nlm.nih.gov/25940717/
618. Walsh, C. S., Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy?, Gynecologic Oncology, 2015. 137(2): p. 343-350., https://pubmed.ncbi.nlm.nih.gov/25725131/
619. Bao, Z., Cao, C., Geng, X., Tian, B., Wu, Y., Zhang, C., et.al. Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: A systematic review and meta-analysis, Oncotarget, 2016. 7(7): p. 7629-39., https://www.ncbi.nlm.nih.gov/pubmed/26399274
620. Bekaii-Saab, TS, Yaeger, R, Spira, AI, Pelster, MS, Sabari, JK, Hafez, N, et.al. Adagrasib in Advanced Solid Tumors Harboring a , J Clin Oncol, 2023. 41 (25)(25): p. 4097-4106., https://pubmed.ncbi.nlm.nih.gov/37099736/
621. Strickler, JH, Satake, H, George, TJ, Yaeger, R, Hollebecque, A, Garrido-Laguna, I, et.al. Sotorasib in , N Engl J Med, 2023. 388 (1)(1): p. 33-43., https://pubmed.ncbi.nlm.nih.gov/36546651/
622. Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., et.al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade, Science, 2017. 357(6349): p. 409-413., https://pubmed.ncbi.nlm.nih.gov/28596308/
623. Humphris, J. L., Patch, A. M., Nones, K., Bailey, P. J., Johns, A. L., McKay, S., et.al. Hypermutation In Pancreatic Cancer, 2017. 152(1): p. 68., https://pubmed.ncbi.nlm.nih.gov/27856273/
624. Johansson, H., Andersson, R., Bauden, M., Hammes, S., Holdenrieder, S., Ansari, D., Immune checkpoint therapy for pancreatic cancer, World J Gastroenterol, 2016. 22(43): p. 9457-9476., https://pubmed.ncbi.nlm.nih.gov/27920468/
625. Azad, N. S., Gray, R. J., Overman, M. J., Schoenfeld, J. D., Mitchell, E. P., Zwiebel, J. A., et.al. Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study, J Clin Oncol, 2020. 38(3): p. 214-222., https://www.ncbi.nlm.nih.gov/pubmed/31765263
626. Ribas, A., Releasing the Brakes on Cancer Immunotherapy, N Engl J Med, 2015. 373(16): p. 1490-2., https://pubmed.ncbi.nlm.nih.gov/26348216/
627. Hu, Z. I., Shia, J., Stadler, Z. K., Varghese, A. M., Capanu, M., Salo-Mullen, E., et.al. Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: Challenges and recommendations, Clinical Cancer Research, 2018. 24(6): p. 1326-1336., http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emexb&NEWS=N&AN=622381571, https://clincancerres.aacrjournals.org/content/clincanres/24/6/1326.full.pdf
628. Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., et.al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency, N Engl J Med, 2015. 372(26): p. 2509-2520., PM:26028255, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4481136/pdf/nihms698054.pdf
629. Marabelle, A., Le, D. T., Ascierto, P. A., Di Giacomo, A. M., De Jesus-Acosta, A., Delord, J. P., et.al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study, J Clin Oncol, 2020. 38(1): p. 1-10., https://www.ncbi.nlm.nih.gov/pubmed/31682550
630. Taïeb, J, Sayah, L, Heinrich, K, Kunzmann, V, Boileve, A, Cirkel, G, et.al. Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort., Eur J Cancer, 2023. 188 (): p. 90-97., https://pubmed.ncbi.nlm.nih.gov/37229836/
631. Wang, M., Shi, S. B., Qi, J. L., Tang, X. Y., Tian, J., S-1 plus CIK as second-line treatment for advanced pancreatic cancer, Med Oncol, 2013. 30(4): p. 747., https://pubmed.ncbi.nlm.nih.gov/24122257/
632. Middleton, Gary, Silcocks, Paul, Cox, Trevor, Valle, Juan, Wadsley, Jonathan, Propper, David, et.al. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial, Lancet Oncology, 2014. 15(8): p. 829-840., https://pubmed.ncbi.nlm.nih.gov/24954781/
633. Nishida, S., Ishikawa, T., Egawa, S., Koido, S., Yanagimoto, H., Ishii, J., et.al. Combination gemcitabine and WT1 peptide vaccination improves progression-free survival in advanced pancreatic ductal adenocarcinoma: A phase II randomized study, Cancer Immunology Research, 2018. 6(3): p. 320-331., https://pubmed.ncbi.nlm.nih.gov/29358173/
634. Le, Dung T., Picozzi, Vincent J., Ko, Andrew H., Wainberg, Zev A., Kindler, Hedy, Wang-Gillam, Andrea, et.al. Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study), Clinical cancer research : an official journal of the American Association for Cancer Research, 2019., https://pubmed.ncbi.nlm.nih.gov/31126960/
635. Ulrich-Pur, H., Raderer, M., Verena Kornek, G., Schüll, B., Schmid, K., Haider, K., et.al. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma, British journal of cancer, 2003. 88(8): p. 1180-1184., https://pubmed.ncbi.nlm.nih.gov/12698181, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2747555/
636. Ciuleanu, T. E., Pavlovsky, A. V., Bodoky, G., Garin, A. M., Langmuir, V. K., Kroll, S., et.al. A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine, Eur J Cancer, 2009. 45(9): p. 1589-96., https://www.ncbi.nlm.nih.gov/pubmed/19188061
637. Pelzer, U., Schwaner, I., Stieler, J., Adler, M., Seraphin, J., Dorken, B., et.al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group, Eur J Cancer, 2011. 47(11): p. 1676-81., https://pubmed.ncbi.nlm.nih.gov/21565490/
638. Oettle, H., Riess, H., Stieler, J. M., Heil, G., Schwaner, I., Seraphin, J., et.al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial, J Clin Oncol, 2014. 32(23): p. 2423-2429., https://pubmed.ncbi.nlm.nih.gov/24982456/
639. Gill, S., Ko, Y. J., Cripps, C., Beaudoin, A., Dhesy-Thind, S., Zulfiqar, M., et.al. PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy, J Clin Oncol, 2016. 34(32): p. 3914-3920., https://pubmed.ncbi.nlm.nih.gov/27621395/
640. Wang-Gillam, Andrea, Chung-Pin, Li, Bodoky, GyÇôrgy, Dean, Andrew, Yan-Shen, Shan, Jameson, Gayle, et.al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial, The Lancet, 2016. 387 North American Edition(10018): p. 545-557., https://pubmed.ncbi.nlm.nih.gov/26615328/
641. Macarulla, T., Blanc, J. F., Wang-Gillam, A., Chen, L. T., Siveke, J. T., Mirakhur, B., et.al. Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer" A subgroup analysis of the pivotal NAPOLI-1 trial, Journal of Geriatric Oncology, 2019., https://pubmed.ncbi.nlm.nih.gov/30842038/
642. Wang-Gillam, A., Hubner, R. A., Siveke, J. T., Von Hoff, D. D., Belanger, B., de Jong, F. A., et.al. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors, European Journal of Cancer, 2019. 108: p. 78-87., https://pubmed.ncbi.nlm.nih.gov/30654298/
643. Chen, L. T., Siveke, J. T., Wang-Gillam, A., Li, C. P., Bodoky, G., Dean, A. P., et.al. Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial, Eur J Cancer, 2018. 105: p. 71-78., https://www.ncbi.nlm.nih.gov/pubmed/30414528
644. Hubner, R. A., Cubillo, A., Blanc, J. F., Melisi, D., Von Hoff, D. D., Wang-Gillam, A., et.al. Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin, European Journal of Cancer, 2019. 106: p. 24-33., https://pubmed.ncbi.nlm.nih.gov/30458340/
645. Berk, V., Ozdemir, N., Ozkan, M., Aksoy, S., Turan, N., Inal, A., et.al. XELOX vs. FOLFOX4 as second line chemotherapy in advanced pancreatic cancer, Hepato-gastroenterology, 2012. 59(120): p. 2635-2639., https://pubmed.ncbi.nlm.nih.gov/22534542/
646. Bodoky, GyÇôrgy, Timcheva, Constanta, Spigel, David, Stella, Phillip, Ciuleanu, Tudor, Pover, G., et.al. A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy...[corrected] [published erratum appears in INVEST NEW DRUGS 2012; 30(3):1273-3], Investigational New Drugs, 2012. 30(3): p. 1216-1223., https://pubmed.ncbi.nlm.nih.gov/21594619/
647. Minimally invasive test may detect early pancreatic cancer, AORN Journal, 2007. 86(6): p. 1053-1053.
648. Chung, V., McDonough, S., Philip, P. A., Cardin, D., Wang-Gillam, A., Hui, L., et.al. Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial, JAMA Oncol, 2017. 3(4): p. 516-522., https://www.ncbi.nlm.nih.gov/pubmed/27978579
649. Ioka, T., Ueno, M., Ueno, H., Park, J. O., Chang, H. M., Sasahira, N., et.al. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial), European Journal of Cancer, 2019. 106: p. 78-88., https://pubmed.ncbi.nlm.nih.gov/30471651/
650. Hurwitz, H., Van, Cutsem E., Bendell, J., Hidalgo, M., Li, C. P., Salvo, M. G., et.al. Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies, Investigational New Drugs, 2018. 36(4): p. 683-695., https://pubmed.ncbi.nlm.nih.gov/29508247/
651. Herman, Joseph M., Chang, Daniel T., Goodman, Karyn A., Dholakia, Avani S., Raman, Siva P., Hacker-Prietz, Amy, et.al. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma, Cancer (0008543X), 2015. 121(7): p. 1128-1137., https://pubmed.ncbi.nlm.nih.gov/25538019/
652. Loehrer, P. J., Sr., Feng, Y., Cardenes, H., Wagner, L., Brell, J. M., Cella, D., et.al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial, J Clin Oncol, 2011. 29(31): p. 4105-12., https://pubmed.ncbi.nlm.nih.gov/21969502/
653. Chauffert, B., Mornex, F., Bonnetain, F., Rougier, P., Mariette, C., Bouche, O., et.al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study, Ann Oncol, 2008. 19(9): p. 1592-9., https://www.ncbi.nlm.nih.gov/pubmed/18467316
654. Ambe, C., Fulp, W., Springett, G., Hoffe, S., Mahipal, A., A Meta-analysis of Randomized Clinical Trials of Chemoradiation Therapy in Locally Advanced Pancreatic Cancer, J Gastrointest Cancer, 2015. 46(3): p. 284-90., https://www.ncbi.nlm.nih.gov/pubmed/26018826
655. Krishnan, S., Chadha, A. S., Suh, Y., Chen, H. C., Rao, A., Das, P., et.al. Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation, Int J Radiat Oncol Biol Phys, 2016. 94(4): p. 755-65., https://pubmed.ncbi.nlm.nih.gov/26972648/
656. Ma, S. J., Prezzano, K. M., Hermann, G. M., Singh, A. K., Dose escalation of radiation therapy with or without induction chemotherapy for unresectable locally advanced pancreatic cancer, Radiat Oncol, 2018. 13(1): p. 214., https://pubmed.ncbi.nlm.nih.gov/30400962/
657. Chuong, Michael D., Springett, Gregory M., Freilich, Jessica M., Park, Catherine K., Weber, Jill M., Mellon, Eric A., et.al. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated, International Journal of Radiation Oncology, Biology, Physics, 2013. 86(3): p. 516-522., https://pubmed.ncbi.nlm.nih.gov/23562768/
658. de Geus, S. W. L., Eskander, M. F., Kasumova, G. G., Ng, S. C., Kent, T. S., Mancias, J. D., et.al. Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review, Cancer, 2017. 123(21): p. 4158-4167., https://www.ncbi.nlm.nih.gov/pubmed/28708929
659. Balaban, Edward P., Mangu, Pamela B., Khorana, Alok A., Shah, Manish A., Mukherjee, Somnath, Crane, Christopher H., et.al. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline, Journal of Clinical Oncology, 2016. 34(22): p. 2654-2668., https://pubmed.ncbi.nlm.nih.gov/27247216/
660. Palta, M., Godfrey, D., Goodman, K. A., Hoffe, S., Dawson, L. A., Dessert, D., et.al. Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline, Pract Radiat Oncol, 2019. 9(5): p. 322-332., https://pubmed.ncbi.nlm.nih.gov/31474330/
661. Zhu, C. P., Shi, J., Chen, Y. X., Xie, W. F., Lin, Y., Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis, Radiother Oncol, 2011. 99(2): p. 108-13., https://pubmed.ncbi.nlm.nih.gov/21571383/
662. Hurt, C. N., Falk, S., Crosby, T., McDonald, A., Ray, R., Joseph, G., et.al. Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer, Br J Cancer, 2017. 116(10): p. 1264-1270., https://pubmed.ncbi.nlm.nih.gov/28376080/
663. Stiel, S, Matthes, ME, Bertram, L, Ostgathe, C, Elsner, F, Radbruch, L, [Validation of the new version of the minimal documentation system (MIDOS) for patients in palliative care : the German version of the edmonton symptom assessment scale (ESAS)]., Schmerz, 2010. 24 (6)(6): p. 596-604., https://pubmed.ncbi.nlm.nih.gov/20882300/
664. Bruera, E, Kuehn, N, Miller, MJ, Selmser, P, Macmillan, K, The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients., J Palliat Care, 1991. 7 (2)(2): p. 6-9., https://pubmed.ncbi.nlm.nih.gov/1714502/
665. Schildmann, EK, Groeneveld, EI, Denzel, J, Brown, A, Bernhardt, F, Bailey, K, et.al. Discovering the hidden benefits of cognitive interviewing in two languages: The first phase of a validation study of the Integrated Palliative care Outcome Scale., Palliat Med, 2016. 30 (6)(6): p. 599-610., https://pubmed.ncbi.nlm.nih.gov/26415736/
666. Velikova, G, Booth, L, Smith, AB, Brown, PM, Lynch, P, Brown, JM, et.al. Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial., J Clin Oncol, 2004. 22 (4)(4): p. 714-24., https://pubmed.ncbi.nlm.nih.gov/14966096/
667. Mackay, TM, Latenstein, AEJ, Sprangers, MAG, van der Geest, LG, Creemers, GJ, van Dieren, S, et.al. Relationship Between Quality of Life and Survival in Patients With Pancreatic and Periampullary Cancer: A Multicenter Cohort Analysis., J Natl Compr Canc Netw, 2020. 18 (10)(10): p. 1354-1363., https://pubmed.ncbi.nlm.nih.gov/33022643/
668. Muscaritoli, M, Arends, J, Bachmann, P, Baracos, V, Barthelemy, N, Bertz, H, et.al. ESPEN practical guideline: Clinical Nutrition in cancer., Clin Nutr, 2021. 40 (5)(5): p. 2898-2913., https://pubmed.ncbi.nlm.nih.gov/33946039/
669. Arends, J, Bachmann, P, Baracos, V, Barthelemy, N, Bertz, H, Bozzetti, F, et.al. ESPEN guidelines on nutrition in cancer patients., Clin Nutr, 2017. 36 (1)(1): p. 11-48., https://pubmed.ncbi.nlm.nih.gov/27637832/
670. Hendifar, AE, Petzel, MQB, Zimmers, TA, Denlinger, CS, Matrisian, LM, Picozzi, VJ, et.al. Pancreas Cancer-Associated Weight Loss., Oncologist, 2019. 24 (5)(5): p. 691-701., https://pubmed.ncbi.nlm.nih.gov/30591550/
671. Roeland, EJ, Bohlke, K, Baracos, VE, Bruera, E, Del Fabbro, E, Dixon, S, et.al. Management of Cancer Cachexia: ASCO Guideline., J Clin Oncol, 2020. 38 (21)(21): p. 2438-2453., https://pubmed.ncbi.nlm.nih.gov/32432946/
672. Schuetz, P, Seres, D, Lobo, DN, Gomes, F, Kaegi-Braun, N, Stanga, Z, Management of disease-related malnutrition for patients being treated in hospital., Lancet, 2021. 398 (10314)(10314): p. 1927-1938., https://pubmed.ncbi.nlm.nih.gov/34656286/
673. Schuetz, P, Fehr, R, Baechli, V, Geiser, M, Deiss, M, Gomes, F, et.al. Individualised nutritional support in medical inpatients at nutritional risk: a randomised clinical trial., Lancet, 2019. 393 (10188)(10188): p. 2312-2321., https://pubmed.ncbi.nlm.nih.gov/31030981/
674. Kaegi-Braun, N, Schuetz, P, Mueller, B, Kutz, A, Association of Nutritional Support With Clinical Outcomes in Malnourished Cancer Patients: A Population-Based Matched Cohort Study., Front Nutr, 2020. 7 (): p. 603370., https://pubmed.ncbi.nlm.nih.gov/33777987/
675. Pathanki, AM, Attard, JA, Bradley, E, Powell-Brett, S, Dasari, BVM, Isaac, JR, et.al. Pancreatic exocrine insufficiency after pancreaticoduodenectomy: Current evidence and management., World J Gastrointest Pathophysiol, 2020. 11 (2)(2): p. 20-31., https://pubmed.ncbi.nlm.nih.gov/32318312/
676. Roberts, KJ, Schrem, H, Hodson, J, Angelico, R, Dasari, BVM, Coldham, CA, et.al. Pancreas exocrine replacement therapy is associated with increased survival following pancreatoduodenectomy for periampullary malignancy., HPB (Oxford), 2017. 19 (10)(10): p. 859-867., https://pubmed.ncbi.nlm.nih.gov/28711377/
677. Bruno, MJ, Haverkort, EB, Tijssen, GP, Tytgat, GN, van Leeuwen, DJ, Placebo controlled trial of enteric coated pancreatin microsphere treatment in patients with unresectable cancer of the pancreatic head region., Gut, 1998. 42 (1)(1): p. 92-6., https://pubmed.ncbi.nlm.nih.gov/9505892/
678. Woo, SM, Joo, J, Kim, SY, Park, SJ, Han, SS, Kim, TH, et.al. Efficacy of pancreatic exocrine replacement therapy for patients with unresectable pancreatic cancer in a randomized trial., Pancreatology 16 (6)(6): p. 1099-1105., https://pubmed.ncbi.nlm.nih.gov/27618657/
679. Saito, T, Nakai, Y, Isayama, H, Hirano, K, Ishigaki, K, Hakuta, R, et.al. A Multicenter Open-Label Randomized Controlled Trial of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer., Pancreas, 2018. 47 (7)(7): p. 800-806., https://pubmed.ncbi.nlm.nih.gov/29851751/
680. Iglesia, D, Avci, B, Kiriukova, M, Panic, N, Bozhychko, M, Sandru, V, et.al. Pancreatic exocrine insufficiency and pancreatic enzyme replacement therapy in patients with advanced pancreatic cancer: A systematic review and meta-analysis., United European Gastroenterol J, 2020. 8 (9)(9): p. 1115-1125., https://pubmed.ncbi.nlm.nih.gov/32631175/
681. Gianotti, L, Besselink, MG, Sandini, M, Hackert, T, Conlon, K, Gerritsen, A, et.al. Nutritional support and therapy in pancreatic surgery: A position paper of the International Study Group on Pancreatic Surgery (ISGPS)., Surgery, 2018. 164 (5)(5): p. 1035-1048., https://pubmed.ncbi.nlm.nih.gov/30029989/
682. Marimuthu, K, Varadhan, KK, Ljungqvist, O, Lobo, DN, A meta-analysis of the effect of combinations of immune modulating nutrients on outcome in patients undergoing major open gastrointestinal surgery., Ann Surg, 2012. 255 (6)(6): p. 1060-8., https://pubmed.ncbi.nlm.nih.gov/22549749/
683. Moss, A. C., Morris, E., Mac Mathuna, P., Palliative biliary stents for obstructing pancreatic carcinoma, Cochrane Database Syst Rev, 2006. p. CD004200., https://pubmed.ncbi.nlm.nih.gov/16437477/
684. Hausegger, K. A., Thurnher, S., Bodendorfer, G., Zollikofer, C. L., Uggowitzer, M., Kugler, C., et.al. Treatment of malignant biliary obstruction with polyurethane-covered Wallstents, AJR Am J Roentgenol, 1998. 170(2): p. 403-8., https://pubmed.ncbi.nlm.nih.gov/9456954/
685. Isayama, H., Komatsu, Y., Tsujino, T., Sasahira, N., Hirano, K., Toda, N., et.al. A prospective randomised study of "covered" versus "uncovered" diamond stents for the management of distal malignant biliary obstruction, Gut, 2004. 53(5): p. 729-34., https://pubmed.ncbi.nlm.nih.gov/15082593/
686. Speer, A. G., Cotton, P. B., Russell, R. C., Mason, R. R., Hatfield, A. R., Leung, J. W., et.al. Randomised trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice, Lancet, 1987. 2(8550): p. 57-62., https://pubmed.ncbi.nlm.nih.gov/2439854/
687. Aranha, G. V., Prinz, R. A., Greenlee, H. B., Biliary enteric bypass for benign and malignant disease, Am Surg, 1987. 53(7): p. 403-6., https://pubmed.ncbi.nlm.nih.gov/3605859/
688. DiFronzo, L. A., Egrari, S., O'Connell, T. X., Choledochoduodenostomy for palliation in unresectable pancreatic cancer, Arch Surg, 1998. 133(8): p. 820-5., https://pubmed.ncbi.nlm.nih.gov/9711954/
689. Urbach, D. R., Bell, C. M., Swanstrom, L. L., Hansen, P. D., Cohort study of surgical bypass to the gallbladder or bile duct for the palliation of jaundice due to pancreatic cancer, Ann Surg, 2003. 237(1): p. 86-93., https://pubmed.ncbi.nlm.nih.gov/12496534/
690. Baron, TH, Expandable metal stents for the treatment of cancerous obstruction of the gastrointestinal tract., N Engl J Med, 2001. 344 (22)(22): p. 1681-7., https://pubmed.ncbi.nlm.nih.gov/11386268/
691. Camúñez, F, Echenagusia, A, Simó, G, Turégano, F, Vázquez, J, Barreiro-Meiro, I, Malignant colorectal obstruction treated by means of self-expanding metallic stents: effectiveness before surgery and in palliation., Radiology, 2000. 216 (2)(2): p. 492-7., https://pubmed.ncbi.nlm.nih.gov/10924576/
692. Law, WL, Choi, HK, Lee, YM, Chu, KW, Palliation for advanced malignant colorectal obstruction by self-expanding metallic stents: prospective evaluation of outcomes., Dis Colon Rectum, 2004. 47 (1)(1): p. 39-43., https://pubmed.ncbi.nlm.nih.gov/14719149/
693. Lowe, AS, Beckett, CG, Jowett, S, May, J, Stephenson, S, Scally, A, et.al. Self-expandable metal stent placement for the palliation of malignant gastroduodenal obstruction: experience in a large, single, UK centre., Clin Radiol, 2007. 62 (8)(8): p. 738-44., https://pubmed.ncbi.nlm.nih.gov/https://pubmed.ncbi.nlm.nih.gov/17604761//
694. Nassif, T, Prat, F, Meduri, B, Fritsch, J, Choury, AD, Dumont, JL, et.al. Endoscopic palliation of malignant gastric outlet obstruction using self-expandable metallic stents: results of a multicenter study., Endoscopy, 2003. 35 (6)(6): p. 483-9., https://pubmed.ncbi.nlm.nih.gov/https://pubmed.ncbi.nlm.nih.gov/12783345//
695. Telford, JJ, Carr-Locke, DL, Baron, TH, Tringali, A, Parsons, WG, Gabbrielli, A, et.al. Palliation of patients with malignant gastric outlet obstruction with the enteral Wallstent: outcomes from a multicenter study., Gastrointest Endosc, 2004. 60 (6)(6): p. 916-20., https://pubmed.ncbi.nlm.nih.gov/https://pubmed.ncbi.nlm.nih.gov/15605006//
696. Watt, AM, Faragher, IG, Griffin, TT, Rieger, NA, Maddern, GJ, Self-expanding metallic stents for relieving malignant colorectal obstruction: a systematic review., Ann Surg, 2007. 246 (1)(1): p. 24-30., https://pubmed.ncbi.nlm.nih.gov/https://pubmed.ncbi.nlm.nih.gov/17592286//
697. Espinel, J, Sanz, O, Vivas, S, Jorquera, F, Muñoz, F, Olcoz, JL, et.al. Malignant gastrointestinal obstruction: endoscopic stenting versus surgical palliation., Surg Endosc, 2006. 20 (7)(7): p. 1083-7., https://pubmed.ncbi.nlm.nih.gov/https://pubmed.ncbi.nlm.nih.gov/16703436//
698. Fiori, E, Lamazza, A, Volpino, P, Burza, A, Paparelli, C, Cavallaro, G, et.al. Palliative management of malignant antro-pyloric strictures. Gastroenterostomy vs. endoscopic stenting. A randomized prospective trial., Anticancer Res 24 (1)(1): p. 269-71., https://pubmed.ncbi.nlm.nih.gov/https://pubmed.ncbi.nlm.nih.gov/15015607//
699. Laval, G, Marcelin-Benazech, B, Guirimand, F, Chauvenet, L, Copel, L, Durand, A, et.al. Recommendations for bowel obstruction with peritoneal carcinomatosis., J Pain Symptom Manage, 2014. 48 (1)(1): p. 75-91., https://pubmed.ncbi.nlm.nih.gov/https://pubmed.ncbi.nlm.nih.gov/24798105//
700. Shaw, C, Bassett, RL, Fox, PS, Schmeler, KM, Overman, MJ, Wallace, MJ, et.al. Palliative venting gastrostomy in patients with malignant bowel obstruction and ascites., Ann Surg Oncol, 2013. 20 (2)(2): p. 497-505., https://pubmed.ncbi.nlm.nih.gov/https://pubmed.ncbi.nlm.nih.gov/22965572//
701. Rath, KS, Loseth, D, Muscarella, P, Phillips, GS, Fowler, JM, O'Malley, DM, et.al. Outcomes following percutaneous upper gastrointestinal decompressive tube placement for malignant bowel obstruction in ovarian cancer., Gynecol Oncol, 2013. 129 (1)(1): p. 103-6., https://pubmed.ncbi.nlm.nih.gov/https://pubmed.ncbi.nlm.nih.gov/23369942//
702. DeEulis, TG, Yennurajalingam, S, Venting Gastrostomy at Home for Symptomatic Management of Bowel Obstruction in Advanced/Recurrent Ovarian Malignancy: A Case Series., J Palliat Med, 2015. 18 (8)(8): p. 722-8., https://pubmed.ncbi.nlm.nih.gov/https://pubmed.ncbi.nlm.nih.gov/26218581//
703. Dittrich, A, Schubert, B, Kramer, M, Lenz, F, Kast, K, Schuler, U, et.al. Benefits and risks of a percutaneous endoscopic gastrostomy (PEG) for decompression in patients with malignant gastrointestinal obstruction., Support Care Cancer, 2017. 25 (9)(9): p. 2849-2856., https://pubmed.ncbi.nlm.nih.gov/https://pubmed.ncbi.nlm.nih.gov/28434096//
704. Issaka, RB, Shapiro, DM, Parikh, ND, Mulcahy, MF, Komanduri, S, Martin, JA, et.al. Palliative venting percutaneous endoscopic gastrostomy tube is safe and effective in patients with malignant obstruction., Surg Endosc, 2014. 28 (5)(5): p. 1668-73., https://pubmed.ncbi.nlm.nih.gov/https://pubmed.ncbi.nlm.nih.gov/24366189//
705. Lilley, EJ, Scott, JW, Goldberg, JE, Cauley, CE, Temel, JS, Epstein, AS, et.al. Survival, Healthcare Utilization, and End-of-life Care Among Older Adults With Malignancy-associated Bowel Obstruction: Comparative Study of Surgery, Venting Gastrostomy, or Medical Management., Ann Surg, 2018. 267 (4)(4): p. 692-699., https://pubmed.ncbi.nlm.nih.gov/https://pubmed.ncbi.nlm.nih.gov/28151799//
706. Pinard, KA, Goring, TN, Egan, BC, Koo, DJ, Drainage Percutaneous Endoscopic Gastrostomy for Malignant Bowel Obstruction in Gastrointestinal Cancers: Prognosis and Implications for Timing of Palliative Intervention., J Palliat Med, 2017. 20 (7)(7): p. 774-778., https://pubmed.ncbi.nlm.nih.gov/https://pubmed.ncbi.nlm.nih.gov/28437204//
707. Teriaky, A, Gregor, J, Chande, N, Percutaneous endoscopic gastrostomy tube placement for end-stage palliation of malignant gastrointestinal obstructions., Saudi J Gastroenterol 18 (2)(2): p. 95-8., https://pubmed.ncbi.nlm.nih.gov/https://pubmed.ncbi.nlm.nih.gov/22421713//
708. Campagnutta, E, Cannizzaro, R, Gallo, A, Zarrelli, A, Valentini, M, De Cicco, M, et.al. Palliative treatment of upper intestinal obstruction by gynecological malignancy: the usefulness of percutaneous endoscopic gastrostomy., Gynecol Oncol, 1996. 62 (1)(1): p. 103-5., https://pubmed.ncbi.nlm.nih.gov/https://pubmed.ncbi.nlm.nih.gov/8690280//
709. Laval, G, Arvieux, C, Stefani, L, Villard, ML, Mestrallet, JP, Cardin, N, Protocol for the treatment of malignant inoperable bowel obstruction: a prospective study of 80 cases at Grenoble University Hospital Center., J Pain Symptom Manage, 2006. 31 (6)(6): p. 502-12., https://pubmed.ncbi.nlm.nih.gov/https://pubmed.ncbi.nlm.nih.gov/16793490//
710. Campagnutta, E, Cannizzaro, R, Percutaneous endoscopic gastrostomy (PEG) in palliative treatment of non-operable intestinal obstruction due to gynecologic cancer: a review., Eur J Gynaecol Oncol, 2000. 21 (4)(4): p. 397-402., https://pubmed.ncbi.nlm.nih.gov/https://pubmed.ncbi.nlm.nih.gov/11055494//
711. Frere, C, Bournet, B, Gourgou, S, Fraisse, J, Canivet, C, Connors, JM, et.al. Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes., Gastroenterology, 2020. 158 (5)(5): p. 1346-1358.e4., https://pubmed.ncbi.nlm.nih.gov/https://pubmed.ncbi.nlm.nih.gov/31843588//
712. Tempero, MA, Malafa, MP, Al-Hawary, M, Behrman, SW, Benson, AB, Cardin, DB, et.al. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology., J Natl Compr Canc Netw, 2021. 19 (4)(4): p. 439-457., https://pubmed.ncbi.nlm.nih.gov/https://pubmed.ncbi.nlm.nih.gov/33845462//
713. Maraveyas, A., Waters, J., Roy, R., Fyfe, D., Propper, D., Lofts, F., et.al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer, European Journal of Cancer, 2012. 48(9): p. 1283-1292., http://dx.doi.org/10.1016/j.ejca.2011.10.017
714. Pelzer, Uwe, Opitz, Bernhard, Deutschinoff, Gerd, Stauch, Martina, Reitzig, Peter C., Hahnfeld, Sabine, et.al. Efficacy of Prophylactic Low–Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial, Journal of Clinical Oncology, 2015. 33(18): p. 2028-2034., http://dx.doi.org/10.1200/jco.2014.55.1481
715. Farge, D, Frere, C, Connors, JM, Ay, C, Khorana, AA, Munoz, A, et.al. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer., Lancet Oncol, 2019. 20 (10)(10): p. e566-e581., https://pubmed.ncbi.nlm.nih.gov/31492632/
716. Key, Nigel S., Khorana, Alok A., Kuderer, Nicole M., Bohlke, Kari, Lee, Agnes Y. Y., Arcelus, Juan I., et.al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update, Journal of Clinical Oncology, 2020. 38(5): p. 496-520., http://dx.doi.org/10.1200/jco.19.01461
717. Lyman, Gary H., Carrier, Marc, Ay, Cihan, Di Nisio, Marcello, Hicks, Lisa K., Khorana, Alok A., et.al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer, Blood Advances, 2021. 5(4): p. 927-974., http://dx.doi.org/10.1182/bloodadvances.2020003442
718. Tun, Nay Min, Guevara, Elizabeth, Oo, Thein Hlaing, Benefit and risk of primary thromboprophylaxis in ambulatory patients with advanced pancreatic cancer receiving chemotherapy, Blood Coagulation & Fibrinolysis, 2016. 27(3): p. 270-274., http://dx.doi.org/10.1097/mbc.0000000000000413
719. Tempero, M. A., Arnoletti, J. P., Behrman, S. W., Ben-Josef, E., Benson, A. B., 3rd, Casper, E. S., et.al. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines, J Natl Compr Canc Netw, 2012. 10(6): p. 703-13., https://pubmed.ncbi.nlm.nih.gov/22679115/
720. Ducreux, M., Cuhna, A. Sa, Caramella, C., Hollebecque, A., Burtin, P., Goéré, D., et.al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, 2015. 26: p. v56-v68., http://dx.doi.org/10.1093/annonc/mdv295
721. Khorana, Alok A., McKernin, Shannon E., Berlin, Jordan, Hong, Theodore S., Maitra, Anirban, Moravek, Cassadie, et.al. Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update, Journal of Clinical Oncology, 2019. 37(23): p. 2082-2088., http://dx.doi.org/10.1200/jco.19.00946
722. Elmi, Azadeh, Murphy, Janet, Hedgire, Sandeep, McDermott, Shaunagh, Abtahi, Seyed-Mahdi, Halpern, Elkan, et.al. Post-Whipple imaging in patients with pancreatic ductal adenocarcinoma: association with overall survival: a multivariate analysis, Abdominal Radiology, 2017. 42(8): p. 2101-2107., http://dx.doi.org/10.1007/s00261-017-1099-2
723. Groot, Vincent P., Daamen, Lois A., Hagendoorn, Jeroen, Borel Rinkes, Inne H. M., van Santvoort, Hjalmar C., Molenaar, I. Quintus, Use of imaging during symptomatic follow-up after resection of pancreatic ductal adenocarcinoma, Journal of Surgical Research, 2018. 221: p. 152-160., http://dx.doi.org/10.1016/j.jss.2017.08.023
724. Daamen, Lois A., Groot, Vincent P., Besselink, Marc G., Bosscha, Koop, Busch, Olivier R., Cirkel, Geert A., et.al. Detection, Treatment, and Survival of Pancreatic Cancer Recurrence in the Netherlands, Annals of Surgery, 2020. 275(4): p. 769-775., http://dx.doi.org/10.1097/sla.0000000000004093
725. Daamen, Lois A., Groot, Vincent P., Heerkens, Hanne D., Intven, Martijn P. W., van Santvoort, Hjalmar C., Molenaar, I. Quintus, Systematic review on the role of serum tumor markers in the detection of recurrent pancreatic cancer, HPB, 2018. 20(4): p. 297-304., http://dx.doi.org/10.1016/j.hpb.2017.11.009
726. Samawi, Haider H., Yin, Yaling, Lim, Howard J., Cheung, Winson Y., Primary Care Versus Oncology-Based Surveillance Following Adjuvant Chemotherapy in Resected Pancreatic Cancer, Journal of Gastrointestinal Cancer, 2017. 49(4): p. 429-436., http://dx.doi.org/10.1007/s12029-017-9988-8
727. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), Entwicklung von leitlinienbasierten Qualitätsindikatoren. Methodenpapier für das Leitlinienprogramm Onkologie, Version 2.1, 2017., http://www.leitlinienprogramm-onkologie.de/methodik/informationen-zur-methodik/